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A polyphenol rich extract derived from the leaves of olive trees (Olea europaea) may be 
used as a nutritional supplement. This olive leaf extract (OLE) has a high concentration of 
the secoiridoid, oleuropein and its derivative, hydroxytyrosol (HT). Recent randomised 
control trials demonstrate hypotensive and anti-hyperglycaemic activity for OLE in human 
volunteers; the mechanisms for these effects are still uncertain. The high consumption of 
olive polyphenols may, in part, explain the noted protection against chronic disease 
associated with the Mediterranean diet. The classical Mediterranean lifestyle as observed 
by Ancel Keys, involved not only a healthy diet, but also a high level of physically activity. 
Research investigating the synergistic benefits of including olive polyphenols as part of an 
active lifestyle is limited.  
The aims of this thesis were; first, to explore plausible mechanisms that might explain 
previously observed anti-glycaemic and hypotensive responses to OLE in human 
volunteers; and second, to investigate the synergistic hypotensive effects of consuming 
olive leaf extract alongside increasing physical activity in individuals with slightly elevated 
blood pressure. Our hypotheses were that olive polyphenols would inhibit enzymes 
involved in glucose and fat digestion in the small intestine, and that these polyphenols 
inhibit glucose uptake by the gut epithelia resulting in improved blood sugar control. In 
relation to their anti-hypertensive effects we hypothesised that they would enhance NO 
production and suppress angiotensin enzymes. Finally, we hypothesised that there might 
be a synergistic effect of consuming the OLE and increasing physical activity in terms of 
reducing blood pressure. 
OLE may influence the digestion of macronutrients. We show it to inhibit pancreatic α-
amylase and lipase in a dose dependent manner; IC50 OLE; 3.23 ± 0.33 mM and 1.83 ± 
0.03 mM, respectively. Further, we suggest that the rate of sugar absorption in the small 
intestine may be influenced by the presence of OLE, this is based on our observation of a 
reduction in the mRNA expression for genes encoding intestinal glucose transporters 
(SGLT1, GLUT2) in Caco-2 cells which was coupled to a reduction in glucose uptake 




To explain the anti-hypertensive effects of OLE, we first studied NO production in HUVEC 
cells. At concentrations of OLE equivalent to 100 µM oleuropein, NO production is 
enhanced compared to that observed in untreated controls (p < 0.05). However, we 
deem these concentrations super-physiological, and more work is needed to establish the 
potency of olive leaf phenolic metabolites on this cell system. The inhibitory effects of 
OLE and its principal polyphenols were assessed against renin and against the angiotensin 
converting enzyme (ACE). OLE inhibited renin and ACE activity with an IC50 value of 63.08 
± 2.90 µM and 60.86 ± 5.68 µM, respectively, again the concentrations required to reduce 
the activity of these enzymes in order to explain the reductions in blood pressure 
observed in intervention study are unlikely to be achieved in vivo. 
Following the in vitro studies, we conducted a double-blind, four-arm parallel trial in 63 
pre-hypertensive overweight adults aged 25-70y who were assigned to one of four 
treatment arms for 12 weeks: i) a placebo control group- with a daily capsule; ii) an 
increasing physical activity and a placebo capsule group; iii) an olive leaf extract arm 
(equivalent to 132 mg of oleuropein per day; iv) a physical activity and olive leaf extract 
arm. The primary outcome measure for the study was the change in 24-h ambulatory 
blood pressure (ABP). Secondary outcome measures were arterial stiffness index, plasma 
HbA1C levels, fasted glucose and insulin, serum lipid profiles and body composition. 24-h 
SBP (-5.80 (±SD 7.63), p = 0.011) and day time SBP (-5.07 (±SD 7.16), p = 0.025) were 
significantly lower following OLE intake. The PA intervention alone resulted in lower 24-h 
SBP (-3.69(±SD 9.39), p = 0.031) and daytime SBP (-4.19 (±SD 10.27), p = 0.041). 
Consuming the OLE alongside being increasing physical active reduced 24-h SBP (-3.88 
(±SD 6.65), p = 0.027) relative to the baseline. The magnitude of SBP change observed in 
this thesis would suggest that regular OLE intake as part of healthy lifestyle may be 
associated with a 9-14 % reduction in CHD risk and a 20-22 % reduction in risk of stroke. 
There were however, no effects on stiffness index, body composition, lipids, HbA1c, 
glucose and insulin in all groups after 12 weeks (p > 0.05).  
In this thesis, we provide mechanistic explanations for the findings of previous 
intervention studies. Understanding the biological mechanisms is a key component of the 
Bradford-Hill criteria when it comes to proving efficacy. Publications arising from this 




olive producers in the European market. In addition, we believe that following this thesis, 
there is now abundance of data proving that, olive phenolics when consumed chronically, 
at appropriate doses, reduce blood pressure in pre-hypertensive consumers. However, 
we still do not have a fundamental grasp of the mechanisms involved or an understanding 
of the relative potency of the individual phenolics in this crude extract. Nevertheless, the 
findings presented herein have commercial and public health significance. Consuming the 
OLE delivers the beneficial polyphenols at high doses and minus the need to ingest large 
amounts of energy dense olive oil. OLE consumption, in the absence of increasing physical 
activity, led to a more optimal blood pressure profile, however the benefits of increasing 
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Chapter 1 General background 
 
1.1    The burden of chronic, non-infectious diseases  
The four chronic, non-infectious diseases (CNIDs) of the greatest burden to public health 
are cardiovascular diseases, cancers, diabetes and chronic lung diseases [1]. CNIDs are 
seen as the leading causes of death and disease worldwide accounting for 38 million, or 
68% of global deaths each year. Furthermore, CNIDs are projected to account for more 
than 75% of deaths worldwide by 2030 [2].  In the UK, CNIDs are estimated to account for 
89% of total deaths. Figure 1 shows causes of death in the UK; Cardiovascular diseases 
account for most CNIDs deaths (31%), followed by cancer (29%), respiratory disease (8%), 
and diabetes (1%) [3]. The total cost of CVD to the UK economy is estimated as £30 
billion, 60% due to health-care costs [4], and diabetes costs the NHS around £10 billion 
each year [5].  
 
Figure 1 Proportional mortality (% of total deaths, all ages, both sexes) in UK [3]. 
 
1.2 Risk factors of chronic, non-infectious diseases 
Intermediate biological risk factors in the pathogenesis of CNIDs include hypertension, 
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and linked directly to lifestyle factors, including smoking, alcohol abuse, unhealthy diets 
and physical inactivity [6]. 
1.2.1 Metabolic risk factors 
Metabolic risk factors include central obesity, dyslipidaemia (raised triglycerides and 
lowered high-density lipoprotein cholesterol), raised blood pressure, and raised fasting 
glucose [7]. People exhibiting a cluster of these abnormalities may be defined as 
satisfying the criteria for the metabolic syndrome (MetS). Diagnostic criteria for the 
metabolic syndrome have been establish by the International Diabetes Federation (IDF) in 
2006 (Table 1). The IDF estimates that one-quarter of the world’s adult population has 
the MetS [8]. The MetS confers a 5-fold increase in the risk of type 2 diabetes mellitus 
(T2DM) and 2-fold the risk of developing CVD over the next 5 to 10 years [9]. 
According to the IDF definition, for a person to be defined as having the metabolic 
syndrome they must have: 
Central obesity (defined as waist circumference ≥ 94cm for Europe men and ≥ 80cm 
for Europe women, with ethnicity specific values for other groups) 
plus, any two of the following four factors: 
raised TG level ≥ 150 mg/dL (1.7 mmol/L), or specific treatment for this 
lipid abnormality 
reduced HDL cholesterol < 40 mg/dL (1.03 mmol/L) in males and < 50 mg/dL (1.29 
mmol/L) in females, or specific treatment for this lipid 
abnormality 
raised BP systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg, or 
treatment of previously diagnosed hypertension 
raised fasting plasma glucose ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 
2 diabetes. If above 5.6 mmol/L or 100 mg/dL, OGTT is 
strongly recommended but is not necessary to define 
presence of the syndrome. 
TG, triglycerides; HDL, High-density lipoproteins; BP, blood pressure 





Obesity is a condition in which abnormal or excessive fat accumulation in adipose tissue 
impairs health. It increases the risk of all-cause mortality by approximately 50% [10]. In 
the UK, 62.9% of adults are overweight or obese [11]. An increased risk of CNIDs is 
associated with obesity. Table 2 shows the classification developed by a National Heart, 
Lung, and Blood Institute task force, along with the associated disease risk with increasing 
BMI. A 10-kg higher body weight is associated with a 3.0 mm Hg higher systolic and a 2.3 
mmHg higher diastolic blood pressure[12]. For an 8- to 10.9-kg increase in body weight, 
the relative risk of diabetes was 2.7 among women [13]. The global increase in the 
prevalence of obesity is projected to add 6–8.5 million incidence cases of type 2 diabetes 
and 5.7–7.3 million cases of CVD, in the UK the projected cost to the economy is £1.9–2 
billion per year by 2030 [14].  
 
 
                                                   BMI (kg/m2) 
                                                   
Disease Risk Relative to Normal Weight 
and Waist Circumference 
Men ≤ 102 cm; 
Women ≤ 88 cm 
Men ≥ 102 cm; 
Women ≥ 88 cm 
Underweight <18.5 *** *** 
Normal 18.5–24.9 *** *** 
Overweight 25.0–29.9 Increased High 
Obesity, class    
I 30.0–34.9 High Very high 
II 35.0–39.9 Very high Very high 
III (extreme obesity) ≥40 Extremely high Extremely high 
 
Table 2 Classification of overweight and obesity by BMI, waist circumference and 
associated disease risk for type 2 diabetes, hypertension, and CVD [15]. 
 
Blood pressure is defined as the pressure within the arteries as the heart forces blood to 




as a single value of the systolic (SBP) and diastolic pressures (DBP). SBP is the maximum 
blood pressure during contraction of the ventricles; DBP is the minimum pressure 
recorded just prior to the next contraction [16]. Table 3 provides a classification of BP for 
adults aged 18 years and older in reference to the Seventh Joint National Committee (JNC 
7), with hypertension, defined as a persistent raised blood pressure of 140/90 mmHg. 
Major pathophysiologic mechanisms of hypertension include activation of the 
sympathetic nervous system and renin–angiotensin–aldosterone system [17]. Changing 
patterns of BP occur with increasing age [18]. Nearly 30 per cent of adults in the UK have 
high blood pressure [19]. Public Health England (PHE) reveal that diseases caused by high 
blood pressure are estimated to cost the NHS over £2 billion every year. In addition, 
prolonged exposure to elevated blood pressure is associated with an increased risk for 
cardiovascular mortality (e.g. stroke, heart failure), and renal failure events. Longitudinal 
data from the Framingham Heart Study have specified that BP values of 130–139/85–89 
mmHg (prehypertension) are associated with a more than two-fold increase in relative 
risk of CVD as compared with those with normal BP levels [20]. Moreover, NICE 
hypertension guidelines indicate that BP control can be achieved by both pharmacological 
and lifestyle interventions. Angiotensin-converting enzyme inhibitors and angiotensin 
receptor blockers are useful antihypertensive treatments. A blood pressure reduction of 
10 mmHg systolic or 5 mmHg diastolic can reduce the risk of CHD events by 22%   the 
incidence of stroke by 41% [21]. 
BP classification SBP mmHg DBP mmHg 
Normal <120 and <80 
Prehypertension 120–139 or 80–89 
Stage 1 Hypertension 140–159 or 90–99 
Stage 2 Hypertension ≥160 or ≥100 
BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure 





The presence of both the metabolic syndrome and impaired fasting glucose was 
associated with approximately a 9-fold (7.47–10.45) increased risk of new onset diabetes 
[22]. Besides, a cohort study of nondiabetic individuals, showed that insulin resistance is 
related with a 2.8-fold increased risk of first ischemic stroke [23]. In addition, impairment 
in glucose metabolism leads to physiological imbalance with the onset of the 
hyperglycaemia. Epidemiological studies show that postprandial glucose, together with 
related hyperinsulinemia and lipidaemia is implicated in the aetiology of chronic 
metabolic diseases such as cardiovascular disease (CVD) and type 2 diabetes mellitus 
(T2DM) [24]. Therefore, maintenance of glucose homeostasis is of utmost importance to 
human physiology. Figure 2 gives an overview of the putative relationships between 
postprandial glycaemia and CNIDs.  
 
 
Figure 2 Putative relationships between postprandial glycaemia and risk factors for 




Dyslipidaemia is characterised by an elevation or attenuation of the plasma concentration 
of lipoproteins including triglycerides, chylomicron remnants, and of free fatty acids. The 
subsequent increased transport of FFAs into non-adipose tissue, such as liver and skeletal 
muscle, contributes to the formation of reactive lipid moieties such as diacylglycerol and 
fatty acyl-CoA accumulation, resulting in cellular dysfunction or cell death, a phenomenon 
known as lipotoxicity, as major mediators of insulin resistance, diabetes and 
cardiovascular disease [26, 27]. Inhibiting pancreatic lipase is an interesting approach to 
reducing fat absorption by the intestine in man and suppressing cholesterol, triglyceride 
and FFA level in the plasma [28]. The results of a meta-analysis of 10 large cohort studies 
showed that for each 0.6 mmol/L reduction in serum cholesterol levels in the risk of CHD 
decreased by 27 percent [29].  
1.2.2 Lifestyle risk factors 
Unhealthy diets, physical inactivity, smoking and the harmful use of alcohol, increase the 
risk of dying from CNIDs [30, 31]. The WHO estimates that approximately 1.7 million 
(2.8%) deaths worldwide are attributable to low fruit and vegetable consumption, and 
that this accounts for about 20% of CVD worldwide. Only a quarter of UK adults and one 
in five children consume the recommended minimum five portions of fruit and vegetables 
per day. About 3.2 million deaths annually can be attributed to insufficient physical 
activity. People who are insufficiently physically active have a 20–30% increased risk of 
all-cause mortality compared to those who adhere to the physical activity guidelines. 
Nearly two out of five adults in the UK do not achieve recommended levels of physical 
activity. Smoking, including exposure to second hand smoke, is responsible for 6.3% of 
the global burden of disease [32]. Exposure to tobacco smoke is associated with a 4-fold 
increased risk of development of metabolic syndrome that most likely contribute to 
smoking-induced CVD [33]. In 2015, there were 8,758 deaths which were related to the 
consumption of alcohol in the UK [34]. A prospective cohort study has reported an 





1.3 Prevention of chronic, non-infectious diseases 
Lifestyle modification regarding a healthy diet and physical activity is the preferred 
strategy for preventing chronic disease development. Evidence suggests that combining a 
healthy diet, and increasing physical activity level will have synergistic benefits to health. 
1.3.1 Dietary polyphenols and the prevention of CNIDs 
Increased consumption of plant-based foods such as fruit and vegetables, and plant-
derived beverages has been recommended as a key component of a healthy diet for the 
prevention of CNIDs [36]. A meta-analysis of prospective cohort studies concluded that a 
higher consumption of plant-based foods is associated with a lower risk of all-cause 
mortality, particularly cardiovascular mortality [37]. For example, adequate intake was 
estimated to lead to a 20% to 30% reduction in risk of CVD [38]. and a 2-fold reduction in 
cancer risk [37]. These benefits may be, in part, attributed to the presence of natural 
antioxidants in these foods, such as ascorbic acid, tocopherols, carotenoids and phenolic 
compounds (polyphenols) [39]. Interestingly, among these compounds, polyphenols have 
demonstrated highest in vitro antioxidant capacity [40]. 
Polyphenols are secondary metabolites of plants that generally involved in defence 
against ultraviolet radiation or aggression by pathogens of plants [41]. They have been 
classified by their source of origin, biological function, and chemical structure. With over 
8,000 structural variants, they denote many substances with aromatic ring(s) bearing one 
or more hydroxyl moieties. They are broadly categorized as the phenolic acids, the 
flavonoids, the stilbenes, the coumarins, and the tannins. Flavonoids are the most 
common and widely distributed group of plant phenolic compounds. Fruit and beverages 
such as berries, apples, grape, dark chocolate, olive products, tea, and red wine 
constitute the main sources of polyphenols [42]. The amount and type of polyphenols 
consumed is largely dependent on the dietary patterns of individuals and populations. It 
has previously been estimated that total polyphenol intake in western populations is 
approximately 1 g/day [43]. 
Polyphenols have been shown to have potent antioxidant/anti-inflammatory activities in 
in vitro and in vivo studies, suggesting that they could contribute to the health protective 
properties of plant foods [44]. Epidemiological evidence supports beneficial effects of 




glycaemic through different mechanisms, including the inhibition of carbohydrate 
digestion, glucose absorption in the gut or of its uptake by peripheral tissue [45]. In 
addition, observational studies have indicated an inverse association between the 
consumption of polyphenol-rich foods e.g. red wine, grape juice, tea, dark chocolate and 
olive products and the prevalence of hypertension [41]. The antihypertensive effect of 
polyphenol-rich foods for protection and improving endothelial function with vascular 
relaxation may occur via increasing NO bioavailability and inhibiting renin angiotensin 
system enzymes [46]. The polyphenol-rich extracts from foods such as apple, berries, red 
wine and green tea may also inhibit the lipase enzyme resulting in lowering lipid profiles 
and improving weight control [47]. 
The olive tree is valuable source of bioactive phenolics [48]. Olive oil, is believed to be a 
crucial constituent underpinning the health benefits of the Mediterranean diet; for 
example, supplementation with extra virgin olive oil improves modifiable cardiovascular 
risk factors in hypertensive volunteers [49]. Furthermore, there is evidence that a waste 
product of olive oil production, the olive leaf has a high phenolic content, 30-40 times 
greater than may be found in extra virgin olive oil [50]. Olive leaves (Olea europaea L.) 
have been used as folk remedy for centuries in Mediterranean and Middle Eastern 
countries. The olive leaf extract (OLE) has long been recognized as containing 
antioxidants, such as oleuropein, and hydroxytyrosol. Oleuropein is the most abundant 
phenolic in olive leaves, and has been used in a number of modern therapies [51], for 
instance, it may increase lipid metabolism in the obese, protect against oxidation of 
phospholipids in the arterial wall, an early event in cardiovascular disease [52], and 
regulate enzymes in cancer patients [53]. Other bioactive compounds in OLE also such as 
hydroxytyrosol, luteolin and rutin also demonstrate antioxidant activity; hence, olive leaf 
extract has potent anti-oxidant capacity due to the synergy of all the active phenolic 
compounds. Consuming olive leaf extract reduces some markers of chronic disease risk 
(Table 4); however, the mechanisms for these effects is still not well recognized. In 
intervention studies, olive leaf extract has been shown to reduce risk factors for CVD [54, 
55], and has both anti-inflammatory and anti-cancer activities [50, 56]. Further studies 






Table 4 Beneficial health effects of olive leaf extract on human studies 
Target group Intervention Duration Result References 
Healthy young adult 
male and female 
subjects 


















Type II diabetes 
patients 


























one capsule or 5-mL OLE 
liquid or placebo consisted 
of a 1:9.5:15 mix of vinegar, 
water, and glycerol three 
times per day 
 






treatment with: active 
control drug (Captopril) 
12.5 mg or Olive leaf 




placebo- controlled, clinical 
trial  
a tablet of olive leaf extract 
(500 mg) or matching 





and cross-over  
randomly assigned to 
receive a mouth wash 
containing OLE (333 
mg/ml), benzydamine 
hydrochloride (0.15 
g/100ml), or placebo 
(normal saline) 
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12 weeks extract (OLE; 51.1 
mg oleuropein, 9.7 mg  
hydroxytyrosol per day)or 
placebo, crossing over to 
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In addition, advocating the consumption of a supplement for health benefits is a sub-
optimal public health approach as supplement usage can be used to justify an otherwise 
unhealthy lifestyle such as physically inactive. Accordingly, evidencing the synergistic 
benefits of including a supplement as part of a healthy lifestyle is desirable. However, no 
data are yet available to investigate into health benefits associated with consuming OLE 
as part of a healthy lifestyle. 
1.3.2 Physical activity and disease prevention 
Increasing physical activity (PA) has the potential reduce all-cause mortality and improve 
life expectancy. Prospective cohort studies showed that a higher level of total physical 
activity is strongly associated with a lower risk of breast cancer, colon cancer, diabetes, 
ischemic heart disease, and ischemic stroke [62]. A classic study of CVD risk in London’s 
double-decker bus conductors and drivers demonstrated that the more active conductors 
were less likely to suffer from CVD than the inactive drivers [63]. In addition, a large 
prospective study reported that moderate physical 12, physical fitness is a good predictor 
of death amongst those with chronic disease. Figure 3 adapted from Myers et al. shows 
that subjects with a history of hypertension, or chronic obstructive pulmonary disease 
(COPD), or diabetes, or who smoking, or who had an elevated body mass index (BMI ≥ 30) 
or a high total cholesterol level (TC ≥ 5.70 mmol/L), could mitigate the relative risk of 
death from any cause with increasing exercise capacity [64].  
 
Figure 3 Relative risks of death from any cause among participants with various risk 
factors and exercise capacity (Less than 5 MET, 5 to 8 MET or more than 8 MET. Adapted 

































In 2011, the Chief Medical Officers of the UK revised the guidelines for physical activity to 
state that at least 150 minutes of moderate-intensity PA per week provides some health 
benefits for adults [65]. In a meta-analysis of 54 randomized controlled trials (2419 
participants) with intervention and control groups which differed only in aerobic exercise 
showed that exercise was associated with a significant reduction in blood pressure of 
3.8/2.6 mmHg [66]. Despite the widely reported benefits of PA, adults and children do 
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Here, the effects of consuming polyphenol-rich olive products, including olive leaf and its 
crude extract, and extra virgin olive oil, on aspects of the metabolic syndrome are 
reviewed. We have sought to summarize the available scientific evidence from dietary 
intervention trials demonstrating a role for these phytochemicals in ameliorating 
aberrant glucose metabolism, high blood pressure and elevated blood lipids, and we 
discuss potential mechanisms underpinning these observations. Searches for relevant 
literature published in English were conducted via PubMed and Science Direct. Based on 
this literature there is convincing evidence to show that olive polyphenols, independently 
of olive lipids, reduce risk factors for metabolic syndrome, in particular improving blood 
sugar and blood pressure control. There is more limited evidence to suggest that the 
consumption of olive polyphenols or related products can reduce body weight, visceral 
fat or impede weight gain, and similarly there are some limited data suggesting improved 
lipid profiles. The consumption of olive polyphenols within the context of a healthy 
pattern of food intake may, in part, explain the reduced risk of metabolic disease 











1.4.1   Introduction 
The metabolic syndrome (MetS) is characterised by a cluster of interrelated markers of ill 
health, including obesity, hyperglycaemia, dyslipidaemia and hypertension [7]; up to 25 
percent of the world’s adult population may satisfy the criteria for this syndrome [68]. 
Individuals with the MetS carry a five-fold greater risk of developing type 2 diabetes [69] 
and a two-fold increase in the risk of developing subsequent cardiovascular disease [24]. 
It is generally accepted that the MetS is related to modifiable behavioural risk factors, 
including unhealthy patterns of food consumption, physical inactivity, smoking, and 
alcohol abuse [30, 31].  
Dietary guidelines consistently emphasise the importance of placing plant-based foods at 
the core of a healthy pattern of food consumption [70]. This predominance of plant foods 
is a defining feature of the Mediterranean dietary pattern, which is also characterised by 
a high consumption of olive products. Adherence to the Mediterranean diet is associated 
with a reduced risk of MetS [71]. There may be specific benefits arising from olive 
polyphenols within the context of the Mediterranean diet [50, 72-75]. The most well 
studied bioactive small molecules present in olive products are the catecholic 
compounds, oleuropein (OL) and hydroxytyrosol (HT). Both OL and HT have established 
bioactivity, with demonstrable experimental antioxidant [76], anti-inflammatory [77], and 
antimicrobial properties [78]. These compounds are thus credited with some of the 
health benefits observed in those consuming high quantities of olive foods [79, 80]. The 
current review will present the evidence illustrating the relationship between the chronic 
supplementation of polyphenol-rich olive products and MetS. It will also discuss the 
potential mechanisms linking olive polyphenol consumption to improvements in markers 
of health. 
 
1.4.2   Phenolic content of olive products 
The olive tree is a valuable source of polyphenols [48]; these are present in the plant as 
secondary metabolites to combat pests, bacterial infection and other stresses [41]. Olive 
oil is a product of the mechanical extraction of the olive fruit; compositionally it is an oleic 
acid (MUFA) rich product with a lesser (0.4-5%) non-triglyceride component [81]. Olive 
polyphenols are found in both the lipid and the water fractions of olive oil [82]. The total 




and according to processing, storage and preservation methods [83, 84]. In refined oils, 
phenolics may be present at concentrations of approximately 62±12 mg/kg, whereas in 
high quality extra virgin olive oils (EVOO) this concentration may be much higher [72]. The 
olive leaf has even higher concentrations of total phenolic compounds relative to the 
olive fruit and olive oil: 1350 mg/kg fresh leaf [85] vs. 232 ± 15 mg/kg of EVOO [82, 86]. A 
number of olive leaf extracts (OLE) are available to consumers and are marketed as food 
supplements or nutraceuticals containing concentrated amounts of phenolics (range 
1057– 4831 mg/kg dry extract) [87]. The possibility of using phenolics extracted from 
olive leaves to enrich edible oils is also being explored [88, 89]. OL is the most abundant 
phenolic compound present in olive leaf, seed, pulp and peel of unripe olives [48, 51]. 
During fruit maturation, OL undergoes hydrolysis, yielding different products, including 
(2-(3, 4-dihydroxyphenyl) ethanol) (HT), which is the major phenolic compound in EVOO 
(14.42 mg/kg) [85, 90]. Other phenolics, namely rutin, caffeic acid, verbascoside and the 
flavone-7- glucosides of luteolin and apigenin, are also present in olive products, but in 
lower concentrations [50, 91]. The radical scavenging activity of some of these minor 
phenolics may also be very high [81], and it is feasible that the combination of phenolics, 
when consumed in a food or a crude extract, has a greater influence on the health of the 
consumer than would a purified individual compound.  
 
1.4.3   Effect of olive polyphenols on the main features of metabolic syndrome 
Manuscripts evaluated for the purposes of this review were identified using the following 
key search words: olive phenolics, olive leaf phenolics, olive oil phenolics, HT, OL. 
Abstracts were screened and papers were selected for this review where there was a 
dietary intervention involving the delivery of olive polyphenols, and where the endpoints 
were related to the metabolic syndrome, i.e. obesity, hyperglycaemia, hypertension, lipid 
peroxidation, hyperlipidaemia cardiovascular disease, diabetes mellitus. A summary of 
the identified studies is provided in Table 5.  
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Table 5 Summary of key human studies showing effectiveness of OLE and EVOO on MetS and associated risk factors  
Source Intervention Participants   Dose Main finding References 
Central 
obesity 
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(104 mg OL/day)  
or 1000 mg OLE/day 
(208 mg OL/day) 
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Source Intervention Participants Dose Main finding References 
Central 
obesity 










79 male and 
female 
(Type II diabetic 
subjects) 
500 mg OLE/day 
 
(control group receiving 
placebo) 
ns  ↓HbA1C 
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ns  ↑insulin 
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Source Intervention Participants   Dose Main finding References 
Central 
obesity 







23 male and 




30-40 g of oil per day 
 














30 days,  
A randomized 
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(healthy 
subjects) 
10 g of extra virgin 
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(control group receiving 
corn oil) 
na ↓ blood glucose  
↑ insulin 

















Replacement of culinary 
oils with extra virgin olive 
oil 
 
(control group replacing 
with 10 % corn oil and 90 
% soybean oil) 







351 male and 
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(type 2 
diabetes or ≥3 
CVD risk factors 
MeDiet + extra-virgin 
olive oil  
 
(control group receiving 
MeDiet + nuts (walnuts, 
almonds, and hazelnuts), 













Source Intervention Participants   Dose Main finding References 
Central 
obesity 








7447 male and 
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virgin olive oil 
 
(control group receiving 
MeDiet + 30 g nuts 
(walnuts, almonds, and 
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Source Intervention Participants   Dose Main finding References 
Central 
obesity 
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MeDiet + nuts (walnuts, 
almonds, and hazelnuts), 
or a control low-fat diet. 

















30 mg/day of 
polyphenols from olive oil 
 
(control group receiving 
polyphenol-free olive oil) 





↓↑, significant augmentation or diminution; ns, not significant; na, not assayed or not report




A progressive increase in total adiposity is associated with insulin resistance and all the 
other components of MetS, including increased blood pressure, glucose and lipid 
concentrations [106]. Consumption of foods rich in polyphenols including green tea 
catechins, resveratrol and curcumin are weakly associated with anti-obesogenic effects 
[107]. Further, the Mediterranean dietary pattern (MedDiet) itself is associated with a 
lower risk of obesity despite the relatively high consumption of energy rich olive oils [108, 
109]. In a follow-up of a large Spanish cohort (The SUN project) high intakes of olive oil 
were not associated with increased risk of subsequent weight gain (Table 1.) [110]. At 
least three long-term human dietary intervention studies with the Mediterranean diet 
plus a high intake of olive oil have demonstrated a reduction in body mass [99, 100, 104]. 
The Mediterranean diet has a comparatively lower energy density than the standard 
western diet; however, studies in animal models fed polyphenol-rich olive extracts 
suggest a further contributing role for olive phenolics in body weight management. In one 
study, mice were randomly divided into groups that received either a chow diet, a high-
fat diet (HFD), or a 0.15% OLE-supplemented diet for 8 weeks. The OLE-fed mice showed 
significantly reduced body weight gain, and had lower visceral fat-pad mass, compared to 
the HFD-fed mice [111]. Elsewhere mice fed a 0.03% OL-supplemented HFD for 10 
weeks showed reduced body weight gain (−55%) compared to control [112]. 
Furthermore, HT supplementation 10 mg/kg/day prevented HFD-induced obesity in mice 
at 17-weeks [113].The addition of rutin [114], luteolin [115], caffeic acid [116] and 
apigenin [117] to the diet of experimental animals have all been shown independently to 
ameliorate weight gain, liver, and adipose tissue mass. Unfortunately, human dietary 
intervention studies with polyphenol-rich OLE or with isolated olive phenolics have 
typically been relatively short in duration, and show no demonstrable reduction in body-
weight reported.  
Despite the paucity of human data showing a direct effect on either weight loss, or the 
attenuation of weight gain, potential mechanisms through which olive polyphenols might 
influence body composition have been suggested. In experimental models olive phenolics 
inhibit lipid and carbohydrate digestion in the gut [118], thereby suppressing 
macronutrient absorption and uptake [58]. In addition, in vitro and in vivo models have 




lipogenesis, induce lipolysis, and promote adiponectin secretion [119-121], possibly 
mediated through the suppression of adipogenic gene expression (PPARγ, C/EBPα, CD36, 
FAS, and leptin) at the mRNA and protein levels [111, 115, 117, 122-124]. 
 
Hyperglycaemia  
Impaired carbohydrate metabolism and insulin resistance are defining features of MetS 
[24]. Polyphenol-rich foods, including tea, cocoa, cinnamon, grapes, and berries, are 
reported to modulate carbohydrate metabolism, and attenuate hyperglycaemia and 
insulin resistance [45, 125]. Dietary supplementation with olive polyphenols has been 
shown to exert an anti-hyperglycaemic response in animal models [118, 126, 127]. For 
example, consumption of a phenolic-rich olive extract significantly decreased serum 
glucose in alloxan-induced diabetic rats after a 4 week intervention with a dose of extract 
equivalent to 8 mg/kg OL and 16 mg/kg HT [128]. Similarly, diabetic rats consuming 0.5 
mg/kg OLE for 30 days showed improved blood glucose, and increased plasma insulin 
[129]. These observations are mirrored in a study in obese diabetic mice, which also 
showed improved glucose control when fed an OL-enriched diet independently of any 
change in body weight [130]. Further, in a rabbit model of diabetes, the consumption of 
extracted OL (at 20 mg/kg body weight) reduced blood glucose after 16 weeks compared 
to controls [131].  
More importantly these anti-hyperglycaemic effects are also observed in human dietary 
intervention studies in volunteers with pre-existing elevated blood sugar [58, 60, 97, 132]. 
For example, de Bock et al demonstrated that supplementation with olive leaf extract for 
12 weeks (51.1 mg OL, 9.7 HT per day) was associated with a 15% improvement in insulin 
sensitivity in overweight middle-aged men (n=46) [60]. An intervention study in recent-
onset type-2 diabetic patients consuming 500 mg of OLE once daily led to improved long-
term sugar control as evident by a reduction in glycated haemoglobin (HbA1c) after 14 
weeks [58].  
The minor phenolics may also contribute to the observed anti-hyperglyceamic response. 
Experimental supplementation with luteolin [133] or apigenin [134] have all be shown to 
significantly decrease insulin resistance in diet-induced obese mice. Additionally, a dietary 




over 10 % in diabetic patients at 30 and 60 days compared to baseline; this was possibly 
coupled to a concurrent reduction in body weight [135].  
Potential mechanisms underpinning the anti-hyperglycaemic activity of dietary 
polyphenols have been proposed, in vitro studies show potential inhibition of amylase 
and α-glucosidase in the gut resulting in a suppressed glycaemic response to foods [136-
138]. Other studies have suggested that polyphenols exert a direct suppression of the 
proteins involved in intestinal transport of dietary carbohydrate, this has previously been 
reviewed [45]. Incidentally, green tea phenolics have been credited with directly 
stimulating insulin-mediated glucose uptake in myocytes [139], this has not, as yet, been 
demonstrated for the olive phenolics and certainly not for their circulatory plasma 
metabolites.   
 
Hypertension  
Adherence to the Mediterranean diet is inversely associated with both systolic and 
diastolic blood pressure [49]. Dietary interventions with extra virgin olive oil show marked 
improvements in blood pressure in hypertensive and pre-hypertensive volunteers. For 
example, in a crossover study in which medicated hypertensive volunteers in the south of 
Italy were asked to replace their fats with either EVOO or sunflower oil, The EVOO led to a 
reduction in blood pressure (BP) and for some a decreased reliance on anti-hypertensive 
medication [96]. Similarly, in a dietary intervention in overweight and obese US cohort, 
BP was markedly lowered when the source of fat was replaced with EVOO [98]. Moreno-
Luna et al. compared the effect of interventions with polyphenol-rich olive oil and high-
oleic sunflower oil (polyphenol-free) in hypertensive women; the olive oil rich-diet 
significantly reduced both systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
[105]. Further, Fito et al. reported a decrease in SBP after high-phenolic olive oil 
consumption but not with a low-phenolic refined olive oil, when consumed by 
hypertensive stable coronary heart disease patients [102]. These studies collectively 
suggest that the hypotensive effects of the EVOO may be due to the phenolic compounds 
and that they are not a consequence of the fat composition of the oils. However, Kaseb et 
al., induced a 10.95 mm reduction in blood pressure from baseline in hyperlipidaemic 




are low in polyphenols which would suggest quite significant anti-hypertensive benefits 
from the lipid fraction of the oil [140].  
Human dietary intervention studies with supplemental lipid-free OLE strongly support 
anti-hypertensive effects for the polyphenols. For example, a study with 40 borderline 
hypertensive pairs of monozygotic twins discordantly assigned to consume either 500 mg 
(equivalent to 104 mg OL) or 1000 mg (equivalent to 208 mg OL) of OLE daily for 8 weeks 
was performed by Perrijaquet-Moccetti et al. They observed a dose-dependent drop in 
SBP, with a mean reduction of 6 mmHg on the 500 mg dose and 13 mmHg on the 1000 
mg dose [93]. Elsewhere in a double blind, randomized, parallel and active-controlled 
clinical study, stage-1 hypertensive patients (n = 46) were given either 1000 mg 
(equivalent to 199 mg OL) aqueous OLE daily or captopril for 8 weeks. They observed 
reductions in SBP and DBP from baseline by -11.5 ± 8.5 and -4.8 ± 5.5 mmHg, respectively 
for those in the OLE group and by -13.7 ± 7.6 and -6.4 ± 5.2 mmHg, respectively for those 
in the captopril group [55]. Further, Lockyer et al. performed a randomized placebo-
controlled trial with OLE using ambulatory blood pressure as the primary endpoint. In this 
study 60 volunteers consumed either olive leaf extract, containing 136 mg OL and 6 mg 
HT, or a control for six weeks prior to crossover. They observed a reduction in 24h 
SBP/DBP of about 3 mmHg and following the intervention [61].  
These observations are also mirrored in work performed in animal models of 
hypertension. OLE  (15% w/w OL) when fed to hypertensive rats at 30 mg/kg body weight 
for 5 weeks significantly reduced SBP (−21.6 ± 5.5 mmHg) [141]. Khayyal et al considered 
the dose response to an OLE (containing 18-26% w/w equivalent of OL) in L-NAME 
induced hypertensive rats. With daily oral administration of 25, 50 or 100 mg/kg of OLE, 
they observed a dose-dependent prevention of induced blood pressure with the 100 
mg/kg dose completely preventing any rise in blood pressure after 8 weeks [142].  
The mechanisms of action for olive phenolics in the lowering of blood pressure are 
uncertain. Lockyer et al. observed a decrease in vascular stiffness relatively soon after the 
consumption of OLE in an acute human dietary intervention study [92]. This suggests that 
the phenolics influence production of nitric oxide, thereby improving vascular function in 
the short term, and with sustained consumption resulting in an improvement in blood 
pressure over the longer term. Indeed, in vitro, OL has been shown to increase NO 




of enzymes such as NADPH oxidase and nitric oxide synthase [144]. Further, OL and HT 
may act synergistically with other phenolics such as verbascoside to exert ACE inhibitory 
[145] and calcium channel blocking activities [146]. However, the phenolics themselves 
survive digestion relatively poorly, small quantities are present in the circulation as 
conjugated metabolites [147] and the specifics effects of these metabolites on the blood 
pressure control systems have not been well studied. More mechanistic studies are 
needed to fully elucidate the mechanisms involved. 
 
Dyslipidaemia  
The major components of dyslipidaemia associated with the metabolic syndrome are 
raised flux of free fatty acids, increased fasting and postprandial triglyceride-rich 
lipoproteins (TRLs), decreased high-density lipoprotein (HDL), and increased small, dense 
low-density lipoprotein (LDL) particles [148]. Exaggerated postprandial lipaemia links 
MetS to the progression of atherosclerosis [132]. Olive oil with its high MUFA content is 
shown to reduce TC and LDL-C levels when substituted into the diet in place of saturated 
fats [149]. The additional beneficial effects of the phenolics in EVOO have also been 
studied [72]. In a large multi-centre crossover trial in healthy men (n=200), Estruch et al. 
demonstrated the dose dependent improvements in plasma HDL status in response to 
increasing polyphenol concentrations in olive oils [150]. Several human chronic dietary 
intervention studies with aqueous olive leaf extracts have also demonstrated favourable 
plasma lipid responses. Perrinjaquet-Moccetti et al., Sasulit et al., Lockyer et al. and 
Fonollá J et al. all observed significant reductions in total cholesterol, LDL-cholesterol and 
triglyceride levels in human volunteers [61, 93, 94, 151]. In contrast, De bock et al. did not 
observe improvements in lipid profiles after OLE supplementation [60]. In each of these 
studies plasma lipids were measured as secondary endpoints; and therefore, more 
focussed human studies are needed to fully elucidate potential benefit of the phenolics 
independently of the oil in relation to dyslipidaemia.  
In rodent models, chronic OLE supplementation led to a reduction in total cholesterol, 
LDL-C and triglycerides [111, 152-154]. Further Ghosian Moghaddam et al. observed an 
improvement in HDL-C in diabetic wistar rats fed powdered olive leaf mixed into chow at 
6.25 % w/w [155] and Jemai et al. observed protection against dyslipidaemia in 




The evidence for anti-hyperlipidaemic effects of olive phenolics is not as strong as it is for 
anti-hypertensive and anti-diabetic effects, nevertheless potential mechanisms action has 
been postulated. In the small intestine, phenolics may inhibit pancreatic lipases, thus 
delaying post-prandial lipaemia [157], further better glucose and insulin control would 
reduce the accumulation of lipids in the liver, as observed in a cholesterol fed rat model 
[156], and potentially offset de-novo lipogenic pathways. 
 
Lipid peroxidation 
Oxidation of LDL is a free radical driven process which is believed to stimulate 
macrophage clearance of lipoproteins, and subsequently, to induce foam cell formation 
and inflammatory responses [158]. Elevated oxidized LDL is associated with increased 
incidence of metabolic syndrome and coronary heart disease [159].  
There are consistent data on the effects of extra virgin olive oil on markers of lipid 
peroxidation. The European Food Safety Authority now accepts health claims concerning 
the effectiveness of the ingestion of olive oil with high concentration of HT and its 
derivatives (5 mg/d) at suppressing lipid peroxidation [97, 102, 105, 150, 160]. It has been 
assumed that in vitro the conferred protection against oxidative stress is mediated by HT 
and its derivatives [161], however this hypothesis has never been confirmed in humans 
[162]. Further, in an eight week long chronic intervention trial with 45 mg per day pure 
hydroxytyrosol, Lopez-Huertas et al., observed no significant reduction in oxidised LDL., 
they did however report elevated serum Vitamin C in cases versus controls, suggesting 
the sparing of vitamin C for antioxidant function with HT consumption [163].     
Only one human dietary intervention study with a lipid free olive leaf extract 
demonstrated reduced LDL oxidation, with a 13% reduction in oxidized LDL reported in 
hypercholesteraemic subjects is reported in the literature and this was only presented in 
conference abstract form [94]. Protection against LDL oxidation for lipid free olive 
extracts is observed in animal models. Wistar rats fed a cholesterol-rich diet in 
combination with polyphenol-rich olive leaf extracts for 16 weeks showed reduced LDL 
oxidation, in combination with an upregulation of antioxidant enzymes [156]. Elsewhere 
mice fed 15% olive oil for 6 weeks had demonstrably reduced lipid peroxidation 
compared to controls [164]. Rabbits fed with 10% (w/w) extra virgin olive oil plus 7 mg/kg 




showed a reduction in markers of oxidative stress when given a 20 µg daily oral gavage 
with HT [123].  
In vitro, olive polyphenols inhibit copper sulphate-induced oxidation of LDL [166], and 
counteract both metal- and radical-dependent LDL oxidation [167]. The direct anti-
oxidant actions of polyphenols delivered through routine diet may however be somewhat 
less in vivo given their relatively low bioavailability and rapid clearance; Giordano et al. 
demonstrate a down regulation of the oxidative stress pathways in mouse adipocytes 
post HT consumption [168]. The influence of olive polyphenolics on the Nrf2 pathway in 
the combatting of oxidative stress has recently been reviewed by Piroddi et al., whilst not 
yet proven in man; this may be a viable mechanistic explanation for the antioxidant 
responses to olive polyphenol consumption [169].   
 
1.4.4   Discussion 
In this review, we have summarised the findings of dietary intervention studies with olive 
oil or with lipid free olive phenolic extracts, these studies have explored aspects of the 
MetS (Figure 4.) 
 




The evidence for benefits directly attributable to olive phenolics coming from human 
dietary intervention studies is strongest for the observed protection against the oxidation 
of lipoproteins, protection against hypertension and protection against hyperglycaemia. 
There is limited, but suggestive evidence for effects in dyslipidaemia and the inhibition of 
weight gain.  
In an obese age, the consumption of phenolic-rich, lipid-free valorised olive leaf products 
may be a preferential approach to ingesting these beneficial compounds. Intervention 
studies with EVOO consumed in the Mediterranean diet at quantities of up to 50g per day 
delivers a 5-20x lower dose of the phenolics than can be delivered in an olive leaf extract 
supplement. Directly replacing traditional spreads with EVOO in the UK diet (10g per day) 
would beneficially increase MUFA consumption, but would not substantially change total 
polyphenol intake. The PREDIMED intervention trial clearly demonstrates efficacy of a 
Mediterranean pattern of food consumption over a low fat diet, but does not show a 
reduction in mortality with an EVOO enriched Mediterranean over that observed for the 
same diet supplemented with nuts instead of EVOO [170].       
A current weakness of the available evidence is the paucity of data on mechanisms of 
action, approximately 60% of ingested olive oil phenols are absorbed in man, mainly in 
the small intestine, and peaking, as derivatives, in ng ml concentrations, in plasma 1-2 hr 
post consumption [171]. During digestion and with metabolism oleuropein is hydrolysed, 
and are later recovered in urine, primarily as glucuronides of hydroxytyrosol and tyrosol 
[172] [147]. In vitro, mechanistic studies have typically evaluated the effects of the un-
metabolized major phenolics at supra-physiological doses in cell systems which are often 
poorly validated against the in vivo system. Genomic and transcriptomic studies in animal 
models point to the activation of pathways involved in inflammation, oxidative stress and 
macronutrient metabolism as potential mechanisms of action [173], however further 
molecular nutrition research is still needed in order to complete our understanding of the 
interactions between the bioactive components of olive polyphenols. Further dietary 
intervention studies in which the primary outcome measure is dyslipidaemia or adiposity 






1.5 Thesis structure and General hypotheses 
1.5.1 Thesis structure 
Our starting hypothesis for the PhD was that, consuming olive leaf extract (OLE) as part of 
a healthy lifestyle would confer health benefits. In the chapter 2 we describe the 
methodologies used in our experimental works including in vitro and human studies. Then 
in the chapter 3 and 4, we present our in vitro studies offering mechanistic support 
previous observation that polyphenols present in OLE might exerts anti-hyperglycaemia 
and anti–hypertensive. In the chapter 5 we evidence the synergistic benefits of 
consuming plant (and specifically olive) phenolics alongside being more physically active 
in individuals with elevated blood pressure.  Finally, in the last chapter (chapter 6) we 
conclude with a general discussion of the study limitations, future perspective and impact 
of the studies. 
1.5.2 Hypothesis and Objective of this thesis 
Hypothesis to be tested in this study: 
 Olive polyphenols inhibit enzymes involved in glucose and fat digestion in the 
small intestine, and inhibit glucose uptake by the gut epithelia. 
 Olive phenolics may enhance NO production and/or inhibit angiotensin enzymes 
resulting in improved blood pressure control.  
 Chronic OLE consumption lowers blood pressure in pre-hypertensive volunteers. 
 There is synergistic hypotensive effect of consuming olive leaf extract combined 
with increasing physical activity in individuals with slightly elevated blood 
pressure. 
Objectives of the proposed research 
 To investigate the effects of OLE and its phenolic compounds on the inhibition of 
pancreatic α amylase and lipase activity. 
 To examine the effects of OLE on the expression of intestinal glucose transporters 
in in vitro models. 
 To assess the effects of OLE on the uptake of glucose by intestinal epithelial cell 
lines in vitro. 




 To explore the effects of OLE and its phenolic compounds on the inhibition of 
renin and ACE enzymes. 
 To determine the effects of olive leaf extract consumption by human volunteers, 
over a 12-week period, for markers of blood pressure, lipid profiles and blood 
sugar 
 To investigate the synergistic hypotensive effects of consuming olive leaf extract 
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Chapter 2 General methods 
 
2.1    Phenolic-rich olive leaf extract 
The most common species of olive tree (Olea europaea) is a source of the olive fruit and 
olive leaf from which phenolics can be extracted [1]. Traditional methods of recovering 
polyphenol rich fractions from olive leaf include, maceration and Soxhlet extraction. 
Soxhlet extraction increases the yield of recovered phenolics [2]; however the maceration 
method is the easier approach, is separates soluble phenolic compounds by diffusion, 
briefly a large cloth sack containing milled fresh leaves is placed in boiling vats of water, 
then the solvent is evaporated and a concentrated extract solution is left behind as the 
product [3]. OLE products are now available for human consumption either as liquid or 
capsules.  Comvita® produce the OLE product used in the experimental work presented in 
this thesis, via the maceration extraction protocol. Comvita® OLE capsules are produced 
by mixing the dried extract with a safflower oil carrier. For the liquid extract product, the 
crude extract is mixed with glycerol and water for stability (Figure 5). 
 
Figure 5  The range of commercial OLE products (Comvita, New Zealand), which are 
marketed for general health-promoting effects. 
 
Phenolic compounds present in olive leaf extract are shown in Figure 6. They may be 
divided into different groups with regard to major molecular characteristics: secoiridoids 
(oleuropein); flavones (luteolin-7-glucoside, apigenin-7-glucoside, diosmetin-7- glucoside, 
luteolin, and diosmetin); flavonols (rutin); flavan-3-ols (catechin), and substituted phenols 




content of OLE is influenced by several factors; the harvest seasonal, industrial processing 
techniques such as drying conditions, extraction techniques, storage and preservation 
methods [5,6]. In the same olive-leaf cultivars, dried olive leaf has a higher concentration 
of oleuropein than the fresh leaf;  On a dry matter basis the oleuropein concentration of 
the olive leaf may reach up to 140 mg/g on a dry matter basis in young olives and 60-90 
mg/g of dry matter in the leaves [7]. Olive leaf dried at room temperature provides higher 
oleuropein content than those dried at 50˚C [8].  


































2.2    The fate of dietary olive phenolics 
Studies have been performed looking at the absorption of phenolics after consumption of 
olive oil consumption [9, 10]. Vissers et al. suggest that ~60% of ingested olive oil phenols 
are absorbed in man, mainly in the small intestine 1-2 hrs post consumption. after 
absorption, oleuropein may be hydrolysed, and as is recovered in urine as hydroxytyrosol 
and tyrosol [9]. Hydroxytyrosol may enter intestinal cells via passive diffusion [11]. 
Oleuropein as a glycoside is larger and more polar, entry into the enterocytes may 
therefore be mediated via the sodium-dependent glucose transporter (SGLT1) although 
its large size renders it poorly absorbed [12]. OLE contains a predominance of oleuropein 
glycoside, versus the oleuropein aglycone abundant in olive oil [13], therefore the 
bioavailability and metabolism might be difference the two. However, the bioavailability 
of OLE polyphenols is still unclear, and highly dependent on a number of factors, including 
preparation (capsule/liquid) [14]. Oral administration of a single dose (100 mg/kg) of 
oleuropein in rats allowed the unmodified oleuropein in plasma reaching a peak value of 
200 ng/ml within 2 hrs [15]. In a human intervention trial, de Bock et al., studied the fate 
of oleuropein and hydroxytyrosol ingested as OLE over 24 hr using an LC-ESI-MS/MS 
based analysis of plasma and urine samples. Peak oleuropein concentrations in plasma 
were greater following ingestion of liquid OLE as opposed to capsule preparations (0.47 
versus 2.74 ng/mL; p = 0.004). Conjugated metabolites of hydroxytyrosol (sulfated and 









2.3    Potential mechanisms explaining the anti-glycaemic activity of 
polyphenol rich olive leaf extract 
 
The inhibition of the digestive enzyme pancreatic α amylase and lipase and/or the down 
regulation or inactivation of well as glucotransporter (GLUT2 and SGLT1) in the gut are 
potential therapeutic mechanisms to improve glycaemic control [16, 17].  
2.3.1 Inhibition of α- amylase activity 
α–amylases (α -1,4-glucan-4- glucanohydrolases) of both salivary and pancreatic origins 
are key enzymes in the digestion of dietary carbohydrate [18]. They catalyse the 
hydrolysis of internal α-(1,4) glycosidic linkages in starch releasing maltose and other 




Figure 7  The hydrolysis of starch by α–amylases.  
 
Methods for determination of carbohydrate activity are typically based on the analysis of 
reducing sugars (RSs) formed as a result of the enzymatic hydrolysis of the glycosidic 
bond. The 3, 5- dinitrosalicylic acid (DNS) assay described by Miller is the most 
widespread assay used, and has also been recommended by the IUPAC commission on 
biotechnology for measuring standard cellulase activities against filter paper and 
carboxymethylcellulose (CMC) [19]. In addition, the DNS assay is simple, inexpensive and 
sensitive, and a given solution requires only one standard curve for each sugar [20]. After 
enzymatic activity, a carbonyl group (C=O) of maltose participates in an oxidation-
reduction reaction with DNS (maltose is oxidised into maltonic acid and 3,5-dinitrosalicylic 




(yellow to orange or red with maximum absorption at 540 nm, depending the intensity of 
maltose produced) (See Figure 8 below) [21, 22]. The colour produced is permanent, 
therefore it is unnecessary to pay special attention to the control of the conditions [20]. 
Due to the stability of enzymes, the optimum pH value for pancreatic amylase is 6.7-7 
[23]. 
 
Figure 8  Oxidation-reduction between maltose and DNS. 
 
A standard curve of absorbance at 540 nm against a known concentration of maltose was 
constructed to establish the dose response of the DNS method. The coefficient of 
determination = 0.979, and the inter-assay coefficient of variation was 8.69% (n=3)) 
(Figure 9). 
 
Figure 9 Maltose standard curve for a -amylase inhibitory assay.  
y = 0.3547x 






























Acarbose is a pharmacological inhibitor of amylase that has been used for the treatment 
of diabetes mellitus; although adverse gastrointestinal effects, such as diarrhoea and 
abdominal discomfort limit its utility [24]. Acarbose isolated from Actinoplanesis is a 
pseudotetrasaccharide with a conduritol ring at the non-reducing terminus (Figure 
10a)[25, 26]. It competitively inhibits α–amylase in the brush-border of the small intestine 






Figure 10  (a) Chemical structures of acarbose and (b) Mechanism of pancreatic α– 




The limitations of the DNS method are due to practical difficulties that occur during the 
require boiling or heating steps for colour development [29], and more pressingly that 
DNS reagent strongly interferes with the OH groups of polyphenols such as EGCG, which 
partially reduces the potential inhibition of α–amylase [30]. The Lineweaver-Burk plot is 
used to determine the binding potential of an enzyme, determined the initial velocity of 
the hydrolysis reactions catalysed by α–glucosidase, and found that hydroxytyrosol binds 
with free enzyme or with the enzyme-substrate complex (non-competitive) (Figure 11a) 
whereas, oleuropein only binds to the enzyme-substrate complex (uncompetitive 















Figure 11  (a) Mechanism of pancreatic α– amylase inhibition by Hydroxytyrosol and (b) 
Oleuropein. 
2.3.2 Lipase inhibition assay 
Hyperglycaemia may be precipitated by the availability of lipid for muscle which can 
induce insulin resistance, regulating the rate of lipolysis may therefore also be beneficial 
[32]. Excess free fatty acid competes with glucose for uptake by peripheral tissues and 
influences endogenous glucose production [33]. Ingested fats are metabolized and 
absorbed in the intestine [34]. Human pancreatic lipase is an enzyme secreted from the 
pancreas, with responsibility for hydrolysing the triglycerides (fats) into three fatty acid 
and glycerol [35]. To investigate lipase inhibitory activity, the esters of long chain fatty 
acids, such as p-nitrophenyl laurate, were used as a substrate in our experiment [36-38]. 
The liberation of p-nitrophenol from through hydrolysis a simple and cheap colorimetric 
method of detecting lipase activity [39]. The limitation of this assay is that the reaction 
can only be performed at moderately alkaline pH which may not be suitable for some 
lipases [40]. Orlistat is an anti-obesity drug approved and authorized in Europe, which 
inhibits gastric and pancreatic lipases; thus, it was used as positive control in our study 




Streptomyces toxytriciniis (Figure 12a)[34]. Orlistat is a competitive inhibitor of pancreatic 
lipase which binds covalently to the serine residue of the active site of gastric and 





Figure 12  (a) Chemical structure of orlistat [34]and (b) Mechanism of pancreatic lipase 




A standard curve of absorbance at 540 nm was established for known concentrations of 
p-nitrophenol (PNP) to establish the dose response to the lipase inhibition assay. The 
coefficient of determination was 0.998, and the inter-assay coefficient of variation was 
4.95% (n=3)) (Figure 13). 
 
Figure 13 P-nitrophenol (PNP) standard curves for pancreatic lipase inhibitory assay. The 
standard curve was also generated each time the assay is performed. 
 
2.3.3 Intestinal glucose transporter expression  
Glucose is the main product of carbohydrate digestion; it is very hydrophilic and cannot 
cross biological membranes unaided [44]. In the intestine (see Figure 14 below), glucose 
molecules are absorbed into enterocytes by active transport via the sodium-dependent 
glucose transporter SGLT1 and released into the circulation by facilitated sodium-
independent transport via the glucose transporter GLUT2; conversely, suppression of 
both transporters is strongly related to lowering glucose absorption[44, 45]. 
  
y = 0.115x 



























Figure 14  Absorption of glucose molecules by the enterocyte [44]. 
 
In our study, we have tested the effects of OLE on the sugar transporters GLUT2 and 
SGLT1 in intestinal Caco-2 cells, which express high levels of both transporters [44]. The 
human intestinal Caco-2 cell line represents an excellent in vitro model system for the 
study of drug and nutrient transport and metabolism [46]. These cells are originally 
obtained from a human colon adenocarcinoma; in culture, it exhibits a well-differentiated 
brush border on the apical surface and tight junctions [47] which is akin to the small-
intestinal enterocyte phenotype [48]. Initially suitable exposures OLE and phenolics were 
established by assaying their effect on cell viability in a cytotoxicity assay. DAPI or 4', 6-
diamidino-2-phenylindole is a blue fluorescent nucleic acid stain, which was used to 
quantify both live and fixed caco-2 cells [49]. Further to determine relative gene 
expression, quantitative, or real time, PCR (qPCR) is widely used [50]. PCR or the 
Polymerase Chain Reaction is a technique for amplifying DNA, real-time PCR has become 
a well-established procedure for quantifying levels of gene expression in real-time. SYBR 
Green is a fluorescent DNA binding dye, which specifically binds double-stranded DNA by 
intercalating between base pairs, and fluoresces only when bound to DNA. During the 
PCR cycle, an increase in reporter fluorescent signal at the end of the extension step is 




weakness of intercalating dyes is that they are non-specific, so a combination of primers 
and master mix in the reaction is required to produce a single gene-specific amplicon. 
2.3.4 Glucose uptake assay 
The determination of apical uptake refers to the amount of glucose inside the cell, and 
the amount of glucose in the basolateral side, representing the amount that passes 
through the apical and basolateral side which could be an indicator of how polyphenols 
might obstruct this process [44]. Glucose uptake is typically performed by using 
radiolabelled glucose. The rate of uptake of radioactively tagged glucose in differentiated 
caco-2 cells help to analyse the glucose uptake activity and the effect of plant extract on 
the glucose uptake activity. Treated cells with plant extracts elicit the translocation of 
glucose transporters to the cell surface allowing radiolabelled glucose enters the cell 
alongside with the normal glucose. The amount of radioactivity in labelled samples is 
directly measured are detected by using liquid scintillation counter. In scintillation 
counting, after radioactive samples combined with a liquid scintillation cocktail, the decay 
of radionuclide produces an ionizing particle. These particles are converted into light 
photons which can be detected by a liquid scintillation counter [51].  
The glucose uptake assay was initially developed and validated by Manzano et al. when 
running it we used phlorizin and phloretin as positive controls and ran an untreated 
negative control. The inter assay coefficient of variation for the controls was 1.61% and 
1.72%, respectively (n=3).Therefore, cells were cultured in 3 flasks in biologically 










2.4    Investigating the mechanisms underpinning the anti-hypertensive 
activity of olive leaf extract 
2.4.1 Determination of Endothelial Nitric Oxide Production 
In the vasculature, an imbalance of Nitric oxide (NO) and Angiotensin II (Ang II) has been 
implicated in the pathophysiology of hypertension [52]. Increasing the production of NO 
and modulating Ang II results in vasodilatation [53]. In endothelial cells, NO is synthesized 
by endothelial nitric oxide synthase (eNOS) via the conversion of L-arginine to L-citrulline 
in the presence of O2 and NADPH (Figure 15) [54]. 
 
 
Figure 15   The biosynthesis of nitric oxide from L-arginine [54]. 
 
Human umbilical vein endothelial cells (HUVECs) isolated from the umbilical cord are 
typically used as a model system for the study of the regulation of endothelial cell 
function [55]. It provides a simpler alternative to screen the vasoactive potency of 
compounds [56]. However, NO production of HUVEC becomes limited with a high number 
of passages [57]. In our study, production of NO by HUVEC was measured by the Griess 
reaction, which is the indirect determination of NO through the spectrophotometric 
measurement of its stable decomposition products (NO3
− and NO2
−) [58]. Since the Griess 
reaction is specific for nitrite, enzymatic reduction of nitrate to nitrite is required prior to 
react with the Griess reaction [59]. NO2
−  reacts with a diazotizing reagent, such as 
sulfanilamide (SA) (HO3SC6H4NH2), under acidic conditions to form a transient diazonium 
salt (HO3SC6H4–N N




ethylenediamine (NED) (C10H7NH2), to form water-soluble azo dye (HO3SC6H4–N N–













Standard Nitrite and Nitrate + Nitrite curve was constructed to establish the linearity of 
the Griess assay, coefficients of determination were 0.999 and 0.998 respectively. The 







Figure 17 (a) Nitrite standard curve (b) Nitrate + Nitrite standard curve. The standard 
curve was generated each time the assay is performed. 
 
y = 0.0133x + 0.0071 






















Nitrite concentration (µM) 
y = 0.0123x + 0.0174 



























2.4.2 Inhibition of the renin-angiotensin system (RAS) enzyme activities 
Angiotensin II (Ang II) is a multifunctional peptide hormone of the renin-angiotensin 
system (RAS) [60]. Renin, released from renal juxtaglomerular cells, and angiotensin I-
converting enzyme (ACE), produced by endothelial lung cells, are two principal enzymes 
involved in RAS [61]. Renin cleaves the N-terminus of angiotensinogen to yield 
angiotensin I, which further hydrolysed by ACE to release a potent vasoconstrictor 
(angiotensin II) [62]. Angiotensin II acts directly on blood vessel cells stimulating 
vasoconstriction and also triggers the adrenal gland to release aldosterone, which acts on 
the kidneys to stimulate reabsorption of salt and water (Figure 18) [63]. Inhibition of both 
renin and the ACE enzyme would be therefore an attractive strategy for the control of 
hypertension [64]. 
 








2.4.3 Renin inhibition assay 
In our renin inhibition assay, the renin synthetic peptide substrate; Arg-Glu(EDANS)-Ile-
His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(DABCYL)-Arg, was used to incorporate the renin 
cleavage site that occurs in the N-terminal peptide of human angiotensinogen. Renin 
cleavages a (fluorophore-EDANS) to brightly fluorescent (peptide-EDANS), which can be 
easily determined using fluorescence plate reader, with an excitation of 335-345 nm, and 
an emission wavelength of 465-510 nm [65]. Aliskiren, the orally effective renin inhibitor, 
was used as positive control, it is used clinically to treat patients with hypertension [66].  
Aliskiren is a highly selective, tight-binding inhibitor of human renin, and can be seen to 
occupy the S3 to S2’subsites, thereby blocking the catalytic function of the enzyme 
(Figure 19) [67]. 
 
 
Figure 19  General view of aliskiren in the binding complex with human renin [67]. 
 
A commercial kit was used to perform this assay. It has been validated by the Cayman 
Chemical Company. Intra-assay coefficient of variation = 2.9% (n=75). Inter-assay 





2.4.4 ACE inhibition assay 
ACE inhibition has been widely used as a therapeutic approach to improve endothelium-
dependent vasorelaxation [68]. A Spectrophotometric assay for measuring the inhibition 
activity of OLE on ACE was used. N-(3-(2-furyl)acryloyl)-phe-gly-gly (FAPGG) performs one 
of the highest activities with ACE [69]; therefore it was selected as substrate. During the 
assay the internally quenched fluorescent synthetic substrate, FAPGG, is hydrolysed by 
ACE leading to the production of amino acid (furanacryloyl-L-phenylalanine, FAP) and 
dipeptide (glycylglycine, GG) [70]. The final absorbance of FAP is only measured, since GG 
could not absorb at 340 nm [71].  A potent synthetic ACE inhibitor such as captopril was 
use as positive control. Captopril inhibits competitively the activity of ACE, a sulfhydryl 
(SH) group of captopril chelates the zinc ion contained in the active site of the ACE 
enzyme (Figure 20) [72]. 
 








A standard curve of absorbance at 340 nm versus a known concentration of [N-(3-[2-
furyl]acryloyl)-l-phenylalanine] (FAP)+[glycylglycine] (GG) was constructed to establish the 
dose response for this assay. The coefficient of determination was 0.993 and inter-assay 




Figure 21 Standard curve of [N-(3-[2-furyl]acryloyl)-l-phenylalanine] (FAP)+[glycylglycine] 







y = 1.3599x 





























2.5   The synergistic anti-hypertensive effects of consuming olive leaf 
extract alongside increasing physical activity 
2.5.1 The ambulatory blood pressure measurement 
Ambulatory blood pressure monitoring (ABPM) is a non-invasive blood pressure 
measuring technique that provides a profile of blood pressure behaviour over a period of 
time-usually over a 24 hr period and identifies of individuals with a white coat response 
[73]. ABPM uses an oscillometric method to detect blood pressure, the cuff is inflated 
until the pressure occludes flow within the brachial artery in the arm, when the pressure 
in the cuff is greater than the blood pressure inside the artery, blood starts to flow 
initiating fluctuations in the arterial wall, the pressure in the cuff when blood first passes 
through the cuffed region of the artery is an estimate of systolic pressure, and the 
pressure in the cuff when blood first starts to flow continuously is an estimate of diastolic 
pressure [74]. A large variety of ambulatory blood pressure measurement devices are 
now available on the market, the A&D Medical Ambulatory Blood Pressure Monitoring 
System (Model TM-2430, Scan Med, A&D Medical, UK) is an automated oscillometric 
upper-arm ABPM device, which has been evaluated for measurement accuracy using the 
1990 and 1993 British Hypertension Society (BHS), European Society of Hypertension 




Figure 22  The A&D Medical Ambulatory Blood Pressure Monitoring System (Model TM-




This device has been verified accurate across the whole range of age and blood pressure 
level, and its performance does not vary according to sex [75]. To initiate ABPM, the TM-
2430 recorder must be connected to the computer and be ready for operation via the 
multilingual Doctor Pro™ software. The software of the device issued to the volunteers 
will be programmed in accordance with British Hypertension Society guidelines to obtain 
measurements of BP and heart rate every 30 minutes between 07:00 and 21:59 hr, and 
every 60 minutes between 22:00 and 06:59 hr. The first two readings were excluded. To 
ensure accurate and appropriate data collection, subjects were asked to wear the 
monitors for a duration of 25 hrs. 
The display of the device indicates the clock. The key to successful ABPM is educating the 
volunteer in the process of monitoring and instructions should be explained and printed 
on a diary card [73]. Volunteers were asked to maintain habitual physical activity levels on 
the day of the blood pressure recording. When the measurements are complete, data are 
downloaded; the quality of the recording can be checked. Number of measurements 
necessary for day time and night-time should be greater than 14 and 7 systolic and 
diastolic blood pressure measurements, respectively [76]. The most popular methods of 
analysing blood pressure values recorded during the 24 hrs cycle is to assess the time of 
awakening and sleeping from a diary card of activities, and to use a fixed time method in 
which the daytime period is set at 0900 to 2100 hrs and the night-time from 0100 to 0600 
hrs; however, variations of the fixed time method that may possibly occur between the 
young and the old and in different cultures are to some extent excluded from the analysis 
[73].  
2.5.2 Digital Volume Pulse (DVP)  
A digital volume pulse (DVP), an accurate, simple, inexpensive and non-invasive 
photoplethysmography technique to analyse the peripheral pressure pulse waveform is 
suitable for use in large-scale trials [77]. Previous study has recently shown that DVP is 
ideal for pharmacological studies in which continuous monitoring of drug effects is 
required [78]. The DVP measures infrared light transmission at 940 nm through the finger 
pulp, and the amount of back scattered light is directly proportional to the wave-like 
movement of blood from the aortic root to the finger [77]. The DVP waveforms provide 




correlated to arterial stiffness, and the reflection index (RIDVP) which relates with 
vascular tone [79]. For measurement of the SIDVP, all subjects rested in bed supine for 15 
minutes in a quiet room prior vascular function measurements and the measurement was 
performed by a single trained investigator. A photoplethysmographic probe (Micro 
Medical, Kent, U.K.) is placed on the index finger of the right hand to obtain the DVP. 
Blood pressure and DVP waveforms will be recorded 3 times over 10 second periods with 
5 minute intervals between measurements. The DVP waveform has two components. The 
first part of the waveform (systolic component) is formed as a result of pressure 
transmission along a direct path from the aortic root to the finger (a). The second part 
(diastolic component) is formed by pressure transmitted from the ventricle along the 
aorta to the lower body where it is reflected back along the aorta to the finger (b). The 
average peak-to-peak time (PPT), as the time interval between the first and the second 
peaks of a DVP, for each measurement will be calculated using the Pulse Trace PCA2 
Software (Micro Medical, Kent, U.K.) (Figure 23a). SIDVP will be calculated by dividing the 
PPT value into height in metre and multiplying the result by 1000 to convert the result 
into m/sec. The reflection index (RIDVP) is calculated as the height of the diastolic peak of 
the DVP relative to that of the systolic peak expressed as a percentage of the total 












Figure 23  (a) PulseTrace PCA2 Software (Micro Medical, Kent, U.K.), and (b) The DVP 
waveform and its characteristic parameters as: time between the first and second tip 
(PPT), amplitude of the first tip identified by (a), amplitude of the second tip identified by 
(b).  
 
2.5.3 Motivating physical activity 
The World Health Organization (2011) defined physical activity as “any bodily movement 
produced by skeletal muscles resulting in energy expenditure, includes all forms of 
activity such as leisure time physical activity, transportation (e.g. walking or cycling), 
occupational (i.e. work), household chores, or structured exercise”. Changing physical 
activity behaviour is a big challenge for public health. The four home countries’ Chief 
Medical Officers recognised the importance of physical activity and launched “Start 
Active, Stay Active” campaign recommending that "adult should do at least 150 minutes 
of moderate-intensity physical activity or at least 75 minutes of vigorous aerobic activity 
every week and strength exercises on two or more days a week” [81]. Achieving the 
recommended levels of physical activity has been shown to reduce the risk of the 
development of a number of chronic diseases such as type II diabetes, cardiovascular 
disease and cancer, to improve bone function and also to enhance energy balance and 
weight control [82]. However, public health strategies now focus on regular moderate-
intensity physical activity as part of an activity lifestyle rather than on structure 




is incorporating into daily routines, for example by using the stairs instead of lifts, walking 
or cycling instead of driving, and taking up more active hobbies such as gardening, 
painting.  Physical activity interventions for adults have been predominantly focused on 
walking [84-86]. Walking is commonly associated and utilized in everyday activities, thus 
it is an excellent way for most inactive people to begin regular exercise [87]. Computed 
translations of free-living physical activity study mentioned that recommended 
moderate-to-vigorous physical activity are equivalent to 7,100 to 11,000 steps/day [88]. A 
review of physical activity promotion recommended that brisk walking has the greatest 
potential for increasing overall activity levels of a sedentary population and meeting 
current public health recommendations [89]. A package intervention consisting of self-
monitoring, goal setting, and feedback has been achieved to increase physical activity in 
healthy adults [90]. Physical activity is a complex multi-dimensional construct; thus, 
accurate measurement of physical activity is required to monitor physical activity level 
and better define the dose response relationship between physical activity and health. 
Self-report and objective measures are available to assess free-living physical activity [91]. 
Self-report tools include questionnaires, diaries, logs and recalls, are the simplest and 
cheapest for collecting physical activity data from a large scale of people in a short time, 
but the least accurate including recall bias [92]. Objective methods such as motion 
sensors: pedometer and accelerometer are the best option of estimating energy 
expenditure (EE) [93]. They can provide more accurate information than self-report 
measures, but resources and expertise are required to collect and manage the data [94]. 
Pedometer is increasingly used in physical activity research and health promotion 
initiatives, and most sensitive to walking behaviours [95]. It is a convenient, inexpensive 
tool for estimating of physical activity volume by counting the numbers of steps taken 
and relating the count to guideline equivalents of physical activity [96]. Previous studies 
showed that the use of a pedometer is associated with significant increases in physical 
activity and significant decreases in blood pressure [97]. Although pedometers are 
extensively used as a physical activity–monitoring tool, they are unable to measure 
activity intensity [98]. Nowadays, advanced pedometer models such as Omron 
pedometer HJ-322U-E (Milton Keynes,UK) are available, and seem to provide valid and 
reliable step counting information in both lab-based and free-living settings [99]. Reviews 




with data from accelerometers under free-living conditions [100]. Omron pedometer HJ-
322U-E has a dual-axis acceleration sensor which counts steps when it is placed 
horizontally or vertically, and comes with a USB cable and software for installation on a 
personal computer.  A researcher can set up a user account for each volunteer, connect 
the pedometer to the computer with the USB cable, and click a button to download the 
activity data. Moreover, it also provides an online database (Omron Bi-LINK) to keep track 
health and fitness data, and to set goals. The device stores 7 days of information including 
total step/day, distance, calories burned, aerobic steps on the display and stores 22 days 
in the memory. Aerobic steps are counted separately when walking more than 60 steps 
per minute and more than 10 minutes continuously which can be referred to brisk 
walking. This type of pedometer is unaffected by body mass index and can be worn to 
count an individual’s steps at different positions on the body: at the hip, in the pocket or 
clipped to a bag [101]. However, it is important to be aware of the effect of stride length 
on each person; for example, those with shorter stride lengths will accrue a greater 
number of steps than those with a longer stride length. Thus, the correct average stride 
length is measured by divided the total length of ten steps. Omron pedometer HJ-322U-E 
were given to participants who were in physical activity group. Participants were 
instructed to wear pedometer either in their pocket or clipped with their belts for 12 
weeks. Besides, they were instructed to use the pedometer during the day as 
motivational tools, and to upload their pedometer data every weekend via Omron Bi-LINK 
software where they could track their overall physical activity progress themselves 










Figure 24  (a) Omron pedometer HJ-322U-E (Milton Keynes,UK), and (b) Omron Bi-LINK; 
an online database. 
 
3 days of pedometer data is sufficient to estimate free-living adult pedometer-
determined physical activity in a week [102], and pedometer data collection over a 7-day 
period is reliable estimate of monthly activity in adults [103]. The pedometer is most 
effective as a motivational tool when feedback is used in combination with individualised 
goal-setting and self-monitoring methods [94]. Goal-setting strategies have been used in 
pedometer-based interventions such as a generic fixed goal of 10,000 steps per day [104], 
a fixed increment steps per day over baseline [105, 106]. However, for inactive people, 
goals have to be individualized to feel confident of being achievable, an absolute step 
target may be de-motivating if it appears unachievable [107]. Strategies to improve 
compliance with increasing physical activity include the completion of an activity 
monitoring diary, reminder calls, SMS/email reminders, motivational hint sheets [93]. The 
use of daily activity records should be encouraged as a tool to increase self-efficacy and 
potentially long-term changes in behaviour, since the act of keeping a daily record needs 
conscious thought about activity levels and serves as a reminder to exercise [108]. A 




programmes who recorded their daily step count significantly increased their physical 
activity than those who were not required to record their data [97]. Regular follow-ups 
via mobile text message from healthcare professionals could help patients’ self-
monitoring of goal achievements [109]. Moreover, motivational physical activity 
interventions such as educational and motivational content [110] are modestly effective 
in changing physical activity behaviour among healthy adults [111]. The motivational 
messages including the benefits of exercise and some tips (e.g. walk up the stairs instead 
of taking the lift, get off the bus one stop earlier) and informed of the public health 
guidelines for physical activity are very important to increase awareness of behaviour 
[112, 113]. In our intervention trial participants received weekly motivational hint sheets 
through the post to encourage continued engagement in routine exercise on a regular 
basis over 12 weeks. Each sheet outlined some of the benefits of exercise and offered 
easy tips to be more active, and also provided diary for participants to record their total 
steps and other exercises in each day. (see Figure 25 below). 
 
 




An accelerometer is more sophisticated than pedometer since it can measure the 
intensity of body movement each minute in one (uniaxial), two (biaxial) or three (triaxial) 
planes [117]. Thus, the physical activity data collected with the pedometer was validated 
against data collected using the accelerometer in our study. There are many commercially 
available accelerometer models. ActiGraph GT3X (Pensacola, FL, USA) activity monitors 
were used in our study, have been widely used as tools to measure activity including 
water-based activity in many research and clinical applications [118, 119]. They include 
both a micro-electro-mechanical system (MEMS) based accelerometer that is capable of 
measuring acceleration in three planes (vertical, front-to-back, and side-to-side) and an 
ambient light sensor. It is usually worn at the waist, and does not have a display screen to 
provide feedback to the user; therefore, it is intended for measurement of physical 
activity, not for motivating people to physical activity (Figure 22) [120].  
 
 
Figure 26  ActiGraph GT3X (Pensacola, FL, USA) activity monitor. 
 
Physical activities are regularly measured by determining the energy expenditure in 
kilocalories or by using the metabolic equivalent (MET) of the activity [121]. ActiGraph 
GT3X activity monitors are designed to monitor human activity and record energy 
expenditure (calories spent during normal activity, METs, everyday activity, and exercise). 
Device initialization, data processing and analysis were conducted using Actilife Data 
Analysis Software (Version 6.13.3). Raw data were collected from 7 am. on the first day of 
monitoring at a 30 Hz sample rate. At least 3–4 days of monitoring are needed to achieve 




as well as weekend days need to be included [124]. Therefore, participants were 
instructed to wear device directly above the right iliac crest during sleeping and waking 
hours (except for during water-based activities) for four days, including three weekdays 
and one weekend day. Participants also were required to completed a 4-d activity diary in 
order to data cleaning purposes. For analysis inclusion, participants were needed to have 
made counts on their activity monitor for ≥ 3-d (> 600 min/d of wear time) [125]. Non-
wear-time was defined as ≥ 60 min of zero activity counts [119]. Data were summarized in 
60-s epochs and mean energy expenditure from PA (EEPA) was calculated (kcal/d). Data 
were summarized in 60-s epochs [117] and cut-points were used to classify wear time as: 
sedentary behavior (< 100 counts/min), light/lifestyle PA (760 - 1951 counts/min), 
moderate PA (1952 - 5724 counts/min), vigorous PA (≥ 5725 counts/min) [126]. The 
Freedson equation is commonly used to calculate the cut-points for light, moderate, and 
vigorous activities, and it has been shown to have good agreement with time spent in 
different intensity categories [127].  
However, to correctly interpret physical activity data, it is vital to account for the fact that 
the activity levels may also vary according to the season. Previous studies have indicated 
that adults in the UK displayed higher physical activity level in the summer in comparison 


















overweight female (aged 40 -65 y, n=18) 
SBP (8 mmHg) and DBP (5 mmHg) 
[130] 
 
obese male (aged 32 -59 y, n= 31)  
SBP (13 mm Hg), DBP (7 mmHg) 
[86] 
 
Healthy, sedentary (aged 50-65 y, n=31) 
SBP (11.82 mm Hg), DBP (4 mmHg) 
[131] 
 
Mild hypertensive patients  
(aged 47± 1 y, n= 730)  
SBP (10.2 mm Hg), DBP (8.4 mmHg) 
[84] 
 
Type II diabetes patients (aged 30-74 y, 
n=39) 
SBP (8.4 mmHg), DBP (5.2 mmHg) 
[132] 
 
The stage-1 hypertension patients 
(aged, 43-58 y, n=232) 





(aged 18-65 y, n= 60) 
24hr SBP (3.33 mmHg), Day SBP 
(3.95 mm Hg), 24hr DBP (2.42 mm 
Hg), Day DBP (2.48 mm Hg), FTM 













Type II diabetes patients (aged 40-70 y, 
n=40) 
 HbA1c (0.75mmol/mol)[135] 
 
Type II diabetes patients (adult, 











Healthy male  
(aged 37±9 y, n=44) 




The stage-1 hypertension patients 
(aged, 43-58 y, n=232)  




(aged 18-65 y, n= 60) 






Healthy male  
(aged 37±9 y, n=44) 
TNF-α (0.12pg/ml)[137] 
 
Consecutive cancer patients (aged 
20.5± 9 n=25) 




Table 6 Comparison of the health benefits of olive leaf extract versus physical activity in 
human studies 
 
Table 6 illustrates the common endpoints of intervention studies of both physical activity 
and olive leaf; increasing physical activity level or consuming olive leaf extract reduce 
blood pressure; consequently, in this aspect of the study, blood pressure will be used as 
the primary endpoint with anticipated synergistic benefits for consuming olive leaf 
extract alongside achieving the recommended guidelines for physical activity. Secondary 
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Abnormal postprandial hyperglycaemia is a feature of insulin resistance and is considered 
a risk factor for metabolic and cardiovascular disease. A previous twelve-week 
randomized, double-blinded, placebo-controlled, crossover dietary intervention study 
with olive leaf extract led to improved insulin sensitivity in overweight men; the 
mechanisms for this effect remain uncertain. We hypothesis that olive polyphenols inhibit 
enzymes involved in glucose and fat digestion in the small intestine, and inhibit glucose 
uptake by the gut epithelia. The inhibitory action of OLE and its principal polyphenols, 
hydroxytyrosol and oleuropein, on the intestinal digestive enzymes α-amylase and lipase 
were assessed in vitro. Further, the level mRNA expression for genes encoding intestinal 
glucose transporters (SGLT1, GLUT2) was assessed in Caco-2 cells using real time PCR. 
Glucose uptake in Caco-2 cells was assessed using 14C-labelled glucose. OLE inhibited 
pancreatic amylase activity with an IC50 value of 3.23 ± 0.33 mM and inhibited pancreatic 
lipase, IC50 1.83 ± 0.03 mM. Cells treated with OLE show reduced glucose uptake and a 
decrease in the expression of both glucose transporters compared to untreated control. 
Our data suggest mechanisms that might explain previously observed anti-glycaemic 
effects of OLE and add weight to growing evidence that olive phenolics may be useful as 











3.1  Introduction 
With an ageing and increasingly overweight global population the WHO projects a surging 
prevalence of type 2 diabetes by 2030 to nearly 4.4% of the population, up from 2.8% in 
2000 [106]. Elevated postprandial hyperglycaemia is evident prior to the onset of type 2 
diabetes, and poor blood sugar and lipid control in the diabetic condition, are associated 
with complications, including liver toxicity, renal dysfunction, obesity and cardiovascular 
disease [107]. Intervention studies have demonstrated that blunting postprandial spikes 
in glucose and lipids decreases inflammation and improves endothelial function [108]. 
Thus, dietary, lifestyle or pharmacological approaches to attenuate these spikes may 
benefit those with impaired glucose tolerance.  
Adherence to a Mediterranean dietary pattern reduces the risk of diabetes [109] and 
improves long term blood sugar control [110]. This dietary pattern is low in meat and rich 
in fruit and vegetables, and incorporates a modest contribution to energy from olive oil. 
Independently, supplementation with extra virgin olive oil improves modifiable 
cardiovascular risk factors in hypertensive volunteers [70] and reduces postprandial 
glucose and LDL cholesterol in healthy volunteers [22] 
As a source of lipids, olive oil is an unremarkable blend of monounsaturated, 
polyunsaturated and saturated fatty acids, it is however rich in phenolic compounds, 
principally hydroxytyrosol and oleuropein, which may be of benefit to health [19]. 
Feeding studies in diabetic rodent models show that both oleuropein [58, 111] and 
hydroxytyrosol [41] are capable of exerting anti-hyperglycaemic effects. These 
compounds are present in very high quantities in the oil industry waste by product, olive 
leaf [9], and interest has therefore grown in the salvaging of these potentially beneficial 
compounds for use as dietary supplements [76, 112, 113] 
There are data showing anti-glycaemic activity for OLE supplements in man: following a 
12 week randomised crossover study in 46 overweight male volunteers, consumption of 
OLE resulted in a 15% improvement in insulin sensitivity compared with placebo [30]. 
These data are well supported by feeding studies with olive leaf extracts demonstrating 
anti-glycaemic activity in animal models [47]. A mechanistic explanation for these 




this extract to help control blood sugar, which may be of particular benefit to those at risk 
of diabetes.  
Pharmacological approaches to managing postprandial hyperglycaemia and 
hypertriglyceridemia include targeting the digestive hydrolysing enzymes responsible for 
breaking down starches and triglycerides in the small intestine, and also targeting the 
action of the intestinal glucotransporters [53]. We hypothesised that the phenolics 
present in olive leaf extract might affect these same systems. Here we report findings 
from in vitro studies into the effects of olive leaf extract on digestive enzyme inhibition 
and on the expression and activity of glucose transporters in cultured intestinal epithelial 
cells. 
 
3.2    Materials and Methods 
3.2.1 Olive leaf extract 
OLE liquid was provided by Comvita (Te Puke, New Zealand). This elixir contains Olea 
europaea (Olive) leaf extract (water, olive leaf solids) each 5 mL equivalent to 5 g fresh 
olive leaf standardized to 22 mg of oleuropein and with vegetable glycerine (stabiliser). 
3.2.2 Chemical materials  
Oleuropein, hydroxytyrosol, luteolin, rutin, acarbose, orlistat, phloretin, porcine 
pancreatic α-amylase enzyme (EC 3.2.1.1), Pancreatic lipase enzyme type II (Sigma 
product L3126), sodium phosphate buffer, bovine serum albumin, calcium chloride, 
potato starch, 3, 5-dinitrosalicylic acid (DNS), Triton X-100 and p-nitrophenyl laurate were 
purchased from Sigma-Aldrich (Poole, UK).  Phlorizin dehydrate, fetal bovine serum, 
Dulbecco’s modified Eagle’s minimum essential medium (DMEM)(4.5 g/L Glucose with L-
Glutamine), penicillin 100 U/mL, Trypsin-versene EDTA, glucose stock solution 100 g/L 
and  Dulbecco’s Phosphate Buffered Saline (DPBS) (without Ca & Mg) were purchased 
from Scientific Laboratory Supplies (Nottingham, UK) QIAGEN RNeasy Mini Kit, 
QuantiTech SYBR Green PCR kit, RT2 first strand kit and GAPDH, SGLT1, GLUT1 and GLUT2 
primer were purchased from QIAGEN (Manchester, UK). Glucose, D-[1-14C]-, 50 µCi (1.85 




from American Type Culture Collection (ATCC, Middlesex, UK). All other chemicals were 
obtained from the Department of Food and Nutritional science, University of Reading. 
3.2.3 Inhibition of α- amylase activity 
The amylase inhibition assay was slightly modified from that reported by Ahmed et al. 
Briefly, a maltose standard curve was prepared to determine the optimal concentration 
of starch solution and porcine pancreatic α-amylase enzyme. OLE, OL, HT and acarbose 
(as a positive control) were prepared in DMSO at concentrations ranging from 0 to 2.5 
mg/mL. DMSO was used as negative control. Porcine pancreatic α-amylase (8U) was 
suspended in 50 mM sodium phosphate buffer (pH 6.9 at 20°C) containing 50 mM sodium 
chloride, 0.1% bovine serum albumin and 0.5 mM calcium chloride. Stock starch solution 
was prepared by dissolving 0.6% (w/v) soluble potato starch in 20 mM Sodium Phosphate 
Buffer with 6.7 mM Sodium Chloride (pH 6.9 at 20°C) and boiling the mixture for 15 min.  
A mixture of 0.5 mL of each of the samples and the enzyme solutions was incubated at 
37°C for 30 min. Then 1 mL starch solution was added to the reaction mixture and 
incubated at 20°C for 3 min. Thereafter, 96 mM DNS solution (3, 5- dinitrosalicylic acid 
solution in sodium potassium tartarate tetrahydrate and 2N NaOH) was added to stop the 
reaction. For the blank, the DNS solution was added prior to addition of the starch 
solution. The mixture was then boiled for 10 min. After cooling to room temperature, the 
reaction mixture was diluted with 9 mL distilled water, and absorbance measured at 540 
nm using UV spectrophotometer. Three independent replicates were performed. 
3.2.4 Lipase inhibition assay 
The lipase inhibition assay was conducted according to a previously described method 
[114]. The assay buffer was 100 mM Tris buffer (pH 8.2) and p-nitrophenyl laurate (pNP 
laurate) was used as the substrate. The substrate stock solution was prepared by 
suspending 0.8% (w/v) pNP laurate dissolved in 5 mM sodium acetate (pH 5.0) containing 
1% Triton X-100 and boiled for 1 min for dissolution, this was mixed then cooled to room 
temperature. Lipase from porcine pancreas type II was dissolved in ultra- pure water at 
10 mg/mL and centrifuged at 4,500 rpm for 10 min to provide a supernatant for use in the 
assay. The negative control assay contained 400 μL assay buffer, 450 μL substrate 
solution and 150 μL lipase enzyme. OLE, phenolic compounds and orlistat (positive 




compounds were mixed with substrate and incubated at 37 °C for 2 hrs.  Samples were 
then centrifuged at 4,500 rpm for 5 min and absorbance read at 400 nm in a UV 
spectrophotometer. All samples were assayed in triplicate and an inhibitor blank was 
prepared for each sample. 
3.2.5 Cell cultures 
Caco-2 cell cultures were prepared in 75-cm2 flasks in biologically independent manner 
(n=3) with a seeding density of 3 x 104 to 5 x 104 viable cells/cm2) and cultured at 37oC ± 
1oC in an atmosphere of 5% CO2- 95% air. The growth media was DMEM (4.5 g/L Glucose 
w/L-Glutamine), supplemented with 10% (v/v) heated-inactivated (45 min, 56°C) foetal 
bovine serum (FBS) + 1% (v/v) Penicillin-Streptomycin. The medium was changed every 2-
3 days. Routine passage was carried out at 70-90% confluence with 0.25% Trypsin-EDTA 
solution and washing with Dulbecco’s Phosphate Buffered Saline (DPBS). All experiments 
were carried out on cells between passage numbers 36 to 55. 
3.2.6 Cytotoxicity assay 
Caco-2 cells were cultivated in a 96-well culture plate, and incubated for 24 hr at 37°C. 
After 24 hr, treatments of OLE extract, OL, or HT were applied in DMEM at concentrations 
of 0.001-0.1 mM, or the equivalent of oleuropein in the OLE, were added to cell 
monolayers and these were incubated for a further 24 hrs. The medium was then 
removed from the wells. 100 µL of ice-cold methanol was added to each well and left for 
5 min to incubate at room temperature. The methanol was then removed and the 96-well 
plate air dried in a hood for 15 min. 100 µL of DAPI (4',6-diamidino-2-phenylindole) 
prepared in DPBS (70 μL of DAPI stock solution (3 mM): 10.43 mL DPBS per plate), was 
add to each well and the plate then incubated in the dark for at least 30 min at 37°C. The 
percentage of viable cells relative to control was enumerated using a microplate reader 
(TECAN) with absorbance and emission at 340 nm and 465 nm, respectively. 
3.2.7 Intestinal glucose transporter expression analysis 
Caco-2 cells were grown for 19 days in a 6 well culture plate with the media changed 
every two days. The cells were then treated with 3 mL of OLE, OL and HT or negative 
control (normal cell media (DMEM)) for 24 hrs. The treated cells were washed three times 
with 2 mL DPBS, and then collected by scraping into a falcon tube (15 mL). Total mRNA 




synthesized by using RT2 first strand kit both according to manufacturer’s instruction 
(QIAGEN; Manchester, UK). Purification of both mRNA and cDNA were measured by using 
a Nano drop (ND-1,000 V3.7.1). Following first strand cDNA synthesis the expression 
levels of GAPDH (house-keeping gene) and the respective glucose transporter mRNA were 
explored by real time RT-PCR 7300 system and the QuantiTech SYBR Green PCR kit. 
Primers were GLUT2; forward 5’-AGT TAG ATG AGG AAG TCA AAG CAA-3’ and reverse 5’-
TAG GCT GTC GGT AGC TGG-3’ and SGLT1; forward 5’-TCT TCG ATT ACA TCC AGT CCA-3’ 
and 5’-TCT CCT CTT CCT CAG TCA TC-3’. The PCR condition per cycle was 55°C for 0 min, 
95°C for 15 min, 92°C for 30 secs, 55°C for 1 min and 72°C for 30 secs. 
3.2.8 Glucose uptake assay 
Caco-2 cells were seeded at a density of 1x105 cells/well into Transwell inserts in 6 well 
plates (Corning® Transwell® poly polycarbonate membrane, pore size 0.4 mm, 24 mm 
diameter) and left to differentiate for 19 days with the media changed every two days. 
For the experiment, 1.5 mL of carrier media containing 0.001-0.1 mM were treated with 
1.5 mL of samples or negative control (normal cell media (DMEM)) into apical side for 24 
hrs prior to uptake studies. The media was discarded and cells were washed twice with 2 
mL of HEPES buffer salt (HBSS, pH 7.5, 140 mM; NaCl, 5 mM; KCl, 1 mM; K2HPO4, 1 mM; 
CaCl2, 0.5 mM; MgCl2) or HEPES buffer free salt solution (HBSS, pH 7.5,145 mM; KCl, 1 
mM; K2HPO4, 1 mM; CaCl2, 0.5 mM; MgCl2) applied to both upper and lower 
compartments. 1 mL HEPES buffer salt or free salt solution containing (D-[U-14C] Glucose) 
0.5 μCi/mL and 1 mM total glucose was then added to the Apical side. Cells were then 
incubated at 37°C for 30 min. The media was removed and glucose uptake stopped by 
washing each membrane twice with ice-cold PBS. 1 mL of 0.1 M NaOH was then added to 
apical compartment to lyse the cells, and 300 µL of cell lysate was added to 5mL 
scintillation counting solution (Ultima Gold™) and analysed by scintillation counting using 
Wallac 1409 DSA Liquid Scintillation Counter.  
 
3.2.9 Statistical analysis 
The concentration of the extract required to inhibit the activity of the enzyme by 50% 




calculated using analysis of relative gene expression via the 2-Δ ΔCT method [115], and data 
were normalised to the housekeeping gene (GAPDH). Data were expressed as the mean ± 
standard deviation (n= 3). Statistical analysis was performed by one-way analysis of 
variance using the software package SPSS (IBM SPSS Statistics 21). A p value < 0.05 was 
considered statistically significant. 
 
3.3   Results 
3.3.1 α- Amylase inhibition assay 
OLE and its phenolic compounds inhibited α-amylase in a dose-dependent manner (0.01-
4mM oleuropein equivalent) (Figure 27).  
 
Figure 27 Percent inhibition of pancreatic α-amylase by OLE and individual olive 
phenolics, oleuropein, hydroxytyrosol, luteolin and rutin. Acarbose was used as a 
reference alpha amylase inhibitor; the results are expressed as means ± SD, (n=3). 
 
The IC50 value for each was compared with the anti-diabetic drug, acarbose (Table 7). OLE 
had an IC50 value of 3.23 ± 0.33 mM which is greater than that of acarbose, 0.058 ± 0.001 




different from OLE. Luteolin, rutin and hydroxytyrosol all demonstrated inhibition of 




Table 7 IC50 of pancreatic α-amylase by OLE and individual olive phenolics, OL, HT, luteolin 
and rutin. Acarbose was used as a reference alpha amylase inhibitor; the results are 
expressed as means ± SD, (n = 3). a: p < 0.01 as compared with acarbose. b: p < 0.01 as 
compared with OLE. 
 
3.3.2 Lipase inhibition assay 
OLE and pure polyphenols were tested for their ability to inhibit pancreatic lipase in vitro. 
There was a dose dependent reduction in lipase activity for all treatments. Therefore, the 
highest concentration of OLE (2 mM) tested showed a maximum inhibition of 31.20%. The 
percentage inhibition varied from 3.9-31.2% from the lowest concentration to the highest 
concentration of 2 mM. The IC50 value of this particular extract was compared with 






Figure 28 Percent inhibition of pancreatic lipase by OLE and individual olive phenolics, OL, 
HT. Orlistat was used as a reference alpha amylase inhibitor; the results are expressed as 
means ± SD, (n=3) (**p < 0.01). 
 
The IC 50 value for OLE (1.83 ± 0.03 mM) demonstrates less efficacy than shown for 
orlistat (1.20 ± 0.02 mM) (p = 0.006) (Table 8). Oleuropein and hydroxytyrosol also 
independently inhibited lipase activity but with higher IC50 values than OLE (p < 0.05 and p 
< 0.01, respectively). 
 
Table 8 IC50 of pancreatic lipase by OLE and individual olive phenolics, OL and HT. Orlistat 




(n=3). a: p < 0.01 as compared with orlistat. b: p < 0.05 as compared with OLE. c: p < 0.01 
as compared with OLE. 
3.3.3 Intestinal glucose transporter expression  
No significant toxicity was observed in the Caco2 cells exposed to the OLE at the tested 
concentrations. However, significant toxicity, as indicated by cell viabilities of less than 
70% following exposure, was observed for HT concentrations greater than 0.05 mM and 
oleuropein concentrations greater than 0.10 mM) following incubation for 24 hrs. (Figure 
29). As shown in Figure 30, OLE exerted a marked down regulation of SGLT1 and GLUT2 
mRNA expression (p < 0.05). After 24 hr of treatment, the OLE inhibited SGLT1 and GLUT2 
mRNA expression in a concentration–dependent manner (0.001-0.1 mM OL equivalent 
OLE). OL and HT also inhibited expression although at higher doses the inhibition of 
expression by OL and HTl was lower than OLE (p < 0.01), this may have been associated 
with toxicity.   
 
Figure 29 Viability of Caco-2 cells incubated for 24 hr with (0.001, 0.01, 0.05 and 0.1 mM) 
OLE, OL and HT dissolved in DMEM, as measured by the DAPI method. Each of the four 



























Figure 30 The effect of olive leaf extract and its phenolic compounds; OL and HT on SGLT1 
and GLUT2 mRNA levels normalised to GAPDH as a house-keeping gene: real-time PCR 
analysis of the relative mRNA expression levels of SGLT1 and GLUT2 in differentiated 
Caco-2 cells treated with 0.001-0.1 mM OLE, 0.001-0.05 mM OL and 0.001-0.01 mM HT 
for 24 hrs. Normal cell media (DMEM) were used as a negative control. Results represent 






3.3.4 Glucose uptake assay 
Glucose uptake was measured in sodium-containing buffer, to capture the transport 
action of both SGLT1 and GLUT 2 or sodium-free buffer to capture only facilitated glucose 
uptake via the GLUT2 transporter. Both processes were significantly decreased after 
Caco-2 cells were treated with OLE and its phenolic compounds for 24hrs. The OLE at a 
concentration equivalent to 0.01 mM) of oleuropein inhibited glucose uptake by 50 % in 
both experimental conditions. The phenolics tested exerted similar dose dependent 
reductions in glucose uptake in either the sodium-dependent (SGLT1) or sodium-free 
conditions (GLUT2) in a concentration–dependent manner (0.001-0.01 mM OL equivalent 








Figure 31 The effect of olive leaf extract and its phenolic compounds; OL and HT on 
glucose uptake in sodium (SGLT1) and free sodium condition (GLUT2). Caco-2 cells were 
treated with Caco-2 cells treated with 0.001-0.01 mM OLE, oleuropein and hydroxytyrosol 
for 24 hrs. Phlorizin and phloretin were used as positive control for SGLT1 and GLUT2 
respectively. Normal cell media (DMEM) were used as a negative control. Results 
represent mean ± SD (n=3) (*p <0.05, **p < 0.01), compared with the respective 
untreated control group. 
 
3.4   Discussion 
Supplementation with OLE, containing the equivalent of 51.04 mg of OL, daily for 12 
weeks, significantly improved insulin sensitivity in overweight middle-aged men [61]. 
Here we have set out to understand the mechanisms underpinning that observation. We 
hypothesised that the regulation of glucose and fat uptake in the gut might be involved, 
and we explored this hypothesis under in vitro conditions. In our in vitro studies, we have 
used concentrations of OLE extract which might be achievable in the upper gut through 
supplementation. De bock et al supplemented with a volume of OLE extract equivalent to 
51.04 mg of OL, approximating a 1 litre dilution of the supplement capsule in the stomach 
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Besides, we used positives and negative controls which help to differentiate between 
invalid testing and product failure through observing control test. The positive control is 
used to assess test validity, while the negative control would infer that the treatment had 
no effect.   
OLE inhibited α-amylase in a dose dependent manner (IC50 OLE; 3.23 ± 0.33 mM) although 
less efficiently than the positive control, acarbose (IC50 acarbose; 0.058 ± 0.001 mM). It 
also inhibited pancreatic lipase (IC50 1.83 ± 0.03 mM), again less efficiently than the 
positive control orlistat (IC50 01.20 ± 0.02 mM), but which may still be clinically relevant. 
In addition, olive leaf polyphenols OL, HTl, luteolin and rutin individually inhibit α–
amylase and/or lipase with low IC50 values, hydroxytyrosol exerted a much weaker effect. 
Oleuropein, which is the principle polyphenol in OLE, may be exerting the greatest 
enzyme inhibitory effect in the OLE mixture. OLE and its phenolics also suppressed the 
expression of the genes for glucose transporters (SGLT1 and GLUT2) in cultured human 
intestinal epithelial cells (Caco-2 cells). Furthermore, cultured intestinal epithelial cells 
absorbed less glucose in the presence of OLE relative to control. These data demonstrate 
mechanisms which might explain observations made in human intervention study. Sales 
et al. evidenced that food components which delay the release of nutrients into the blood 
is desirable as this effect may be associated with improved blood sugar and appetite 
control, and may attenuate cardiovascular and metabolic disease risk [116]. 
The α amylase inhibitor acarbose has been used in the management of diabetes, however 
its use can lead to excessive bacterial fermentation of undigested starches in the colon 
with unwelcome side effects [117]. More subtle, food based approaches may therefore 
be preferable. A variety of polyphenolic rich plant extracts including those of pumpkin 
leaf, clove buds, rosella, chrysanthemum, mulberry, blue butterfly pea and Rumex 
acetosella roots, have previously been shown to inhibit α–amylase activity [118-120], 
possibly via non-specific competition for the enzyme’s active site [121]. Sales et al. 




[116]. The phenolic compounds found in OLE, principally OL and HT, are rich in hydroxyl 
groups, which may form hydrogen bonds with polar groups at the enzymes allosteric site. 
The chemical structure of polyphenols might also allow non-competitive inhibition. 
Further experimental work is needed to fully elucidate the interactions involved. 
Hyperglycaemia is exacerbated by elevated plasma lipids with excess free fatty acids 
effectively competing with glucose for uptake in peripheral tissues and enhancing 
endogenous glucose production [122]. Orlistat, a weight-loss agent, inhibits pancreatic 
lipase to decrease systemic absorption of dietary fat, but with undesirable side effects 
[123].  Previous studies report that polyphenol-rich extracts from foods such as berries, 
red wine, green tea and some dietary phenolic compounds, such as cocoa procyanidins 
(IC50 = 0.034 mM), and tea (-)-epigallocatechin-3,5-digallate (IC50 = 0.00028 mM) can 
inhibit pancreatic lipase inhibitory activity in vitro [114, 124, 125]. We demonstrate here 
that OLE and its phenolic compounds also inhibit lipase, although not as efficiently as 
orlistat. Orlistat inhibits pancreatic lipases by forming a covalent bond with serine in the 
active site of the enzyme[123], no data are yet available to explain the inhibitory effect of 
the olive leaf phenolics. 
GLUT2 and SGLT1 protein levels are upregulated about threefold in the intestinal tract of 
patients with type 2 diabetes [126], suppressing their expression decreases the rate of 
sugar transport across the gut barrier. Here, we have tested the effects of OLE on the 
expression of sugar transporters, GLUT2 and SGLT1, in intestinal Caco-2 cells, at sub-toxic 
concentrations achievable in the intestinal tract with supplementation.  Caco-2 cells have 
a small intestinal phenotype and express high levels of both transporters. We 
demonstrated a dose-dependent decrease in the level of GLUT2 and SGLT1 mRNA in 
Caco-2 cells following a 24 hrs exposure to OLE or its phenolics (oleuropein and 
hydroxytyrosol). Polyphenol rich berry extracts induce a similar down regulation in GLUT2 
and SGLT1 expression  [127]. We then assessed the effects of OLE on radiolabelled 
glucose uptake in the Caco-2 cells under two distinct conditions: firstly, in the presence of 
sodium, thereby favouring glucose uptake via SGLT1, and secondly in the absence of 
sodium, favouring glucose uptake via GLUT2. In parallel to the decrease in glucose 
transporter expression, we observed a decrease in uptake of the glucose under both 
conditions with cells pre-incubated with OLE or its polyphenols. Green tea, strawberry 




radiolabelled glucose into Caco-2 cells [128, 129]. It has been suggested that polyphenol-
glucosides act primarily on sodium-dependent transport, while the corresponding 
aglycones regulate facilitated transport [130], however, we found that in this case the 
glycosides, OL and HT inhibited the expression of both transporters in a dose dependent 
manner (GLUT2 and SGLT1).  
The strengths of this work are that we have explored a variety of potential mechanisms to 
directly explain the findings of an intervention study using a comparable dose as a 
treatment. Our data have demonstrated a number of mechanisms which might 
contribute to the in vivo anti-hyper-glycaemic activity, and these data are reinforced by 
similar findings for other polyphenol rich foods elsewhere in the literature. The 
weaknesses of this study are that we used in vitro models and that we did not account for 
the effects of digestive processes on the bioactivity of our compounds. However, 
oleuropein has previously been shown to be resistant to simulated gastric digestion by 
Ahmad-Qasim et al. although other olive phenolics were significantly degraded in that 
model [131]. 
Delaying the release of nutrients into the blood has implications for blood sugar, plasma 
lipids and appetite control, and may therefore attenuate cardiovascular and metabolic 
disease risk. Our data offer mechanistic support to intervention study demonstrating that 
OLE and its phenolics may confer protection from metabolic disease when consumed as 
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Previous studies have demonstrated an anti-hypertensive effect for polyphenol rich OLE 
in both human volunteers and in experimental animals. The mechanisms for this effect 
remain undefined. We hypothesised that olive phenolics may enhance NO production 
and/or inhibit angiotensin enzymes resulting in improved blood pressure control. To test 
these hypotheses, NO production was measured in HUVEC cells using an indirect method 
(Griess reagent method). Further, the inhibitory effects of OLE and its principal 
polyphenols, hydroxytyrosol and oleuropein, delivered at doses achievable in the 
bloodstream, were assessed against renin and against the angiotensin converting enzyme 
(ACE). OLE, and separately, the individual olive polyphenols, at 100 µM concentrations in 
cell culture carrier media, induced increases in NO production compared to untreated 
controls. In addition, OLE inhibited renin activity with an IC50 value of 63.08 ± 2.90 µM, 
oleuropein and to a lesser extent hydroxytrosol both also inhibited Renin activity. OLE 
extract also inhibited ACE activity, IC50 60.86 ± 5.68 µM; oleuropein had no significant 
effect on ACE activity, but hydroxytyrosol induced a comparable level of ACE inhibition to 
OLE. These results demonstrate plausible mechanisms which might explain the observed 
hypotensive effects of consuming OLE. The benefits of OLE may be attributable to the 
synergistic presence of oleuropein and hydroxytyrosol acting on different components of 
the blood pressure regulation systems. The complete food supplement may be more 
useful for the prevention of hypertension related disease than the supplementation of 






4.1   Introduction 
Hypertension is a major age-related risk factor for the development of cardiovascular 
diseases including stroke, kidney disease, heart failure and myocardial infarction [1]. The 
prevention and treatment of hypertension is a long standing public health priority. Anti-
hypertensive drugs, include ACE inhibitors, angiotensin II receptor blockers, and calcium-
channel blockers. The use of these drugs may be associated with undesirable side effects, 
including persistent cough, renal failure, postural hypotension, and angioedema [2]. 
Therefore, including anti-hypertensive foods and/or supplements in the diet might be 
both more cost effective and have fewer potential side effects. Polyphenol rich foods 
such as cocoa, tea, wine and olive oil are associated with lower blood pressure in 
epidemiological studies and with improved endothelial function in intervention study [3-
6]. It is hypothesised that polyphenols may attenuate vasodilator activity by influencing 
the generation of NO in the vascular endothelium [7]. Red wine, and green tea (-) 
epicatechin for example have both been shown to induce vasorelaxation via a mechanism 
related to nitric oxide (NO) production [8]. 
The Mediterranean diet is associated with a reduced risk of CVD. A key feature of the diet 
is a moderate to high consumption of olives and of olive oil. Olive leaf is a by-product of 
the olive industry it is rich in polyphenols which can be extracted for use in supplements. 
In human intervention and animal model studies these extracts are shown to exhibit anti-
hypertensive effects [9-12]. Understanding the mechanisms of action of bioactive food 
components is essential to proving efficacy and ensuring the public are not misled. The 
present study therefore aims to investigate the in vitro production of NO in cultured 
human umbilical vein endothelial cells (HUVECs) in response to OLE, and in response to 
the olive polyphenols contained within OLE, and further, to explore the effects of these 






4.2   Materials and Methods 
4.2.1 Olive leaf extract 
Olive leaf extract was provided as an elixir by Comvita (Te Puke, New Zealand). This elixir 
contains Olea europaea (Olive) leaf extract (water, olive leaf solids) each 5 mL is 
equivalent to 5g of fresh olive leaf, standardized to 22 mg of oleuropein, and with a 
vegetable based glycerine stabiliser. 
4.2.2 Chemical materials  
OL, HT, captopril, aliskinrine, angiotensin converting enzyme (A6778 Sigma), sodium 
chloride, tris (hydroxymethyl) methylamine, hydrochloric acid, FAPGG – N-[3-(2-furyl) 
acryloyl]-Phe-Gly-Gly, glycerol solution and Nitrite/Nitrate Assay Kit, including   NaNO2 
Standard Solution (100 mM), NaNO3 Standard Solution (100 mM), Buffer solution (20 
mM, pH 7.6), Nitrate reductase (lyophilized), Enzyme Co-factor (lyophilized), Griess 
Reagent A and Griess Reagent B were all purchased from Sigma-Aldrich (Poole, UK). The 
human recombinant renin inhibitor screening assay kit, including human recombinant 
renin, substrate (Arg-Glu(EDANS)-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(Dabcyl)-Arg) 
and Tris-HCl buffer (50 mM, pH 8.0, containing 100 mM NaCl) was purchased from 
Cayman Chemical Co. (Ann Arbor, MI, U.S.). Human Umbilical Vein Endothelial Cells 
(HUVEC), Trypsin Neutralizer Solution, Low Serum Growth Supplement (LSGS), 
Trypsin/EDTA Solution (TE) and Medium 200 (Gibco™) were purchased from Fisher 
Scientific UK Ltd (Loughborough, UK). All other chemicals were obtained from the 
Department of Food and Nutritional science, University of Reading. 
4.2.3 Cell cultures 
Human Umbilical Vein Endothelial Cells (HUVEC) were purchased from Fisher Scientific UK 
Ltd (Loughborough, UK). Cells were prepared in three 75-cm2 flasks in biologically 
independent manner (n=3) with a seeding density of 2.5 x 103 cells/cm2 and they were 
grown in Medium 200 supplemented with Low Serum Growth Supplement (LSGS) at 37∘C 
in a humidified atmosphere of 5% CO2 and 95% air. The culture media was changed every 
other day thereafter, until approximately 80% confluent. Routine passage was carried out 
with phosphate-buffered saline solution (1x) containing 0.025% trypsin and 0.01% EDTA 
and neutralizing with phosphate buffered saline solution (1x) containing 0.5% new born 




HUVEC cells were cultured in 12 well plates at a density of 1x105 cells/well and treated 
with OLE, OL and HT (1-100 𝜇M) for 24hrs. Medium was removed and stored at -80 ∘C 
until NO measurement. 
4.2.4 Determination of Endothelial Nitric Oxide Production 
Production of NO by HUVEC was measured as its stable oxidation product; nitrite, using 
colorimetric nitrite/nitrate assay kit (Sigma). Briefly, cell culture media was centrifuged at 
1000 x g for 15 min to remove insoluble material. In a 96 well plate, 50 𝜇L of the culture 
medium supernatant was diluted with 30 𝜇L assay buffer and mixed with 10 𝜇L of the 
nitrate reductase solution and 10 𝜇L of the enzyme co-factors solution. The plate was 
incubated at 25°C for 2 hrs to convert nitrate to nitrite. Then 50 𝜇L Griess reagent A 
(sulphanilamide) was added to all wells. After 5 minutes at 25°C of incubation with Griess 
reagent A, 50 𝜇L Griess reagent B (naphthalene-ethylenediamine dihydrochloride) was 
added to all wells following 10 min incubation at 25°C. Total nitrite was measured at 540 
nm absorbance using a Tecan micro plate reader.   
4.2.5 Renin inhibition assay 
Renin inhibitory activity was determined using a human recombinant renin inhibitor 
screening assay kit (Cayman, Michigan, USA). Prior to the assay, 50 𝜇L of human 
recombinant renin enzyme solution was diluted with assay buffer consisting of 50 mM 
Tris-HCl, pH 8.0, and 100 mM NaCl (assay buffer). A 95μM solution of renin substrate 
(Arg-Glu(EDANS)-Ile-His-Pro-Phe-Leu-Val-Ile-His-Thr-Lys (Dabcyl)-Arg) in 
dimethylsulfoxide (DMSO) (substrate solution) was ready to use as supplied. The positive 
control wells contained 150 μL of assay buffer and 10 μL of DMSO. Aliskiren (positive 
control), OLE and its phenolic compounds were dissolved in DMSO at a range of 
concentrations (1-100 µM). 150 μL of assay buffer and 10 μL of the test compound 
solution were prepared in a 96 well dark polypropylene plate. Assay blanks were 
prepared in wells containing 150 μL of assay buffer and 10 μL of DMSO. The reaction was 
initiated by adding 10 μL of renin enzyme solution to the control and test compound 
wells. The microplate was covered and shaken for 10 secs. The reaction plate was 
incubated at 37 °C for 15 min. The fluorescence intensity (FI) was determined on a 




emission wavelength of 465 nm. The analyses were performed in triplicate. The renin 
inhibitory activity was calculated as follows:  
Renin inhibitory activity (Inhibition%) = (FI(control)- FI(sample))/(FI(control)) × 100 
The IC50 value was defined as the concentration of the inhibitor required to inhibit 50% of 
the renin activity, and calculated using the linear function of percentage renin inhibition 
versus the logarithm of the inhibitor concentration. 
4.2.6 ACE inhibition assay 
The method was adapted from a previous study with slight modifications [33]. Briefly, a 
substrate solution (0.88 mM FAPGG) was prepared by mixing 0.0176 g of N-[3-(2-furyl) 
acryloyl]-Phe-Gly-Gly (FAPGG), in 40 mL of 50 mM Tris-HCL buffer with 300 mM of NaCl, 
pH 7.5 (assay buffer). The enzyme solution (250 mU) was prepared by mixing ACE (1U) in 
4 mL of 0.1 M Tris and 0.6 M NaCl in 86% glycerol solution. Captopril (positive control), 
OLE and its phenolic compounds were dissolved in assay buffer at the desired 
concentration (0.7-50 µM). In the first step, 150 μL of 0.088 mM FRAPGG and 10 μl of test 
compounds were mixed in each well. The mixture was incubated at 37 °C for 5 minutes. 
The reaction was catalysed by adding 10 μL ACE enzyme (250 mU). For the control, assay 
buffer was used instead of the test compounds. The product of the reaction was assessed 
at 340 nm after 30 min. The ACE inhibition was expressed as percentage of inhibition and 
calculated by the following equation: 
ACEi%= = (1-(ρAinhibitor)/ρAcontrol) × 100 
ρAinhibitor = slope with inhibitor 
ρAcontrol = slope with control 
The IC50 value was defined as the concentration of the inhibitor required to inhibit 50% of 
the ACE activity, and calculated using the linear function of percentage ACE inhibition 
versus the logarithm of the inhibitor concentration. 
 
4.2.7 Statistical analysis  
All data are the means of triplicate analyses and expressed as means ± standard 




of variance was applied to compare treatment effects. A p value < 0.05 was considered 
statistically significant. 
 
4.3   Results 
4.3.1 Determination of Endothelial Nitric Oxide Production 
OLE and its associated polyphenols were tested for their ability to enhance NO 
production. There was a significant increase (p < 0.001) in the level of NO produced by 
HUVEC cells treated with OLE at a concentration equivalent to 100 μM of OL, as 
compared to the carrier control. At the highest concentrations tested (100 μM), both 
oleuropein and hydroxytyrosol induced significant increases in the level of NO produced 
compared to control (p < 0.001). Neither OL or HT performed significantly differently to 
the OLE (Figure 32).  There appears to be a dose response but at the lower 





Figure 32 The effect of olive leaf extract and its phenolic compounds; OL and HT on NO 
production. HUVECs treated with 1-100 µM OLE, OL and HT for 24 hrs. Bar chart showing 
NO level in control, OLE, OL, and HT. Values are expressed as means ± SD of n = 4. ∗p < 




4.3.2 Renin inhibition assay 
Aliskerin, the positive control, inhibited renin with high efficacy at low concentrations 
(IC50 value 24.50 ± 0.02 μM). OLE suppressed renin activity with less-efficacy than 
aliskerin, but in a dose-dependent manner (1-50 μM oleuropein equivalents). The 
percentage inhibition of OLE varied from 1.12-39.96% from the lowest concentration to 
the highest concentration tested (Figure 33) with an IC50 value of 59.63 ± 0.06 μM 
(expressed as equivalent oleuropein content) (Table 9); OL also independently inhibited 
renin in a dose dependent manner (IC50 94.49 ± 4.71 μM) and may account for the bulk of 
the inhibition observed with the elixir. Hydroxytyrosol exerted some enzyme inhibition 
again in a dose dependent manner but much more weakly then OLE and OL (IC50 193.6 ± 





Figure 33 Percent inhibition of renin by OLE and individual olive phenolics, oleuropein, 
and hydroxytyrosol. Aliskinrine was used as a reference renin inhibitor; the results are 















26.01 ± 0.82 
OLE 
Oleuropein 
63.08 ± 2.90 
94.49 ± 4.71a 




Table 9 IC50 of renin by OLE and individual olive phenolics, oleuropein, and 
hydroxytyrosol. Aliskinrine was used as a reference renin inhibitor; the results are 
expressed as means ± SD, (n=3). a: p < 0.01 as compared with aliskinrine. b: p < 0.01 as 
compared with OLE. 
4.3.3 ACE inhibition assay 
The percentage inhibition of ACE exhibited by OLE, and its derivatives are shown in Figure 
34. Captopril was used as a positive control and was shown to inhibit ACE activity with 
high efficacy (IC50 19.16 ± 0.89 μM) (Table 10). OLE induced a dose dependent inhibition 
of ACE activity with less efficacy than captopril (IC50 60.86 ± 5.68 μM (expressed as 
equivalent oleuropein content)). Hydroxytyrosol inhibited ACE activity with similar 
efficacy to OLE, (IC50 value of 70.87 ± 6.49 μM) and thus may explain the bulk of ACE 
inhibitory activity of the OLE. Oleuropein relatively weakly inhibited ACE (IC50 135.21 ± 






Figure 34 Percent inhibition of ACE by OLE and individual olive phenolics, oleuropein, 
hydroxytyrosol. Captopril was used as a reference alpha amylase inhibitor; the results are 




 IC50 (µM) 
ACE 
Captopril 19.16 ± 0.89 b 
OLE 
Oleuropein 
60.86 ± 5.68a 
135.21 ± 14.52 a,c 
Hydroxytyrosol 70.87± 6.49 a 
  
 
Table 10 IC50 of ACE by OLE and individual olive phenolics, oleuropein, and 
hydroxytyrosol. Captopril was used as a reference ACE inhibitor; the results are expressed 
as means ± SD, (n=3). a: p < 0.05 as compared with captopril. b: P<0.05 as compared with 
OLE. c: p < 0.01 as compared with OLE. 
 
4.4    Discussion  
A dietary intervention study with daily OLE containing 136 mg of OL has previously been 
shown to reduce blood pressure in pre-hypertensive male volunteers [10]. The purpose of 




hypothesised that polyphenols present in OLE might stimulate NO production in 
endothelial cells and/or inhibit the enzymes involved in the renin-angiotensin system. In 
our in vitro studies, we have used concentrations of OLE extract which might be 
detectable in human plasma through supplementation. De Bock et al. demonstrated that 
following ingestion of OLE, containing 51.1-76.6 mg OL, plasma metabolites of OL and HT 
are detectable at 0.3-1 µM concentrations [13]. The HUVEC cell line is widely used as an 
NO producing model of vascular function [14]. We show that treating HUVEC cells with 
OLE and with the olive polyphenols, OL and HT, resulted in significantly increased NO 
production. This is consistent with a previous observation from Romero et al. who report 
endothelium-dependent, NO mediated vasorelaxation in rat aorta treated with OLE [12]. 
In vitro elucidating the active fraction of OLE responsible for inducing NO release in the 
HUVEC cells, and we therefore tested the effects of the two principle phenolic 
compounds present in OLE, oleuropein and hydroxytyrosol; both induced NO production. 
OL, HT and the minor olive phenolics, verbascoside, rutin and luteolin, have previously 
been shown to induce dose dependent increases in NO production [14-19]. These effects 
are seemingly not unique to olive polyphenols but are a characteristic response to an 
array of plant derived-phenolics; caffeic acid, resveratrol, quercetin, epigallocatechin 
gallate, and rutin have all been shown to significantly increase NO levels, inducing eNOS 
mRNA expression, protein synthesis, and eNOS activity [8, 14]. Storniolo et al, suggest 
that olive oil polyphenols modulate NO production through the control of Ser1177 eNOS 
phosphorylation and eliciting changes in [Ca2+] in smooth muscle [20]. Intervention with a 
dose of OLE containing 136 mg OL is unlikely to achieve circulating OL or HT approaching 
the 100 µM concentration, and the biological activity of the individual metabolites 
present in blood has not been quantified. We therefore conclude that the NO stimulatory 
activity of the individual phenolics play relatively minor roles in the total effect of OLE 
consumption on blood pressure. 
The renin-angiotensin system affects control over blood pressure via activation of 
angiotensin II, which regulates blood volume as well as vasodilation, independently of NO 
[21, 22]. Renin cleaves the N-terminus of angiotensinogen to yield angiotensin I, which 
may be further hydrolysed by ACE to release a potent vasoconstrictor (angiotensin II) 
[23]. Like NO synthase, the components of the renin-angiotensin system are frequently 




of OLE and its phenolic compounds on the renin-angiotensin system as an alternative, or 
perhaps complimentary, mechanism of anti-hypertensive action to the effects on NO 
synthesis. OLE inhibited renin with an IC50 value of 63.08 ± 2.90 (µM oleuropein 
equivalent) versus 26.01 ± 0.82 µM for the pharmacological agent Aliskiren which was 
used as a positive control. It also suppressed ACE activity in a dose dependent manner 
(IC50 OLE; 60.86 ± 5.68 µM) although less efficiently than the positive control, and 
pharmacological agent captopril (IC50 captopril; 19.16 ± 0.89 µM).  
 Other polyphenol-rich foods have previously shown to influence the RAS system, and 
phenolic compounds including (-)-epigallocatechin gallate (IC50 = 44.53 μM), (-)-
epicatechin gallate (IC50 = 619 μM) and (-)-epigallocatechin (IC50 = 2175 μM) are 
individually also effective against renin in vitro [24, 25]. Similarly, extracts of blueberry 
(IC50 = 46 µg/mL), Hibiscus sabdariffa (IC50 = 91 µg/mL), green tea (IC50 = 125 µg/mL), and 
Senecio inaequidens (IC50 = 192 µg/mL) have been shown to inhibit ACE activity. And both 
quercetin (IC50 = 0.42 mM), and tannic acid (IC50 = 0.23 mM) have been identified as ACE 
inhibitors in vitro [26-30]. We observed that OLE inhibits ACE in a dose-dependent 
manner; and further, that hydroxytyrosol (IC50= 70.87± 6.49 µM) is more inhibitory than 
oleuropein (IC50= 135.21 ± 14.52 µM). Hansen et al. also reported higher ACE inhibitory 
activity for hydroxytyrosol relative to oleuropein (95%; at 0.33 mg/mL versus 8% of ACE 
enzyme at the same dose [31]. The mechanism of ACE inhibition is uncertain but presence 
of the B-ring and the hydroxyl groups may be of importance [26]. Substitution of the 
hydroxyl groups for methoxyl groups decreased the ACE activity of rutin, luteolin and 
quercetin and kaempferol [32]. This may explain the differences in the functionality of 
hydroxytyrosol versus oleuropein in ACE inhibition.  
The data we have presented suggests diverse and perhaps synergistic mechanisms which 
might explain the observed functional reduction in blood pressure. OLE extract may work 
directly on both NO release and on the renin-angiotensin system.  
The weaknesses of this study are that it is entirely in vitro in nature and that we only 
report bioactivity data on the two principle olive leave phenolics; other small molecules 
present in the olive leaf extract may also have bioactivities, further we have not sought to 





The strengths of the study are that we are replicating the observations from a human 
dietary intervention study in established models of blood pressure control. It is important 
to provide mechanistic support explain to the observed anti-hypertensive effects of OLE. 
This mechanistic understanding adds strength to any guidance that may be given around 
the use of olive leaf extract in the management of hypertension. The use of a 
supplemental extract recovered from food production waste is attractive commercially 
and may be preferable to pharmacological intervention in the prevention of 
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The olive leaf is rich in polyphenols that can be extracted (Olive Leaf Extract; OLE) for use 
as a food supplement or nutraceutical. Recent randomised control trials demonstrate 
hypotensive effects for OLE when consumed by pre-hypertensive volunteers. Advocating 
the consumption of a supplement for the prevention of hypertension is a sub-optimal 
public health approach as supplement usage can be used to justify an otherwise 
unhealthy lifestyle. Accordingly, evidencing the synergistic benefits of including a 
supplement as part of a healthy lifestyle is desirable. To evidence the synergistic benefits 
of consuming plant (and specifically olive) phenolics alongside being more physically 
active in individuals with elevated blood pressure. In this randomized, double blinded, 
four-arm parallel study, 63 pre-hypertensive overweight adults aged 25-70y were 
assigned to one of four treatment arms for 12 weeks: i) a placebo control group- with a 
daily capsule ii) an increasing physical activity and a placebo capsule group iii) an olive leaf 
extract arm (equivalent to 132 mg of oleuropein per day (OLE); iv) a physical activity and 
olive leaf extract arm. Individuals on the physical activity arms were equipped with 
pedometers and received weekly motivational guidance on gradually increasing physical 
activity over 12 weeks. The primary outcome measure for the study was the change in 24-
h ambulatory blood pressure. Secondary outcome measures were arterial stiffness index, 
plasma HbA1C levels, fasted glucose and insulin, serum lipid profiles and body 
composition. 24-h systolic blood pressure (SBP) (-5.80 mmHg ± 7.63, p = 0.011) and day 
time SBP (-5.07 mmHg ± 7.16, p = 0.025) were significantly lower following OLE intake. 
The PA intervention alone resulted in lower 24-h SBP (-3.69 mmHg ± 9.39), p = 0.031) and 
daytime SBP (-4.19 mmHg ± 10.27), p = 0.041). Consuming the OLE alongside being 
increasing physical active reduced 24-h SBP (-3.88 mmHg ± 6.65), p = 0.027) from 
baseline. There were however, no effects on stiffness index, body composition, lipids, 
HbA1c, glucose and insulin in all groups after 12 weeks. Our data support previous 
research, showing that both OLE, and increasing PA, independently reduce systolic blood 
pressure in pre-hypertensive volunteers, there is no additive effect of combining PA with 





5.1    Introduction 
Hypertension affects 30% of the UK population and is causally implicated in the aetiology 
of renal disease, cardiovascular disease and stroke. Ageing, obesity, a poor diet and low 
levels of physical activity are all risk factors [1]. A meta-analysis of studies in the 
treatment of systolic hypertension demonstrated that for every 20 mmHg reduction in 
systolic BP there is a 40-45% reduction in CVD risk [2]. Adherence to a Mediterranean diet 
is protective against hypertension and its associated morbidities and olive oil is believed 
to be a key beneficially bioactive component of that diet [3]. As a source of lipids, olive oil 
is an unremarkable blend of monounsaturated, polyunsaturated and saturated fatty 
acids. It is however also rich in phenolic compounds, principally OL and HT, which may be 
of benefit to health. A recent randomised intervention trial, in predominantly 
hypertensive volunteers, showed that adherence to a Mediterranean diet supplemented 
with extra virgin olive oil reduced blood pressure and other measures of cardiovascular 
disease risk [4]. Olive phenolics can be extracted cheaply from the waste products of olive 
oil manufacture, such as the plant leaf for use as dietary supplements. In intervention 
studies in hypertensive or borderline hypertensive patients, olive leaf extract 
consumption has been shown to reduce blood pressure and improve vascular function [5-
9]. 
Another intervention with established efficacy for improving blood pressure is to increase 
physical activity [10]. Engaging in regular PA is effective at preventing cardiovascular 
disease[11], type 2 diabetes [12], cancer [13], obesity [14], and mental health problems 
[15]. The ‘Start Active, Stay Active’, Chief Medical Officers report on physical activity 
recommends that adults achieve 150 minutes of moderate intensity physical activity per 
week, while data in that report suggest that fewer than 40% of adult men and 30% of 
adult women achieve these targets. Adherence to the physical activity guidelines may in 
fact be much worse in sub-sections of the population at higher risk of hypertension. 
Research evidencing best practice for population specific interventions is therefore 
needed [16, 17]. Home based interventions of moderate intensity, such as increased 
walking activity may be the most effective approach to increasing activity levels over the 
long-term [18]. One promising strategy for motivating PA is the use of pedometers [19]. 
Pedometers are relatively cheap, non-invasive, easy to use and can provide immediate 




prompt behaviour change as it raises awareness of current walking behaviours[21]. 
However, pedometers may be more effective as a motivational tool when pedometer 
feedback is used in combination with individualised goal-setting and self-monitoring 
methods (recording/PA per day)[22]. 
From a public health perspective, holistic guidelines for the prevention of hypertension, 
or its early diagnosis and management, based around a healthy diet and lifestyle are 
preferable to pharmaceutical intervention. Lifestyle interventions are economically 
favourable and they come with fewer side effects and perhaps wider health benefits than 
antihypertensive drugs. However, few intervention studies have considered the 
synergistic benefits of diet and exercise [23, 24]. This study therefore aims to evaluate the 
synergistic benefits of consuming olive phenolics alongside increasing physical activity in 
individuals with elevated blood pressure. Our hypothesis was that OLE and physical 
activity would reduce blood pressure and that a combination of the two would be more 
effective than either treatment alone. 
5.1.1  Subjects  
Volunteers residing in Reading, UK, were informed about the study via flyers, posters in 
community buildings, local shops and on the Reading University campus. Invitation 
letters, emails or phone calls were sent to Reading University students staff and 
volunteers from the Hugh Sinclair Unit of Human Nutrition volunteer database. All 
volunteers provided written informed consent prior to commencing the trial. Based on 
previous studies demonstrate hypotensive activity [6, 8, 25]for OLE in human volunteers, 
all focused on defined cohorts, but men and woman of all ages suffer hypertension, we 
are demonstrating the consistency of the effect across the life-course regardless of 
gender. Inclusion criteria were male or female, age 25–70 years, body mass index (BMI) ≥ 
25 kg/m2 and BP recorded at screening session between 120–160 mmHg systolic and/or 
80–99 mmHg diastolic. Exclusion criteria were as follows: (1) smokers; (2) taking 
antihypertensive or lipid-lowering medications; (3) serious disease such as diabetes (4) 
pregnant or currently breastfeeding; (5) unwilling to wear the ambulatory blood pressure 
(ABP) monitor or to undergo BP monitoring for 24 hrs; (6) unwilling to maintain habitual 
diet; (7) unwilling to increase physical activity level and (8) inability to swallow capsules. 
During screening, a fasting blood sample was taken and BMI, waist circumference and BP 




5.1.2  Study design 
This study was structured as a four-way parallel study design in pre-hypertensive 
volunteers, as shown in Figure 35. The study arms were: i) Placebo control, on which 
volunteers consumed a placebo capsule daily over 12 weeks. ii) Increased physical activity 
(PA): volunteers consumed a placebo control supplement and received guidance on 
achieving the PA guidelines. They were asked to wear an accelerometer daily and were 
asked to gradually increase their physical activity levels, working towards a target of 
achieving thirty minutes of moderate exercise on five days of the week over the 12-week 
period. iii) OLE supplement: volunteers consumed capsules of OLE over a 12-week period 
with no guidance on PA. iv) PA+ OLE supplement. Primary outcome for the study was 
change in 24-h ABP. Secondary outcome measures for the study were digital pulse wave 

















































Figure 35 Consolidated Standards of Reporting Trials (CONSORT) diagram. 
Expression of interest 
N = 213 
Declined to participate 
N = 73 
Screened for eligibility 
N = 140 
BP not within inclusion range n = 21 
Placed on medication n = 6 
Low BMI n = 7 
Diabetic n = 4 
Eligible for study inclusion (enrolled) 
N = 66 
Group POB 
N = 16 
Group POB + PA 
N = 17 
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5.1.3 Supplement and Treatment Regime 
The study product OLE and placebo capsules were provided by Comvita (Te Puke, New 
Zealand). The capsules were composed of an opaque chocolate brown soft gelatine. Each 
OLE capsule contained a total of 350 mg Olea europea leaf extract dry concentrate 10:1 
(equivalent to 3.5 g of fresh olive leaf 3.5 g), delivering 66-79.2 mg oleuropein. 
Compositionally, OLE contained oleuropein, oleoside, hydroxytyrosol, luteolin-7-O-
glucoside, tyrosol, verbascoside, apigenin-7-O glucoside, rutin, vanilic acid, vanilin and 
luteolin (Comvita, Limited). The placebo capsule contained 350 mg of maltodextrin per 
capsule and were identical in appearance to OLE capsules.  Subjects were instructed to 
take 2 tablets daily, preferably after breakfast or the first meal of the day, and to record 
each intake in the assigned supplement diary. If a dose was missed, participants were 
requested to indicate the reason for missing and not to carry over the dose to the next 
day. Any changes in medication, dietary supplement intake, general well-being, bowel 
movements, and/or any adverse effects during the intervention were to be self-reported 
in the supplement diary.  
5.1.4 Physical activity intervention 
The physical activity intervention was designed to encourage a progressive increase in 
physical activity over 12 weeks. Volunteers were asked to wear an Omron hip mounted 
pedometer (Omron Walking Pro.2). The data from this instrument can be uploaded onto 
an online database and the subjects were encouraged to record the data with the 
ultimate goal of achieving 10000 steps per day. They received weekly motivational hint 
sheets by mail that also encouraged continued engagement. These sheets were 
structured such that activity was increased progressively over the duration rather than 




5.1.5 Randomization and Masking 
Randomized allocation was done using the Covariate Adaptive Randomization 
programme. At screening, individuals were categorised by gender, age group and BP 
range to ensure well-balanced groups in the intervention phase.  Both researchers and 
subjects were ‘blinded’ to the contents of capsules being taken. The products were 
labelled using A and B and provided in identical bottles made from opaque plastic. The 
investigational product was safely stored in a locked and limited access area. The code 
was kept by an independent third party, and was not released until after statistical 
analysis.  
5.1.6 Assessment Protocol 
Enrolled participants were required to visit the Hugh Sinclair Unit of Human Nutrition on 
5 occasions (screening visit, familiarisation visit, baseline visit, 6-week visit and 12-week 
visit) during the study period, as shown in Figure 36. On the measurement days, subjects 
attended having fasted for at least 12 hrs before the visit. A ‘familiarisation visit’, was 
conducted to minimise the impact of stress on the subsequent (baseline) assessments as 
well as to equip/instruct the subjects with 24-h ABP monitors and the accelerometers. At 
baseline 24-hour ambulatory blood pressure was assessed using the A&D Medical 
Ambulatory Blood Pressure Monitor (Model TM-2430, Scan Med, A&D Medical, UK). 
Blood samples were taken and anthropometric measures were made. Subjects were 
given the relevant capsules and instructed to maintain their habitual diet and physical 
activity throughout the intervention, unless otherwise directed. The measurements of 24-
h ABP, physical activity, clinical BP, arterial stiffness, anthropometrics and the collection 



























Figure 36 Outline of study design. 
5.1.7 Outcome Assessments 
Compliance measures 
At the end of 12 weeks, the treatment bottle containing any unused tablets was returned 
with a participant diary (self-report), noting adverse effects, and/or reasons for missed 
doses. At the end of the trial, all tablets were manually counted and tallied with the 
corresponding diary records to monitor compliance. 24-h urine and blood samples were 
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analysed for phenolic compounds deriving from the OLE via LC-MS to assess subject 
compliance Adherence to the PA arm was assessed through the assessment of pedometer 
and accelerometer data. 
24-h ambulatory blood pressure 
The description of methods is presented in chapter two (section 2.5.1). 24h ambulatory 
BP monitoring was carried out prior to each clinical assessment (baseline, week 6, week 
12).  
Arterial stiffness 
The description of methods is presented in chapter two (section 2.5.2). Arterial stiffness 
was carried out at baseline, week 6, week 12.  
Anthropometric measurement 
Standing height and body weight were measured before vascular assessments 
commenced. Height was measured using a wall-mounted Stadiometer (Medical scales 
and measuring system, Seca Lt., UK). A Tanita BC-418MA Body Composition Analyser 
(TANITA, UK, Ltd.) was used to measure weight and body composition following the 
instructions of the manufacturers. Body mass index (BMI) was calculated as 
weight/height2 (kg/m2). Waist circumference was measured using a flexible non-
stretchable tape.  
Blood collection 
Fasting blood samples were collected at baseline 6 weeks and after 12 weeks. Venous 
blood samples were collected in serum lithium heparin, EDTA and serum separator 
vacutainers (SST; Greiner Bio-one, USA) with no additives. Blood collected in SST was 
allowed to coagulate at room temperature for 30 min before further centrifugation. Then 
all samples were centrifuged at 1800 g for 15 min at 4°C to separate plasma. Plasma was 
stored in 2 ml screw cap microtube (Sarstedet Ltd, Leicester, UK) at - 80°C until analysis. 
Biochemical measures 
HbA1C was measured by HPLC at Royal Berkshire Hospital, Reading. Total cholesterol 
(TC), HDL cholesterol (HDL-C), triglycerides (TAG), non-essential fatty acid (NEFA) and 
fasting glucose were enzymatically measured using an automated ILAB 600 clinical 




lipoprotein cholesterol (LDL-C) was calculated using the Friedewald formula: ([LDL-C] = 
[TC] – [HDL-C] – ([TAG]/2.2). Plasma insulin was measured using an ELISA assay kit (Dako 
Ltd, Denmark) following standard instructions provided by the manufacturer. Insulin 
resistance (HOMA-IR) was calculated using the formula: (glucose x insulin)/22.5 and 
insulin sensitivity (QUICKI) was evaluated by using standard equations: 1/ (log insulin + log 
glucose). 
5.1.8 Sample size and Statistical analysis 
Sample size was calculated by using G * Power 3 program [26]. A power calculation was 
based upon data from a crossover study investigating the effect of the same OLE on blood 
pressure in 45 pre-hypertensive volunteers. In that study, the mean difference in 24-hour 
systolic blood pressure between treatment (dose OLE equivalent to 136.2 mg oleuropein 
per day) and placebo was -3.33 mm Hg with an sd of 7.9, thus giving an effect size 
(Cohen’s d) of 0.422 with the cut off for α at 0.05 and with 85 % power, predicted total 
sample size is 112 volunteers; 28 per group, or 30 per group allowing for drop outs. 
Due to time and resource the study was cut short with 63 volunteers per group. A post 
hoc power analysis given the mean and the between-groups comparison effect size 
observed in the present study (Cohen’s d= 1.03), where n= 63 gave a statistical power 
greater than 99% to detect a mean difference in 24-h SBP of -9.23 (±17.76) mmHg 
between treatment and placebo.  
All statistical analyses were performed using SPSS statistic software version 24 for 
Windows (IBM Corporation, USA). Descriptive statistics are presented as means and 
standard deviations. Data were initially checked for normality using the Kolmogorov-
Smirnov and Shapiro-Wilk test. One-way ANOVA was used to determine difference in 
treatment for the groups. The least significant difference was used as Tukey’s HSD post 
hoc test. There were sufficient numbers in each treatment arm to additionally perform a 
parallel comparison; independent t-tests were used to compare pre-post treatment 
differences in four arms during the first intervention phase. P-values below 0.05 were 
deemed to be statistically significant. In addition, we determined whether there were any 







Sixty-six eligible subjects were randomised in to the four arms of the trial (Figure 1).  
Three subjects dropped out of the study prior to the assessment point in week 6. One 
subject fell ill (abdominal pain) and two subjects withdrew due to work commitments. 
Consequently, 63 subjects completed all assessment time points and were included in the 
primary and secondary outcomes analyses. Compliance with consuming the study 
capsules was greater than 90 % as measured by counting capsules in returned containers 
for all groups (compliance rates were 96.67 % (±4.23) of placebo group, 95.98 % (±5.16) 
for the placebo + PA group, 96.43 % (±3.25) for the OLE group and 91.76 % (±6.02) for 
OLE + PA group. Subsequently all 63 datasets were included in the analysis. Total steps 
taken/day was significantly increased during the intervention period by an average of 
64.41% to 9,499 (±587) for Placebo+PA group (P < 0.001). Subjects in OLE+PA group 
significantly increased their total steps/day by an average of 40.21% to 8,043 (±723) 
throughout the study (p < 0.001). There was no significant difference in total steps 
count/day between Placebo+PA and OLE+PA. The step count in the non-PA groups 
remained unchanged during the 12-week intervention, as measured by accelerometer 
data. 
Baseline characteristics of the subjects 
Baseline characteristics of the subjects can be found in Table 11-12. All subjects were 
overweight (range 27.1-30.1 kg/m2), with a mean age of 45.7 years (range 42.18-49.28). 
Mean daytime BP at baseline was 133/80 mmHg, and all were deemed pre-hypertensive 
[27] Subjects mean triglyceride and HDL-C levels were within the ideal range set by NHS 
choices guideline UK (1.3 and 1.4 mmol/L vs. guideline values of <1.7 and ≥1 mmol/L, 
respectively). Mean total cholesterol and LDL-C levels were slightly above the ideal lipid 
values (5.5 mmol/L and 3.5 mmol/L vs. guideline values of <4 mmol/L and <2 mmol/L, 
respectively). There were no differences in baseline characteristics between those 






Table 11 Baseline characteristics of subjects (Total) 
Variable Mean (SD) 
Gender (male/female) 29/34 
Age (years) 45.7 (±14.1) 
Weight (Kg) 81.1 (±12.9) 
BMI (kg/m2) 
% Body Fat 
Total cholesterol (mmol/L) 
LDL cholesterol (mmol/L) 
HDL cholesterol (mmol/L) 
Triglycerides (mmol/L) 
TC/HDL cholesterol ratio 
HbA1C (mmol/mol) 
Fasting Glucose (mmol/L) 















24-h SBP/DBP (mmHg) 129 (±12)/78 (±9) 
Daytime SBP/DBP (mmHg) 133 (±13)/80 (±9) 
Night time SBP/DBP (mmHg) 114 (±13)/67 (±8) 
BMI body mass index, TC Total cholesterol, LDL Low-density lipoprotein cholesterol, HDL 
High-density lipoprotein cholesterol, TG Triglycerides, SBP systolic blood pressure, DBP 
diastolic blood pressure, HOMA-IR homoeostasis model assessment-estimated insulin 




Table 12 Baseline characteristics of the subjects (each group) 
Variable Placebo (n=15) Placebo+PA 
(n=16) 
OLE(n=16) OLE+PA (n=16) pǂ 
Gender (male/female) 6/9 8/8 8/8 7/9 0.934 
Age (years) 49.6 ± 13.4 42.1 ±14.4 46.4 ± 14.6 45.0 ±14.1 0.530 
Weight (Kg) 78.6 ± 12.4 85.6 ± 9.6 77.3 ± 12.1 82.4 ± 16.3 0.275 
BMI (kg/m2) 
TC (mmol/L) 
LDL cholesterol (mmol/L) 
HDL cholesterol (mmol/L) 
Triglycerides (mmol/L) 






28.8 ± 5.2 
5.7 ± 0.5 
3.6 ± 1.11 
1.5 ± 0.2 
1.2 ± 0.6 
0.8 ± 0.5 
35.2 ± 3.5 
5.4 ± 0.5 
6.6 ± 3.8 
0.7 ± 0.2 
1.7 ± 1.0 
30.3 ± 5.4 
5.4 ± 0.5 
3.1 ± 1.0 
1.4 ± 0.3 
1.2 ± 0.5 
0.9 ± 0.5 
35.9 ± 4.6 
5.5 ± 0.5 
4.7 ± 0.7 
0.7 ± 0.1 
1.9 ± 2.4 
26.1 ± 8.2 
5.3 ± 0.4 
3.3 ± 0.9 
1.3 ± 0.3 
1.4 ± 0.6 
1.1 ± 0.5 
34.4 ± 4.4 
5.3 ± 0.4 
8.0 ± 10.5 
0.7 ± 0.2 
1.1 ±0.5 
29.1 ± 3.9 
5.5 ± 0.4 
3.8 ± 1.0 
1.4 ± 0.4 
1.3 ± 0.6 
1.0 ± 0.6 
35.9 ± 3.2 
5.5 ± 0.4 
8.0 ± 1.5 
0.7 ± 0.1 












24-h SBP/DBP (mmHg) 125 ±11/76±10  131 ±11 /76 ±7 132 ± 11 /76 ±7 128 ± 16 /78 ± 11 0.361/0.421 
Daytime SBP/DBP (mmHg) 128 ±11/78±10 135 ± 12 /83 ±8 135 ±11 /79 ± 8 132 ± 17 /81 ± 12 0.391/0.478 
Night time SBP/DBP (mmHg) 108 ±7 /63 ± 7 116 ± 14 /68 ± 8 117 ±14 /67 ± 7 115 ± 14 / 68 ± 9 0.245/0.250 
BMI body mass index, TC Total cholesterol, LDL Low-density lipoprotein cholesterol, HDL High-density lipoprotein cholesterol, TG 
Triglycerides, SBP systolic blood pressure, DBP diastolic blood pressure, PA physical activity,OLE olive leaf extract, HOMA-IR homoeostasis 
model assessment-estimated insulin resistance, QUICKI quantitative insulin sensitivity check index 
 
Data points are mean ± SD 




Blood Pressure and vascular function  
24 hour blood pressure 
Mean 24-h, daytime and night-time BP at baseline, 6-weeks and at the end of the 12-
week intervention are summarised for each group in Figure 37-38. When compared with 
placebo, mean 24-h SBP was significantly reduced in the increasing physical activity 
(Placebo+PA) group at the 6 week time-point (-7.07 mmHg ± 5.26; p = 0.048) and at the 
12 week point (-9.05 mmHg ± 6.39; p = 0.001). Those consuming the OLE with no physical 
activity guidance (OLE group) also showed a significant reduction in 24-h SBP of 10.69 
mmHg ± 7.56 and 11.16 mmHg ± 7.88 at 6 and at 12 weeks (p = 0.031 and p = 0.006). 
Amongst those consuming the OLE with physical activity instruction (OLE+PA group) the 
mean 24-h SBP was reduced by 9.23 mmHg ± 6.53 at 12 weeks (p = 0.027) relative to 
control, although the reduction at 6 weeks (6.31 mmHg ± 4.45 did not reach significance 
(p = 0.118). In the OLE group the 24-h SBP fell relative to baseline at 12 weeks by -5.8 
mmHg ± 7.6 (p = 0.011) and in the OLE+PA the reduction from baseline at 12 weeks was 
−3.9 mmHg ± 6.7 (p = 0.034).  
Daytime blood pressure 
Daytime SBP was lower at 12 weeks compared to control following both the physical 
activity guidance intervention by -4.19 mmHg ± 10.27, p = 0.041 and the consumption of 
OLE intervention by -5.07 mmHg ± 7.16, p = 0.025; however, the mean daytime SBP did 
not significantly decrease from baseline to 12 weeks in either group (Figure 37-38). There 
was a near-significant decrease in the mean rate of daytime SBP (p = 0.087), night time 
SBP (p = 0.094), and DBP (p = 0.076), following OLE+PA compared with the control. There 
were no significant differences between the effects of the four treatments on the mean 
change in 24-h DBP, or daytime DBP. However, a within group analysis revealed a 
significant decrease from baseline to 12 weeks in 24-h mean DBP −3.6 mmHg ± 6.3, p = 
0.011 and −1.1 mmHg ± 5.3, p = 0.034) over 12 weeks subsequent to placebo+PA and 
OLE+PA treatment, respectively. No significant effects on arterial stiffness were found for 






Figure 37 Changes in 24-h, Day-time and night-time systolic ambulatory blood pressure at 
the end of the 12-week intervention in OLE, OLE+PA, placebo+PA and placebo groups. 
Data points are mean ± SD (n = 63). *Mean value was significantly different between all 
treatment (p > 0.05). 
Figure 38  Changes in 24-h, Day-time and night-time diastolic ambulatory blood pressure 
at the end of the 12-week intervention in OLE, OLE+PA, placebo+PA and placebo groups. 
Data points are mean ± SD (n = 63). *Mean value was significantly different between all 







Figure 39 Arterial stiffness at baseline, 6-week and at the end of the 12-week intervention 
in OLE, OLE+PA, placebo+PA and placebo groups. Data points are mean ± SD (n = 63). 
*Mean value was significantly different between all treatment (p > 0.05). 
                     
Body composition and biochemical analysis 
There was no impact of any treatments on body weight, waist circumference, relative fat 
mass or fat-free mass (p > 0.05) (Figure 40-43). Compared with placebo, treatment with 
increasing PA alone, or OLE alone, or with OLE +PA did not significantly alter fasting 
serum total cholesterol and LDL-C level (p > 0.05. HDL-C was significantly increased from 
baseline to 12 weeks following consumption of OLE alone (p = 0.024); however, there 
were no significant differences in HDL-C at 12 weeks compared to the control. 
























= 0.005) from baseline to 6 weeks, but there were no significant differences in TAG (p = 
0.366) and TC/HDL-C ratio (p = 0.350) relative to control) (Figure 44-49). The OLE+PA 
group had a significantly reduced HbA1C (p = 0.045) from baseline to 6 weeks; however, 
there were no significant effects on HbA1C compared to the control (p = 0.939). There 
were no effects of OLE intake and/or PA on fasting glucose, insulin or calculated HOMA-IR 







Figure 40 BMI at baseline, 6-week and at the end of the 12-week intervention in OLE, 
OLE+PA, placebo+PA and placebo groups. Data points are mean ± SD (n = 63). *Mean 
value was significantly different between all treatment (p > 0.05). 
 
Figure 41 Fat mass at baseline, 6-week and at the end of the 12-week intervention in OLE, 
OLE+PA, placebo+PA and placebo groups. Data points are mean ± SD (n = 63). *Mean 











































Figure 42 Percentage fat at baseline, 6-week and at the end of the 12-week intervention 
in OLE, OLE+PA, placebo+PA and placebo groups. Data points are mean ± SD (n = 63). 
*Mean value was significantly different between all treatment (p > 0.05). 
 
Figure 43 Waist circumference at baseline, 6-week and at the end of the 12-week 
intervention in OLE, OLE+PA, placebo+PA and placebo groups. Data points are mean ± SD 














































Figure 44 Total cholesterol level at baseline, 6-week and at the end of the 12-week 
intervention in OLE, OLE+PA, placebo+PA and placebo groups. Data points are mean ± SD 
(n = 63). *Mean value was significantly different between all treatment (p > 0.05).  
 
Figure 45 Low-density lipoprotein cholesterol level at baseline, 6-week and at the end of 
the 12-week intervention in OLE, OLE+PA, placebo+PA and placebo groups. Data points 




























































Figure 46  High-density lipoprotein cholesterol level at baseline, 6-week and at the end of 
the 12-week intervention in OLE, OLE+PA, placebo+PA and placebo groups. Data points 




Figure 47 LDL-C/HDL-C ratio at baseline, 6-week and at the end of the 12-week 
intervention in OLE, OLE+PA, placebo+PA and placebo groups. Data points are mean ± SD 















































Figure 48  Triglycerides level at baseline, 6-week and at the end of the 12-week 
intervention in OLE, OLE+PA, placebo+PA and placebo groups. Data points are mean ± SD 
(n = 63). *Mean value was significantly different between all treatment (p > 0.05). 
 
Figure 49 Non-esterified fatty acid level at baseline, 6-week and at the end of the 12-
week intervention in OLE, OLE+PA, placebo+PA and placebo groups. Data points are mean 



















































Figure 50 HbA1c level at baseline, 6-week and at the end of the 12-week intervention in 
OLE, OLE+PA, placebo+PA and placebo groups. Data points are mean ± SD (n = 63). 
*Mean value was significantly different between all treatment (p > 0.05). 
 
Figure 51 Fasted glucose level at baseline, 6-week and at the end of the 12-week 
intervention in OLE, OLE+PA, placebo+PA and placebo groups. Data points are mean ± SD 
























































Figure 52 Insulin level at baseline, 6-week and at the end of the 12-week intervention in 
OLE, OLE+PA, placebo+PA and placebo groups. Data points are mean ± SD (n = 63). 
*Mean value was significantly different between all treatment (p > 0.05).
 
Figure 53 Homoeostasis model assessment-estimated insulin resistance at baseline, 6-
week and at the end of the 12-week intervention in OLE, OLE+PA, placebo+PA and 
placebo groups. Data points are mean ± SD (n = 63). *Mean value was significantly 

























































Figure 54 Quantitative insulin sensitivity check index at baseline, 6-week and at the end 
of the 12-week intervention in OLE, OLE+PA, placebo+PA and placebo groups. Data points 





































5.2      Discussion and Summary 
We hypothesised that consuming OLE, in combination with increasing physical activity, 
would lower blood pressure to a greater extent than either intervention alone in pre-
hypertensive British adults. As expected, we observed a reduction in blood pressure 
amongst those consuming the OLE alone, this has now been shown consistently in 
chronic intervention studies with OLE in pre-hypertensive volunteers. Lockyer et al. 
demonstrated that OLE at dose of 136.2 mg oleuropein/day has the potential to 
significantly reduce 24-hour SBP (3.33 mmHg) and daytime SBP (3.95 mmHg) and 24-hour 
DBP (2.42 mmHg) and daytime DBP (3.00 mmHg) relative to control  [8]. In addition, OLE 
at dose of oleuropein, 200 mg/day resulted in mean reductions in SBP and DBP of 12 and 
5 mmHg, respectively, in hypertensive patients [25] and 13 and 5 mmHg, respectively, in 
pre-hypertensive MZ twins [6]. These reductions in BP have not been reported in 
intervention studies with normotensive subjects [28, 29]. In the present study, the OLE 
intervention led to a reduction in 24-hour systolic blood pressure, from baseline, of 6 mm 
Hg at 6 weeks, and of 5.8 mm Hg at 12 weeks. In contrast, the non-physical activity 
placebo group, showed an actual increase in 24-hour systolic blood pressure from 
baseline at both time-points. The magnitude of the reduction in SBP with treatment is 
clinically meaningful; each 2 mm Hg reduction in SBP is associated with 7% reduction in 
coronary artery disease and a 10% reduction in the risk of stroke [30]. Curiously however 
we observed no reduction in DBP, although this was an average not elevated at baseline, 
it is thought that SBP may be a more valuable measurement in evaluating health 
outcomes related to hypertension [31].  
The intervention with the physical activity guidance plus the placebo capsule also led to a 
reduction in 24-hour systolic blood pressure, amounting to -2.8 and -3.69 mmHg at weeks 
6 and 12 respectively. This clinically meaningful reduction in blood pressure was 
precipitated by an average increase in total steps taken per day of 65% (3722 steps) 
above that observed at baseline. A recent meta-analysis of 9 studies suggested achievable 
reductions in SBP amongst hypertensive patients, guided towards increasing PA over a 
sustained period, of between 4-10 mmHg, and with more modest reductions of between 
1 and 6 mmHg for diastolic pressure [32]. These and our own data support current 
physical activity guidelines for hypertension [33, 34]. The underlying mechanisms 




sympathetic nervous system activation [35], decreased renin activity and increased 
endothelial nitric oxide synthase activity [36], improved endothelium mediated 
vasodilatation and systemic arterial compliance in large vessels [37], and reduced 
peripheral vascular resistance [38]. 
Those volunteers who consumed both the OLE and who were given the PA guidance, 
showed a reduction in 24-hour systolic blood pressure from baseline in 24-h SBP, which 
was only observed at week 12. Further this reduction at -3.9 ± 6.7 mmHg was significantly 
less pronounced than that observed for the OLE group, and was of a comparable 
magnitude to that observed for the PA and placebo capsule group. Thus, our original 
hypothesis, that combining physical activity with the consumption of olive polyphenols 
would lead to greater reductions in blood pressure than either individual intervention 
alone, is not supported. It is however worth noting that the OLE+PA group were slightly 
less adherent to the physical activity intervention, they achieved an increase from 
baseline in their total step count of 40 % (2307 steps) versus 65% (3722 steps 
PA+placebo).  In addition to moving less than the PA + placebo group, these volunteers 
adhered less well to the capsule consumption, with a compliance rate of (91.76%) versus 
their sedentary peers (96.43%) Further, the mean baseline 24-hour systolic blood 
pressure was slightly lower in the OLE+PA cohort (128 mmHg) than both the OLE group 
and placebo+PA group (131 mmHg and 132 mmHg, respectively).   There is some 
argument that interventions with both physical activity and diet are not more effective 
for BP control than diet alone [38, 39], however the merits of adding physical activity to a 
polyphenol rich diet need further investigation.  
The BP-lowering benefits of consuming plant polyphenols are hard to discern in studies 
with whole foods, where the effects can be masked by the hypotensive activity of the 
fibre or monounsaturated fatty acid - rich foods that they are found in [40-43]. In the 
present study, we observed that supplementation with an OLE, with a high dose of 
phenolics (equivalent to 132 mg of oleuropein), in the absence of fibre and lipids, 
significantly reduced 24-h and daytime SBP relative to control. The possible mechanisms 
of hypotensive activity for these phenolics include inhibition ACE enzymes [44], inhibition 
of calcium channel blockers [45] and the induction of NO synthesis [46]. Proof of these 




In our analysis of secondary endpoints, we observed a reduction in the mean TC/HDL-C 
ratio (-0.290, p = 0.005) and TAG (-0.33 mmol/L, p = 0012) from baseline at 6 weeks for 
volunteers consuming the OLE, and an increase in the HDL- C (0.13 mmol/L, p = 0.024) 
from baseline at 12 weeks. HbA1C was reduced by OLE+PA combination after 6 weeks 
compared to baseline (−1.15 mmol/mol, p = 0.045). Other endpoints measured namely 
vascular stiffness index, body composition, lipids, glucose or insulin were not significantly 
affected by any of the treatments over 12 weeks These findings mirror previous work in 
hypertensive patients prescribed either OLE or an increased physical activity intervention. 
In these studies improvements in blood pressure were observed without changes in the 
vascular stiffness index [47, 48], BMI [8, 39, 49] or in the metabolism of glucose  [6], or 
lipids [49].  
In contrast to Wainstein et al., Lockyer et al., Salisu et al., and Ammar et al., we did not 
observe any significant changes in total cholesterol, LDL-C and HDL relative to control [6, 
8, 25, 50]. The mean baseline cholesterol was in the high normal category for all study 
groups. Our physical intervention was not of a high enough intensity to expect significant 
changes in body composition over the study timeframe and our participants had good 
initial blood sugar control.  
Study strengths and limitations. This study has several strengths. We used a randomised 
double-blind (to the OLE intervention), four-arm, parallel-group controlled trial design, 
and we 24-h ambulatory blood pressure as a primary endpoint. This is a well validated 
measure causally implicated in disease risk [51]. The compliance with respect to OLE 
consumption was excellent. We conducted a familiarisation visit for subjects in order to 
minimise the impact of stress on the subsequent (baseline) assessments. All subjects 
were free of antihypertensive drugs, as potential confounding factors. However, this 
study has several limitations. The starting 24-h DBP levels of the subjects were not 
elevated. We did not implicitly control the amount and intensity of the physical activity 
prescription, and none of the participants achieved the national physical activity 
guidelines. The volunteers adherence to the physical activity intervention also decreased 
over time. We did not measure the effects of the intervention arms on habitual diet. The 
subject of the study included both men and women; variance in the female cycle and oral 
contraceptives in pre-menopausal women might be a possible confounding factor in our 




To conclude, OLE consumption, increasing physical activity and the combination of these 
interventions significantly improved 24-h SBP. Both interventions may be considered as 
beneficial in the control of blood pressure, consumption of supplemental olive leaf 
phenolics may be easier for a free living otherwise sedentary pre-hypertensive 
population. Further work is needed to establish the benefits which might be achieved 
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Chapter 6 General discussion 
6.1  Summary and discussion 
Diets rich in plant foods are strongly associated with reduced risk of chronic diseases [1]. 
This effect may be mediated through a combination of mechanisms; plant foods are high 
in fibre which of itself is protective, they are nutrient dense and act as low energy 
displacers of other foods associated with weight gain and adverse health outcomes. They 
are also a rich source of biologically active phytochemicals including the polyphenols.  
A suggested intake of polyphenols as contributors to health and lifespan might be based 
on the amount of polyphenols in ‘5-a-day’[2]. A significant percentage of the global 
population consume low quantities of dietary polyphenols as a result of inadequate fruit 
and vegetable intake, despite public health messages encouraging fruit and vegetable 
consumption [3]. Given the persistent public health failures in achieving the 
recommendations on fruit and vegetables, the development of dietary supplements 
which contain high doses of beneficial polyphenols is desirable.  
Polyphenol supplements are increasingly popularity with the consumer, as they are 
presumed to be safe, and are freely available without prescription to all. The UK market 
for dietary supplements is worth more than £670 million, with consumers believing that 
they can provide a useful vehicle for increased consumption of dietary phytochemicals 
which may be otherwise under-consumed in the western diet [4]. However, effective 
supplements have the greatest potential to improve health and/or help prevent certain 
diseases when taken as part of a balanced diet and a healthy lifestyle. Consumers must 
realize that functional foods and supplements are not a “magic bullet” or a panacea for 
poor health habits. There are not good and bad “foods,” only good and bad dietary 
patterns [5]. 
Currently, olive oil polyphenols are the only polyphenols to have achieved a positive 
opinion for a health claim in Europe. There has been a 1.7-fold increase in the global 
consumption of olive oil between 1991 and 2015 due to its associations with health [6]. 
Nevertheless, the consumption of phenolic-rich, lipid-free valorised olive leaf products 
may be a preferential approach to ingesting these beneficial compounds. Supplemental 
OLE may be a sensible source of olive polyphenols negating the need to consume large 
amounts of energy dense olive oil [7]. Intervention studies with EVOO consumed in the 




phenolics than can be delivered in an olive leaf extract supplement [8]. Directly replacing 
traditional spreads with EVOO in the UK diet (10g per day) would beneficially increase 
MUFA consumption, but would not substantially change total polyphenol intake. 
Although, there is a growing body of research demonstrating health benefits from olive 
polyphenols, there are currently no approved claims in regard to OLE. Publications arising 
from this thesis may therefore provide further evidence for the assessment of health 
claims by olive producers in the European market. 
Recent randomised control trials demonstrate hypotensive, hypolipidemic [9-11] and 
anti-glycaemic activity [12, 13] for OLE in human volunteers. The mechanisms for these 
effects are still uncertain. In this thesis, we provide mechanistic support for the previous 
intervention studies, an understanding of the biological modes of action is a key 
component of the Bradford-Hill criteria when it comes to proving efficacy.  In chapter 3, 
we showed that OLE and its phenolics may exert anti–glycaemic effects via the inhibition 
of porcine pancreatic α-amylase and lipase activity and the suppression of cellular glucose 
transporters hence impeding glucose uptake. Anti-diabetic and anti-obesity drugs like 
acarbose and orlistat are widely used, but may induce side effects, including abdominal 
distension, bloating, and flatulence, which are linked to excessive inhibition of the 
digestive enzymes [14]. OLE showed lower, but potentially clinically meaningful inhibition 
of digestive enzymes, thus it may be a safer, cheaper and more acceptable intervention 
[15]. In chapter 4, we explored mechanisms which might explain the antihypertensive 
activities of OLE and its polyphenols. We showed that polyphenols present in OLE might 
act through stimulating NO production in endothelial cells; and we also showed that they 
inhibited the enzymes involved in the renin-angiotensin system. Again, the OLE had lower 
efficacy than the standard antihypertensive drugs, but these weaker effects in a pre-
hypertensive population might also be clinically meaningful.  
A potential public health draw back which may be associated with the consumption of 
supplements is the demotivating influence on the individual towards pursuing other 
healthy lifestyle choices such as physical activity. However, research investigating the 
synergistic benefits of including a specific dietary supplement as part of a healthy lifestyle 
is limited. Physical inactivity is an established major global health risk, and few adults in 
the UK meet current Physical Activity Guidelines [16]. Stronger scientific evidence might 




amongst people at high risk of chronic disease. In our intervention study, we therefore 
aimed to combine the consumption of phenolics with increasing physical activity with a 
view to maximising the benefit to the pre-hypertensive participants. Getting free-living 
people, especially those at high risk of disease to change their physical activity behaviours 
was a particular challenge. We used a combination of goal setting and the availability of 
immediate feedback via a pedometer to motivate this intervention. Analysis of the 
physical activity data showed that our PA intervention successfully induced behaviour 
change in this UK cohort. However, the PA was not universally adhered to by the 
participants, and the degree of behaviour change was not quite as strong as we had 
hoped for. Moreover, our study also confirmed that higher physical activity is associated 
with a reduction in blood pressure. This result has been observed before but adds to the 
body of evidence, and helps raise awareness of the importance of physical activity. In 
addition, we assessed the synergistic benefits of consuming OLE alongside being more 
physically active in individuals with elevated blood pressure for 12 weeks.  We observed 
that OLE consumption, increasing physical activity and the combination of these 
interventions significantly improved 24-h SBP. We observed a significant decrease in 24-h 
SBP after consumption of OLE alongside being increasing physical activity (OLE+PA). The 
magnitude of SBP change observed in this thesis would suggest that regular OLE intake as 
part of healthy lifestyle may be associated with a 9-14 % reduction in CHD risk and a 20-
22 % reduction in risk of stroke. According to the results presented in chapter 5, our 
original hypothesis, that combining physical activity with the consumption of olive 
polyphenols would lead to greater reductions in blood pressure than either individual 
intervention alone, is not supported. There is some argument that interventions with 
both physical activity and diet are not more effective for BP control than diet alone [17, 
18], however the merits of adding physical activity to a polyphenol rich diet need further 
investigation. A higher dose of physical activity than we employed may exert a different 
interaction with the hypotensive activity of the OLE.  In the present study, OLE 
consumption, in the absence of increasing physical activity, led to a more optimal blood 
pressure profile, however the benefits of increasing physical activity are wide and we 




6.2     Future perspectives 
The interaction between habitual diet and the consumption of olive polyphenols has not 
been well studied; it is probable that supplementation has the greatest effects in low 
polyphenol consumers. In our intervention study we collected data on habitual dietary 
intakes using a food diary which have not yet been analysed. An immediate priority for us 
is to leverage these data and to consider differences in response to the intervention 
according to habitual intake. 
Our in vitro studies (Chapter 3-4) showed that OLE inhibits key enzymes involved in 
macronutrient digestion (α-amylase and lipase), and also enzymes involved in 
hypertension (renin and ACE). In the intermediate term we intend to expand on this work 
through in silico molecular modelling, we will study the interactions of the olive phenolics 
and their in vivo metabolites with the amino acids in the active sites of these enzymes 
[19]. This will allow us to better understand the human observational study data.   
The biological properties of dietary polyphenols may depend on their absorption in the 
gut and their bioavailability [20]. A priority for future work is to investigate the effects of 
digestive processes on the bioactivity and bioavailability of individual OLE phenolics. We 
have developed in vitro digestion and colonic fermentation models which might be 
leveraged to help us understand the concentrations of these molecules likely to directly 
interact with the vascular endothelium [21]. Further research is also needed to elucidate 
which specific OLE polyphenols exert the most potent effects, here we only considered 
the major phenolics (OL and HT) other related molecules present in OLE might have a 
considerable physiological influence. There remains a lack of knowledge about the 
biological effects of the individual circulating metabolites of OLE. Thus, future 
intervention studies might seek to quantify these in appropriate samples [22]. 
The work presented in this thesis adds to growing evidence demonstrating the benefits of 
OLE for cardiovascular health; from the human intervention trials we can now be fairly 
confident of the anti-hypertensive effects, anti-glyceamic effects and anti-oxidant effects 
of OLE, although mechanisms of action still need to be fully elucidated. Therefore, in the 
long term the strategy for olive polyphenol research may be to focus on wider benefits, 
improved cardiovascular function may have links to cognition which could be explored. 
Extra virgin olive oil consumption has been shown to improve cognitive function [23] and  




The influences of OL polyphenols on macronutrient absorption and glycaemia might have 
consequences for appetite regulation, again this is an exciting and timely area for 
potential research. Polyphenol rich grape extract consumed with a high starch-based 
meal, induced post-meal CHO malabsorption, enhancing satiety and reducing food intake 
at a later meal [25]. 
 
6.3    Concluding remarks 
Taken together, our in vitro studies suggest potential mechanisms involved in the anti-
hyperglycaemic activities and anti-hypertensive activities of OLE polyphenols. OL 
phenolics may influence glucose metabolism by inhibiting enzymes involved in glucose 
and fat digestion in the small intestine, and by inhibiting glucose uptake by the gut 
epithelia. In vitro, OLE phenolics enhanced NO production and inhibit angiotensin 
enzymes albeit at supra-physiological doses, this mechanism may help explain the 
observed improvements in blood pressure, but further studies are needed. It is possible 
that in vivo observations are due to the synergistic effect between the various 
polyphenols in OLE mixture; and this mixture is poorly understood.  
Our data add weight to growing evidence that olive phenolics may be useful as 
supplements for the prevention of chronic diseases. Moreover, the current research 
achieved its objectives of providing evidence that OLE consumption, increasing physical 
activity and the combination of these interventions significantly improved 24-h SBP. Both 
interventions may be considered as beneficial in the control of blood pressure, 
consumption of supplemental olive leaf phenolics may be easier for a free living 
otherwise sedentary pre-hypertensive population. It is hoped that publications arising 
from this thesis may provide further evidence for the assessment of health claims made 
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Appendix: Human studies Ethics Application 
SECTION 1: APPLICATION DETAILS 
 
1.1  
Project Title: Olive leaf extract as part of a healthy lifestyle in the reduction of 
blood pressure   
 
Date of Submission: December 2014   Proposed start date: March 2015   Proposed 




Principal Investigator: Dr Daniel Commane  
Office room number:  3.43     Internal telephone: 0118 378 7108 
 
Email address     d.m.commane@reading.ac.uk           
Alternative contact telephone:  mobile phone:  07834423112 
(Please note that an undergraduate or postgraduate student cannot be a named 
principal investigator for research ethics purposes. The supervisor must be declared 
as Principal  Investigator) 
Other applicants 
 
Name: Miss Bandhita Saibandith (PhD Student) Department of Food and Nutritional 
Sciences 
Email: B.Saibandith@pgr.reading.ac.uk; mobile phone specific for study: 
07475285282 
         Name: Prof Jeremy Spencer. Department of Food and Nutritional Sciences  
         Email: J.P.E.Spencer@reading.ac.uk 
























1.3  Project Submission Declaration 
 
I confirm that to the best of my knowledge I have made known all information relevant to 
the Research Ethics Committee and I undertake to inform the Committee of any such 
information which subsequently becomes available whether before or after the research 
has begun. 
 
I understand that it is a legal requirement that both staff and students undergo Criminal 
Records Checks when in a position of trust (i.e. when working with children or vulnerable 
adults).  
 
I confirm that a list of the names and addresses of the subjects in this project will be 
compiled and that this, together with a copy of the Consent Form, will be retained within 
the School for a minimum of five years after the date that the project is completed. 
 
Signed…………………………… (Principal Investigator)            Date:………… 
 
           …………………………… (Student)                                  Date:………… 
 
           …………………………… (Other named investigators)    Date:………… 
 
  …………………………… (Other named investigators)    Date:………… 
 




University Research Ethics Committee Applications 
Projects expected to require review by the University Research Ethics Committee 
must be reviewed by a member of the School research ethics committee and the 
Head of School before submission. 
 
        Signed…………………………… (Chair of School Committee)  Date:…………………… 
  








Please provide a summary of the project in non-specialist terms, which includes a 
description of the scientific background to the study (existing knowledge), the 
scientific questions the project will address and a justification of these. Please note 
that the description must be sufficient for the committee to take a reasonable view on 
the likely scientific rigour and value of the project. 
 
Hypertension affects about 30% of the UK population and is causally implicated in the 
aetiology of renal disease, cardiovascular disease and stroke. Ageing, obesity, a poor 
diet and low levels of physical activity are all risk factors [1].  
Studies have shown that adherence to a Mediterranean diet is protective against 
hypertension and its associated morbidities; olive oil is believed to be a key 
beneficially bioactive component of that diet [2]. As a source of lipids olive oil is an 
unremarkable blend of monounsaturated, polyunsaturated and saturated fatty acids; 
it is however rich in phenolic compounds, principally oleuropein and hydroxytyrosol, 
which may be of benefit to health. A recent randomised intervention trial in 
predominantly hypertensive volunteers showed that adherence to a Mediterranean 
diet supplemented with extra virgin olive oil, reduced blood pressure and other 
measures of cardiovascular disease risk [3]. Olive phenolics can be extracted cheaply 
from the waste products of olive oil manufacture, such as the plant leaf and these are 
used as dietary supplements. In intervention studies in hypertensive or borderline 
hypertensive patients, olive leaf extract consumption has been shown to reduce 
blood pressure [4-6].  
Another intervention with established efficacy for improving blood pressure is to 
increase physical activity (7). The ‘Start Active, Stay Active’, Chief Medical Officers 
report on physical activity recommends that adults achieve 150 minutes of moderate 
intensity physical activity per week, while data in that report suggest that fewer than 
40% of adult men and 30% of adult women achieve these targets. Adherence to the 
physical activity guidelines may in fact be much worse in sub-sections of the 
population at higher risk of hypertension. 
 
From a public health perspective, holistic guidelines for the prevention of 
hypertension, or its early diagnosis and management, based around a healthy diet 
and lifestyle are preferable to pharmaceutical intervention. Lifestyle interventions are 
economically favourable and they come with fewer side effects and perhaps wider 
health benefits than antihypertensive drugs. This study therefore aims to evidence 
the synergistic benefits of consuming plant (and specifically olive) phenolics alongside 
achieving the recommended guidelines for physical activity in individuals with 
elevated blood pressure.  
 
The proposed study is funded by Comvita Ltd. It will be structured as a four way 
parallel study design in pre-hypertensive volunteers. The study arms are: i) A placebo 
control arm, on which volunteers consume a placebo capsule (Maltodextrin) daily 




control supplement and  receive guidance on achieving the physical activity 
guidelines, they will be asked to wear an accelerometer daily and be asked to 
gradually increase their physical activity levels working towards a target of achieving 
thirty minutes of moderate exercise on five days of the week over the 12 week 
period, the accelerometer will be used both to monitor adherence but also as a 
motivational tool with the data up-loadable on to a community space, and a 
discussion/online support network created to establish a motivational competition for 
participants. iii) An olive leaf extract arm; volunteers will consume capsules of olive 
leaf extract (132 mg of oleuropein per day suspended in olive leaf extract) for 
consumption over the 12 week period with no guidance on physical activity. iv) And 
finally a physical activity and olive leaf extract arm, volunteers will receive the same 
intervention as the physical activity arm plus the OLE supplement over the 12 week 
period.     
The intervention will last for 12 weeks and adherence to the treatment arms will be 
assessed via the analysis of plasma for metabolites of olive extract and through the 
assessment of accelerometer data.  
Primary outcomes for the study will be changes in 24 hour ambulatory blood pressure 
and digital pulse wave velocity (as a measure of vascular function). Secondary 
outcome measures for the study will be the plasma HB1AC levels, (a measure of 
chronic blood sugar control). Volunteers will need to attend the NRG clinical unit on 
five occasions to facilitate screening and the collection of samples.      
No adverse effects are anticipated with any of the treatments.  
Public health guidelines generally advocate a healthy diet and increasing physical 
activity for the prevention of disease, few intervention studies have considered the 
synergistic effects of both. If successful this study may therefore be used to support 




(This box may be expanded as required) 
2.2 
Procedure 
Please briefly describe what the study will involve for your participants and the 




This study is designed to test the hypothesis that olive phenolics and physical activity 
will induce independent and synergistic improvements to blood pressure in non-
medicated pre-hypertensive volunteers in a chronic intervention.  
The study will aim to recruit volunteers with above average blood pressure, but 
without clinically managed stage 2 hypertension (systolic 120 -160 and diastolic 80-
99) 
Suitable participants will be further defined as 
   •Men and women 
   •25−70y 




   •not having suffered a myocardial infarction/stroke in the past 12 months 
   •not diabetic (diagnosed or fasting glucose > 7 mmol/l) or suffer from other endocrine 
disorders 
•not suffering from renal or bowel disease or have a history of choleostatic liver or 
pancreatitis 
•not on drug treatment for hyperlipidaemia, hypertension, inflammation or 
hypercoagulation 
   •no history of alcohol misuse 
   •not planning or on a weight reducing regime 
   •not taking any fish oil, fatty acid or vitamin and mineral supplements 
   •non smokers 
Females who are breast-feeding, who may be pregnant, or if of child-bearing potential 
and are not using effective contraceptive precautions will be excluded. 
 
Interested volunteers will be provided with outline information about the study 
(Appendix D) and asked to complete a medical and lifestyle questionnaire (Appendix 
E). Volunteers who meet the inclusion criteria will be asked to attend a screening 
session during which a fasting blood sample will be taken and their BMI, waist 
circumference and blood pressure measured. The screening blood sample will be 
analysed for total cholesterol (TC), high density lipoprotein (HDL) cholesterol, 
triacylglycerol and glucose; and will also be used to determine blood count and kidney 
and liver function. By screening a blood sample, the general state of health of the 
volunteer may be ascertained by identifying if certain conditions are present, such as 
anaemia, hyperlipidaemia, diabetes and cirrhosis of the liver. The total pre-screening 
volume of blood collected will be 15mL (approximately 1 tablespoon). Individuals who 
are anaemic (Hb <14g/dl male, 11.5g/dl female) or who have ‘abnormal’ blood 
biochemistry based on standard clinical cut-offs, will be automatically excluded. 
Suitable individuals (please see page 4) will be invited to participate in the study. With 
the participants’ permission, a letter informing the General Practitioners of each 
volunteer’s study participation will be sent Appendix F).  
At all stages of the study each participant will be identified by a unique code number. 
 
During an initial two−week run−in period no intervention will be provided to any of the 
volunteers. However, during this period subjects will attend the Hugh Sinclair Unit of 
Human Nutrition for a ‘familiarisation visit’ in order to have their blood pressure (BP) 
measured and vessels elasticity determined via the Digital Volume Pulse (DVP) as a 
surrogate marker of blood flow. Stress is a major determinant of BP and vascular 
function; anxiety caused by unfamiliarity with the procedures may cause atypical values 
on the first visit (white coat effect). Our proposal to include measurement of these 
parameters in the run–in (as a dummy measure) aims to familiarise the participants with 
the techniques in order to minimise the impact of stress on the subsequent (baseline) 
assessments. 
Volunteers will then be randomised to one of the four study arms.  
i) A placebo control arm. These volunteers will be asked to consume a placebo 
capsule (maltodextrin) daily over 12 weeks. 
ii) An increasing physical activity arm. Volunteers will be given a placebo control 




be asked to wear an accelerometer daily and given the target of achieving 
thirty minutes moderate exercise on five days of the week over the 12 week 
period, the accelerometer will be used to monitor adherence but also as a 
motivational tool with the data up-loadable on to a community space, and a 
discussion/online support network created to establish a motivational 
competition for participants. 
iii) An olive leaf extract supplement arm: volunteers will be given capsules of the 
olive leaf extract (containing 132 mg of oleuropein in olive leaf extract) for 
consumption once daily over the 12 week period with no guidance on physical 
activity.  
iv) A physical activity and olive leaf extract combined arm: Volunteers will receive 
the same instruction and support tools regarding exercise as the physical 
activity arm plus they will be asked to consume the OLE supplement capsule 
daily over the 12 week period     
 
Each volunteer will be required to record information daily about their general well-
being, bowel movements, any medication they take during the trial and any adverse 




Motivating physical activity:  
Volunteers on the physical activity arm of the study will be asked to wear an Omron 
hip mounted pedometer. The data from this instrument can be uploaded onto an 
online database and we will provide the individuals with a diary in which they can 
track their daily step count. Volunteers will receive weekly motivational hint sheets 
(Appendix K) through the post to encourage continued engagement. These sheets are 
structured such that activity is increased progressively over the duration rather than 
setting potentially unachievable and therefore demotivating targets.  
 
Volunteers will be required to attend the clinical unit for a total of five clinical visits, 
screening, familiarisation, baseline, 6 weeks and at 12 weeks, volunteers will visit the 
clinical nutrition unit having fasted overnight, in order to provide samples and have 
measurements taken (visits 1-5, Figure1).  
The primary endpoint is 24 hour ambulatory blood pressure measured using the ScanMed 
Oscillometric ABP device (www.scanmed.co.uk). Volunteers will be asked to wear the 
device which will be programmed to record BP measurements every 30 minutes during 
the day (7am-10pm) and every hour by night (10pm-7am). Measurements will be made in 
accordance with British Hypertension Society guidelines. Subjects will be asked to 
complete a diary card of activities during the 24 hour measurement period. 
 
Vascular reactivity will also be assessed using a technique called Digital Volume Pulse 
(DVP) during the clinical visit. The DVP is recorded by placing an infra−red 
light−transmitting unit on the participants’ finger and measuring the changes in the 
volume of blood in the fleshy part of the finger caused by participants’ normal pulse. 
The measurements are painless, and will take 10 seconds. Three measurements will 





 Blood samples will be collected from the cannula and used for assessing: 
 Average plasma glucose concentration (a measure of chronic blood sugar 
control) by measuring of glycated haemoglobin (HbA1c)  
 
 Plasma biomarkers of endothelial function including nitric oxide, vascular cell 
adhesion molecule (VCAM), Inter-Cellular Adhesion Molecule (ICAM), E-
selectin, von Willebrand factor 
 
 Fasting lipid profile including measures of total, low density lipoprotein (LDL) 
and high density lipoprotein (HDL) cholesterol, triglycerides and non-esterified 
fatty acids 
 
 Indices of insulin resistance derived from fasted measures of glucose, insulin 
and non-esterified fatty acids (revised QUICKI statistical analysis) (Brady et al., 
2004) 
 
  Haemostatic factors including Plasminogen activator inhibitor-1 (PAI-1) 
 
 Inflammatory biomarkers including the acute phase proteins, C-reactive 
protein (CRP), tumour necrosis factor alpha (TNFα), Interleukin-6 (IL6) 
 
 Serum will be extracted by centrifugation of fasting, venous blood collected 
into lithium heparin tubes immediately after collection at each time point and 
stored at _80oC before being analysed by 1H-NMR-based metabolomics for 
serum low molecular weight metabolite profiles, and used for assessing 
adherence to the supplement intervention. 
 
A total of 65 mL of blood shall be collected at each visit. 
 
Urine samples will be analysed for phenolic compounds deriving from the OLE via LC-
MS to assess subject compliance 
 
During each visit anthropometric measurements will be taken and recorded 
 Supine blood pressure 
 Weight 
 Waist circumference 







Setting: study visits will take place at the Hugh Sinclair Human Nutrition Unit which 
has significant experience of performing dietary intervention studies. The Department 
of Food and Nutritional Sciences is fully licensed under the Human Tissue Act 2004 
and as such will adhere to the guidelines necessary for the storage of faeces and 
blood. A detailed log will be kept to record when the samples were taken, the place of 
storage, when analysis was conducted on the samples and how and when the samples 
were disposed of. 
 
 
Assessment of physical activity 
The new lifestyles NL1000 is a hip worn pedometer that can be worn daily for the 
duration of the study it reports steps taken directly to the wearer and can therefore 
be used to motivate participants as well as to capture physical activity data. 
Individuals on the physical activity arms of the study will be asked to wear these for 
the duration. These measures will be validated against data collected using the 
wGT3X actigraph http://www.actigraphcorp.com/product-category/activity-monitors/ 
Volunteers will be asked to wear the actigraph, periodically 4 x 3 days over the 
duration of the study.  
  
 
Details of the ambulatory blood pressure measurement 
Ambulatory blood pressure will be measured using the ScanMed Oscillometric ABP 
device (www.scanmed.co.uk). This device has been validated independently 
according to the British Hypertension Society (BHS, www.bhsoc.org) Protocol (A/A 
grade). The software of the device issued to the volunteers will be programmed to 
record BP measurements every 30 minutes during the day (7am-10pm) and every 
hour by night (10pm-7am). Measurements will be made in accordance with British 
Hypertension Society guidelines. Subjects will be asked to complete a diary card of 
activities during the 24 hour measurement period. 
 Details of the procedure of Digital Volume Pulse (DVP) 
The DVP is recorded by placing an infra-red light-transmitting unit on the participants’ finger 
and measuring the changes in the volume of blood in the fleshy part of the finger caused by 




transmission of infra-red light absorbed through the finger. The amount of light is directly 
proportional to the volume of blood in the finger pulp. It has been shown that the stiffness 
index (SIDVP) that can be derived from the DVP waveforms is highly correlated to arterial 
stiffness. For measurement of the SIDVP, a photoplethysmograph (Micro Medical, Gillingham, 
Kent, UK) is placed on the index finger of the right hand to obtain the DVP.  Blood pressure 
and DVP waveforms will be recorded 3 times over 10 second periods with 5 minute intervals 
between measurements. The DVP waveform has two components. The first part of the 
waveform (systolic component) is formed as a result of pressure transmission along a direct 
path from the aortic root to the finger. The second part (diastolic component) is formed by 
pressure transmitted from the ventricle along the aorta to the lower body where it is reflected 
back along the aorta to the finger. The average peak-to-peak time (PPT) for each 
measurement will be calculated using the PulseTrace Softwave (version 1.0, Micro Medical) 
and SIDVP index will be calculated by dividing the PPT value into height in m and multiplying 
the result by 1000 to convert the result into m/sec. The reflection index (RI) is calculated as 
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(Note: All questionnaires or interviews should be appended to this application) 
2.3  Where will the project take place? 
 
 The project will take place at the Food Biosciences building 
(Department of Food and Nutritional Sciences), within the Hugh 
Sinclair Unit of Human Nutrition. 
 
If the project is to take place in Hugh Sinclair Unit of Human 







Is the research supported by funding from a research council or 
other external sources (e.g. charities, business)? Yes 
  
If Yes, please give details:  
Comvita Ltd are funding this study  
 
Please note that all projects, (except those considered as low risk, 
questionnaire-based studies which require Head of School approval) 
require approval from the University Research Ethics Committee.  
2.5 
Ethical Issues 
Could this research lead to any risk of harm or distress to the 
participants? Please explain why this is necessary and how any risk 
will be managed. 
 
There are no reported side effects of the study treatment, the supplement is a 
commercially available extract of olive leaf and all procedures (venepuncture, Digital 
Volume Pulse) will be performed by trained researchers. However, in case of an 
emergency (e.g. fainting, blood spillage) researchers will take immediate action according 
to Hugh Sinclair Unit of Human Nutrition relevant SOP that describes in detail the actions 
that need to be taken by. Also, a Departmental First Aider will be available in the building 
when blood is being taken. In case of emergency, the research scientists will call the 
emergency services (999).  
 




Will you be paying your participants for their involvement in the study? Yes 





Based on standard remuneration to volunteers on other similar studies a total of £170 
will be paid, to cover time and travel expenses incurred (5 visit days). There is no 
payment for the initial screening visit. 
 
Early dropouts will have payment pro-rated according to time spent. 
Reserve volunteers will be paid £20 if they are not required to 
participate in the treatment phases of the trial.  
 
Note: excessive payment may be considered coercive and therefore 
unethical. Travel expenses need not to be declared. 
2.8 
Data protection and confidentiality 
What steps will be taken to ensure participant confidentiality? How will the data be 
stored? 
 
Confidentiality will be maintained by allocating volunteers an identification code, 
which will be used to identify all samples and data obtained. Volunteer’s names will 
not be used in any reports or publications. All data from the study will be held 
securely throughout the duration of the project, however, a record of the names of 
the volunteers will not be held on the same file. Information matching volunteer’s 
names with identification code will be kept by a departmental secretary and the 
investigators will only use identification codes. The only time data will be matched 
with volunteer’s names is for those volunteers that request to have their personal 
results discussed with them. A request for individual results to be discussed will 






Please describe the process by which participants will be informed about the nature 
of the study and the process by which you will obtain consent 
 
Interested volunteers will be provided with outline information on the study and will 
be asked to complete a medical and lifestyle questionnaire. Volunteers who meet the 
inclusion criteria will be asked to attend a screening session during which consent will 
be asked for (Appendix C). Following agreement, a fasting blood sample will be taken 
and BMI, waist circumference and blood pressure measured. The screening blood 
sample will be analysed for total cholesterol (TC), high density lipoprotein (HDL) 
cholesterol, triacylglycerol; and glucose and will also be used to determine blood 
count and kidney and liver function. Individuals who are anaemic (Hb <14g/dl male, 
11.5g/dl female) or who have ‘abnormal’ blood biochemistry based on standard 
clinical cut-offs, will be automatically excluded. Suitable individuals will be invited to 
participate in the study. 
 




be appended to this application. 
  
2.10  
        Genotyping 
         Are you intending to genotype the participants? Which genotypes will be determined? 
No 
 
Please note that a copy of all information sheets on the implications of determining the 





SECTION 3: PARTICIPANT DETAILS 
3.1 
Sample Size 
How many participants do you plan to recruit? Please provide a 
suitable power calculation demonstrating how the sample size has 
been arrived at or a suitable justification explaining why this is not 
possible/appropriate for the study. 
 
Data from an investigation of the effect of the same extract on blood pressure in 45 pre-
hypertensive volunteers with a crossover study design was used to predict effect size. In that 
study the mean difference in systolic blood pressure between treatment and placebo was -
3.33 mm Hg with an sd of 7.9, thus giving an effect size (cohens d) of 0.422 
With the cut off for α at 0.05 and with 85 % power, predicted total sample size is 112 







Will the research involve children or vulnerable adults (e.g. adults with mental health 
problems or neurological conditions)? No 
 
If yes, how will you ensure these participants fully understand the study and the 
nature of their involvement in it and freely consent to participate? 
 
(Please append letters and, if relevant, consent forms, for parents, guardians or 
carers). Please note: information letters must be supplied for all participants 




children wherever possible in addition to that required from parents. 
 
3.3 
Will your research involve children under the age of 18 years? No  
Will your research involve children under the age of 5 years? No  
 
3.4 
Will your research involve NHS patients, Clients of Social Services or will GP or NHS 
databases be used for recruitment purposes? No 
 
Please note that if your research involves NHS patients or Clients of Social Services 
your application will have to be reviewed by the University Research Ethics 





Please describe the recruitment process and append all advertising and letters of 
recruitment. 
 
The Hugh Sinclair Unit in the Department of Food and Nutritional Sciences has 
extensive experience, and uses a variety of approaches, in the recruitment of 
subjects for dietary intervention studies. The approaches to be used here will 
include: 
 
 posters, gumtree and newspaper advertising, articles and radio interviews 
 
 advertising the study by e-mailing all staff members in large local 
organisations and companies i.e. Reading Borough Council, The Prudential, 
Oracle and ING Direct, the University of Reading  
 
 Invitation letters to be sent to potential volunteers from the sensory 
dimensions volunteer database  
 
 Invitation letters, emails or phone calls to be sent/conducted to volunteers 
from The Hugh Sinclair Unit of Human Nutrition volunteer database 
containing approximately 1000 names 
 
 Email to be sent to organisations managers to be displayed within the 
premises of large local organisations, companies and clubs.   
 
 Advertisement around the university, notices on staff and student 
webpages  
 
These approaches have proved very successful in the past as a means of recruiting 





(see appendix I Invitation letter and Invitation by email Appendix J and Volunteer 




1. The Principal Investigator must complete the Checklist in Appendix A to ensure 
that all the relevant steps and have been taken and all the appropriate 
documentation has been appended. 
 
2. If you expect that your application will need to be reviewed by the University 






Appendix A: Application checklist 
 
This must be completed by an academic staff member (e.g. supervisor) 
 
 Please tick to confirm that the following information has been included and is correct. 
 Indicate (N/A) if not applicable:  
  
 Information Sheet  
 
Is on headed notepaper         
    
 
Includes Investigator’s name and email / telephone number   
  
 
Includes Supervisor’s name and email / telephone number    
  
  
Statement that participation is voluntary       
  
   
Statement that participants are free to withdraw their co-operation  
  
 
Reference to the ethical process        
   
 
Reference to Disclosure         
    
 
Reference to confidentiality, storage and disposal of  
personal information collected        
   
 
Consent form(s)            
           
  
 Other relevant material 
 
Questionnaires          
    
 
Advertisement/leaflets         
   
Letters            



















Appendix B: Project submission form 
 
 
Title of Project: Olive leaf extract as part of a healthy lifestyle in the reduction of blood 
pressure   
 
Proposed start date: End of March 2015 
Brief description of Project: A 12 week diet and lifestyle intervention study investigating the 
effects of consuming olive leaf extract, in conjunction with achieving the guideline daily 
physical activity levels, on blood pressure.  
   
I confirm that to the best of my knowledge I have made known all information relevant to the 
Research Ethics Committee and I undertake to inform the Committee of any such information 
which subsequently becomes available whether before or after the research has begun.  
I confirm that if this project is an interventional study, a list of names and contact details of the 
subjects in this project will be compiled and that this, together with a copy of the Consent Form, 
will be retained within the School for a minimum of five years after the date that the project is 
completed.  
Signed:  
…………………………………………………….... Date: ……………….…………………  
(Investigator)  
…………………………………………………….... Date: ……………….…………………  
(Head of School or  
Authorised Head of Department)  
…………………………………………………….... Date: ……………….…………………  
(Student -where applicable)  




1. This form is signed by my Head of School (or authorised Head of Department)   
2. The Consent form includes a statement to the effect that the application has been 
reviewed by the University Research Ethics Committee and has been given a 
favourable ethical opinion for conduct       
          
3. I have made, and explained within this application, arrangements for any 
confidential material generated by the research to be stored securely within the 
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University and, where appropriate, subsequently disposed of securely.  
       
4. I have made arrangements for expenses to be paid to participants in the research, 
if any, OR, if not, I have explained why not.       
     
5. EITHER  
(a) The proposed research does not involve the taking of blood samples;  
OR  
(b) For anyone whose proximity to the blood samples brings a risk of  
Hepatitis B, documentary evidence of protection prior to the risk of exposure will be 
retained by the Head of School or authorized Head of Department.    
    
          Signed:  
…………………………………………... Date……………………  
(Head of School or  
Authorised Head of Department)  
6. EITHER  
(a) The proposed research does not involve the storage of human tissue, as defined by the 
Human Tissue Act 2004;  
OR  
(b) I have explained within the application how the requirements  
of the Human Tissue Act 2004 will be met.        
   
7. EITHER  
(a) The proposed research will not generate any information about the health of 
participants;  
OR  
(b) In the circumstance that any test reveals an abnormal result, I will inform the 
participant and, with the participant’s consent, also inform their GP, providing a copy of 
those results to each and identifying by name and date of birth;     
       
OR  
(c) I have explained within the application why (b) above is not  




8. EITHER  
(a) the proposed research does not involve children under the age of 5;    
  
OR  
(b) My Head of School (or authorised Head of Department) has given details of the 
proposed research to the University’s insurance officer, and the research will not proceed 
until I have confirmation that insurance cover is in place.  
 
Signed:  
…………………………………………... Date………………..…  
(Head of School or  
authorised Head of Department)  
This form and further relevant information (see Sections 5 (b)-(e) of the Notes for 
Guidance) should be returned to:  
Mr Nathan Helsby  
Planning Support Office  
Room 321  
Whiteknights House  
Tel: 0118 378 6972  
Email: n.e.helsby@reading.ac.uk  
- both electronically and in hard copy  
You will be notified of the Committee’s decision as quickly as possible, and you should not 
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General Practitioner/ name 
 
 






(Tick boxes if in agreement) 
 
1. I have read and had explained to me by ……………………………………………..…  
the accompanying Information Sheet relating to the project on A study of diet and lifestyle 
behaviours in the control of blood pressure 
 
 
2. I have had explained to me the purposes of the project and what will be required of me, 
and any questions I have had have been answered to my satisfaction. I agree to the arrangements 
described in the Information Sheet in so far as they relate to my participation.  
 
 
3. I understand that participation is entirely voluntary and that I have the right to withdraw 
from the study at anytime, without giving reason and that this will be without detriment 
 
 
4. I consent to an initial blood sample being taken for screening purposes, followed by a 
series of blood samples throughout the study at times indicated on the Participant Information 
Sheet. 
 
5. I authorise the investigator to inform my General Practitioner concerning my participation 
in this study 
 
6. I authorise the investigator to notify myself and my General Practitioner in the event of 
any abnormal results and to provide a copy of the results to both.  
 
7. This application has been reviewed by the University Research Ethics Committee and has 
been given a favourable ethical opinion for conduct.  
 
8. I have received a copy of this Consent Form and of the accompanying Information Sheet.  
 
 
9. I give consent for a copy of this form to be kept on a database for a minimum of 5 years  
  (a copy of which will be made available to the volunteer) 
 





10. I wish to receive a summary of the results once the study is complete and analysed 
statistically. 















Date   ......................................................................................... 
 
(This form is to be retained by the Head of School or authorised Head of Department. A copy should be 
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Appendix D: Volunteer Information Sheet 
 
Olive leaf extract as part of a healthy lifestyle in the reduction of blood pressure   
 
You are invited to take part in a volunteer research trial at the Department of Food and 
Nutritional Sciences.  
 
Why is this study being carried out? 
High blood pressure is a leading cause of kidney disease, cardiovascular disease and 
stroke. It may be precipitated by dietary and lifestyle choices. In this study we will 
consider the potential for extracts from the olive plant to reduce blood pressure when 
consumed as part of a healthy lifestyle. 
 
 
Before you decide whether to take part in the study, please read the following 
information carefully. If you want to know anything more about the study, or want to 
discuss further, please contact an investigator 
 
 
What will I be asked to do? 
We will first invite you for a 30 minute screening visit to determine your eligibility to take 
part in this study. During this visit we will ask you questions about your health we will 
measure your body shape including your height, weight, waist circumference and blood 
pressure. We will take a fasted blood sample (15 mL ~ 1 tablespoon in volume; which our 
trained staff can collect on site) so that the fat and cholesterol levels in your blood can be 
measured. The levels of insulin and blood glucose will also be assessed - along with 
measures of kidney and liver function. We will also ask you to complete a lifestyle 
questionnaire. From this information we can assess your suitability for the study against 
the inclusion and exclusion criteria detailed below. 
 
Individuals who meet these Exclusion Criteria will be unsuitable for this study: 
• Use of antibiotics within the previous 6 months 
• History of alcohol or drug abuse 
• Intake of any experimental drug within 4 weeks of the start of the study 
• Excessive alcohol consumption (more than 21 units/wk male, 15 units/wk female) 
• Females who are breast-feeding, may be pregnant, or of child-bearing potential 
and not using effective contraceptive precautions  
• Have had recently (in the last 5 years) major surgery, which might limit 
participation in, or completion of, the study. 
• On drug treatment for high blood fats, high blood pressure and blood clotting.  
• Physical or mental diseases that are likely to limit participation or completion of 
the study 
• Diabetic (diagnosed or fasting glucose > 7mmol/l) or suffer from endocrine 
disorders 
• Suffer from renal or bowel disease or have a history of choloeostatic liver or 
pancreatitis 
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• Have suffered from a myocardial infarction/stroke in the past 12 months 
• Anaemic (haemoglobin men >14 g/dl; women >11.5 g/dl)  
• Taking any dietary supplements including dietary antioxidants, other 
phytochemicals, fatty acid supplements including fish oil 
• Aged below 20 or over 70 years 
• Have a BMI of less than 25 kg/m2 
• Lactose allergy or intolerance  
• Calorie restriction or other special diet (e.g. Atkins diet, Montignac diet) 6 weeks 
prior to the start of the study  
• Smokers 
 
If none of the above apply then to participate you also need to satisfy these inclusion 
criteria 
 
• Signed consent form 
• The study will aim to recruit volunteers with above average blood pressure 
but without clinically managed stage 2 hypertension (systolic 120 -160 and 
diastolic 80-99) 
• Body mass index – 25 kg/m2 inclusive 
• Age 20– 70 years 
• Men and women  
 
If deemed suitable, and if you consent to participate in the study, we will invite you to 
attend the clinic once more for a familiarisation visit; during this visit we will introduce to 
the processes by which we measure physical activity, blood pressure and digital pulse 
wave velocity, we will also ask you to take a 3 day food diary away with you for 
completion prior to your next visit and we may equip you with an accelerometer to 
measure how much you move. The familiarisation visit will last no more than 1.5 hours. 
You will then be asked to return to the clinic in a fasted state between 8 and 10 am for 
the baseline visit, we will ask you to bring with you a 24 hour urine sample on this day 
and during this visit we will take measures of blood pressure, pulse wave velocity, and 
physical activity in addition to collecting blood samples. We will then assign you to a 
study treatment arm. The treatment will involve a daily dose of four capsules containing 
either 51.1 mg of the active test compound (oleuropein) in safflower oil or four capsules 
of a safflower oil control. These should be consumed as a single dose once daily with a 
glass of water.  
A second part of the study is to assess the effects of increasing physical activity in 
conjunction with the supplement and so you may, or may not, also be asked to increase 
your physical activity levels in line with targets laid out in the Physical Activity for Health 
report. The recommendations are equivalent to achieving at least 30 minutes of 
moderate-intensity physical activity on five days per week. If you are on a physical activity 
arm of the intervention we will encourage you to progressively increase your physical 
activity levels over the 12 weeks towards these targets. We will ask you to wear a hip 
mounted physical activity monitor and to record your step count each day. Where 
appropriate we will give you guidance on strategies to achieve desirable levels of activity 
based around increasing walking behaviour and decreasing sedentary leisure time 
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behaviour. If you are not on the physical activity arm of the study we would encourage 
you to continue with your normal activity levels. 
Your participation in the intervention will last for 12 weeks and will involve a total of 5 
site visits, including the screening visit, familiarisation, baseline, 6 weeks and 12 weeks. 
The screening visit will last approximately 30 minutes, and the other 4 visits 
approximately 1.5 hours.   
 
 
Study visit schedule 
The final two study visits to the Department of Food and Nutritional Sciences will be 
scheduled between 8 and 10 am in the morning before breakfast. You will be asked to 
attend in a fasted state (i.e. no food or drink apart from water for the 12 hours prior to 
your visit). You will need to provide: 
 
• fasted (12 hour) venous blood (40 mL, which is the equivalent to ~3 tablespoons 
in volume) (collected by our trained staff)  
• a 24 hour urine sample (collected over the 24 hours prior to the visit using the 
water-tight vessel provided for you)  
• If you are equipped with an accelerometer, we will use the study visits to log 
that data.  
 
During each of the study visits we will equip you with a blood pressure monitor which will 
need to be worn for a 24 hour period, and for which we will then arrange for you to 
return by post. 
Diet, lifestyle and medication during study 
Throughout the study you will be asked to keep a Volunteer Diary of your general well-
being 
 Please record any period of sickness or feelings of unwell during the study 
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 It is important that you adhere to your usual diet and lifestyle unless otherwise 
advised through the duration of the study.  
 
General  
•This study has been subject to ethical review by the University of Reading Research and 
Ethics Committee and has been given a favourable ethical opinion for conduct. 
•Your participation in this study is purely voluntary. You may leave the study at any time 
without giving a reason and without detriment. 
•If you would like to receive further information or book an appointment to complete the 
pre-study medical questionnaire then please contact me using the details at the end of 
this information sheet. 
 
Throughout the trial you will be asked to provide a total of 6 urine samples, and a total 
volume of 340 mL of blood which is about 23 tablespoons in volume (see attached 
timetable). During study visits you will be issued questionnaires that you will be asked to 
complete containing some basic information that will help us evaluate the treatment 
products.  
 
Are there any risks? 
It is not envisaged that the volunteers will experience any adverse effects, the olive leaf 
extract is commercially available and previous trials have shown it to be safe. 
 
Confidentiality 
Your records will be kept strictly confidential. Your study results will be recorded in a case 
record form for the study investigator but your name will not appear in this or on any 
report/publication of the results. The investigator or government authorities may need to 
look at your records to check if the information has been correctly collected, but at no 




You will receive £170 for completing the trial if deemed eligible after screening. 
Volunteers that drop out will have their payment pro-rated to cover the part of the study 
completed.  
 
You are free to ask the investigator for more information about this study before you give 
your consent to take part. 
The general results from the study and those relating to an individual may be of interest 
to volunteers. Each volunteer may only request their own individual results and not those 
of any other volunteer on the study. Only at the time of result dissemination will data be 
matched with volunteer’s names. Volunteers that request information on the trial will be 
sent information on the results of their participation, including their blood parameters 
and urine data from the sampling periods although this will not be until after the full 
completion of the study.  
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If you have any queries, please do not hesitate to contact the study team 
 
Investigators 
Miss Bandhita Saibandith, B.saibandith@pgr.reading.ac.uk  
Dr Daniel Commane, d.m.commane@reading.ac.uk  









 Briefing about the study 
 Screening blood samples 
Weight, height, waist circumference and blood pressure 
measurements will be taken 
 Habitual diet recorded 
-14 to -7 Familiarisation 
Visit 2 
 Digital Volume Pulse 
 Blood and urine sample collection  
 24 hour ambulatory blood pressure fitting and instruction 
 




 Digital Volume Pulse 
 Blood and urine sample collection  
 24 hour ambulatory blood pressure fitting and instruction 
Allocation to study arm, and instruction for study 
 






  Digital Volume Pulse 
 Blood and urine sample collection  
 24 hour ambulatory blood pressure fitting and instruction 
 





 Digital Volume Pulse 
 Blood and urine sample collection  
 24 hour ambulatory blood pressure fitting and instruction 
 
*Please note breads can be collected on a weekly basis for ease of storage – please arrange 
with investigator 
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Appendix E: Questions to be asked during recruitment 
 
Olive leaf extract as part of a healthy lifestyle in the reduction of blood pressure   
 





Mobile no:            
Best time to phone: 
DOB: 
Include if born after 1981 
Exclude if born before 1941 
E-mail: 
 








Waist circumference.................... (cm) 
 
 
 Medical questions 
 Please delete as appropriate.  
1. Do you have Coeliac disease or Gluten Allergy YES/NO  
Exclude if yes 
2.  Have you been diagnosed as having any of the following illness? Please give details. 






















 Exclude if they are on blood pressure, hyperlipidaemia, or hyper coagulation 
medication 
 
 d)  Thyroid disorder or any other endocrine disorders? YES/NO 
 






 e)  Heart problems, stroke or any vascular disease in the past 12 months  YES/NO 
 






 f)  Diabetes or other hormone disorders YES/NO 
 
 g)  Inflammatory diseases such as rheumatoid arthritis, psoriasis  YES/NO 






 h) Renal or bowel disease or have a history of liver disease or pancreatitis  YES/NO 
 If ‘YES’, please give details 






    
Exclude if suffering from conditions d) to h).  
 
3. Do you suffer from any conditions involving dermatological/connective tissue?  YES/NO 





4. Do you suffer form any conditions involving head, ears, nose and throat?  YES/NO  





5. Do you suffer from any respiratory conditions? YES/NO 





6. Do you suffer from any abdominal conditions? YES/NO  





7. Do you suffer from any urogenital/rectal conditions YES/NO 






8. Do you suffer from any lymphatic conditions? YES/NO 





9. Do you suffer from any neurological conditions? YES/NO  
(if yes please provide details) 






10. Have you been diagnosed as suffering from any other illness which causes you to take 
any long term medication? YES/NO 
 If ‘YES’, please give details 




11. Are you due to undergo major surgery which might limit participation in, or 





12. Have you used antibiotics within the previous 6 months  YES/NO 
 
 
13. Do you have electronically sensitive support systems e.g. pace-maker?   YES/NO 
 
 Exclude if YES to questions 11-14 
 
14. Do you smoke? YES/NO 





15. Have any of your close relatives (e.g. mum, dad, sister, brother, son, daughter) 
suffered from cardiovascular disease (myocardial infarction) before the age of 55 
years (for males) or before the age of 65 (for females), or been diagnosed with type 2 
diabetes?  YES/NO 
 
 
16. (a) Do you take any pain killing medication (for example, YES/NO 
 aspirin, paracetemol, Nurofen, Ibuprofen) daily or more than 4 times per week? 
 
b) If you take aspirin is it on prescription?       
YES/NO 
Exclude aspirin users if use is prescribed.  
 
 If taking non-steroid anti-inflammatory drugs (NSAID), ask question c below 
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 c) If you were to participate in our study, would you be willing to use paracetemol 
as an alternative during the course of the study?   YES/NO 
 
Exclude if not willing. 
17. Do you suffer from any type of allergies including food and pollen or any intolerance? YES/NO 







Exclude if severe asthma and on regular anti-inflammatory medication or use of 
asthmatic inhalers more than twice per month. In case of lactose or glucose- intolerance 
or allergy exclude 
 
Females please answer/complete question 19; males go to question 20 
 
18. a) Are you premenopausal, perimenopausal or postmenopausal? 
 
If ‘postmenopausal’:  
i) Do you remember the approximate time of your last menstruation period? 
 
Less than a year  
1-2 years  
2-5 years  
More than 5 years  
Don’t know (HRT)  
Can’t remember   
 
ii) Are you on hormone replacement therapy (HRT)?                                                           
YES/NO 
 
If ‘YES’, how long have you been on HRT?  
……………………………………………………………………………………………………………………………………
………………………………………………………… 
b)  I hope you don’t mind the following questions but I need to ask these since 
hormones may affect your lipids and other measurements.  
Are you on contraception?  YES/NO 
If ‘YES’ please give details  including, if relevant, the name of the contraceptive pill) 
      …………………………………………………………………………………………………….. 
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If you are breast-feeding, may be pregnant, or of child-bearing potential and not using 
effective contraceptive precautions you will be excluded from the study 
Dietary questions 




20. (a) Do you take any form of prebiotics or probiotics? ( i.e. fructooligosaccharides or 
live yoghurts)                                                                                    YES/NO 
 (b) To participate in the study volunteers should not have consumed these products 
within four weeks of the start date, and also during the study, would this be an issue 
for you?              




If ‘YES’ for b exclude from the study 
  




 If ‘YES’ Roughly how much do you drink per week? 
A unit of alcohol is half a pint of beer/lager, a single pub measure of spirits (e.g. gin/vodka 
or a small glass of wine (125 mL). 
Exclude those who appear to drink more than 15 units of alcohol (for women) or more 
than 21 units (for men) per week. 
 
Have you ever suffered from alcohol misuse?         
YES/NO                                                                                                                
 
Exclude if ‘YES’. 
22. Are you currently on or planning to start a weight reducing or other diet? YES/NO            
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a) If you were to participate in our study, would you be willing to postpone the 
weight reducing or other diet for after the end of the trial?                                                                                 
 
YES/NO      
 
Exclude if on or not willing to postpone the diet for after the end of the trial. 
        
  Do you currently consume laxatives on a regular basis?                     
             
       YES/NO                                               
 If ‘YES’, please give details 
…………………………………………………………………………………………………………………………………………
………………………………………………………… 
 a) If you were to participate in our study, would you be willing to cease 
consumption of these products until the end of the trial?                              
    YES/NO      
 
Exclude if not willing to cease laxative consumption 
 
        
   
 
23. Are you taking any dietary antioxidant, phytochemical, fatty acid or fish oil 
supplements? 
 





24. Have you taken part in any other nutrition study or clinical trial or been a blood donor 
in the last three months?                                                                                                                  
YES/NO 





 If ‘YES’, when will this study be completed?  
  
Exclude if the study will be completed in more than 1 month 
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25. Do you travel regularly for work?                        YES/NO 
  
26. Do you plan to take a holiday in the next 6 months?                                               YES/NO 
         List holiday period: 
  
 Researcher: _____________________ 
This is the end of the questionnaire.  Thank you for your time. All information provided 
will remain confidential at all times.  
 
NOTE: IF SUITABLE FOR THE STUDY THEN BOOK A DAY FOR SCREENING AND REMIND 
THEM NOT TO WEAR TIGHTS (females - for Tanita) AND VERY TIGHT LONG SLEEVES (for 
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Appendix F: Letter inform GP 
 
 
Dear Name of GP, 
 
Name of Patient, DOB, has expressed an interest in participating in a dietary intervention 
trial at The University of Reading. The trial will aim to study the effects of consuming olive 
leaf extract in conjunction with achieving the recommended physical activity guidelines 
on the reduction of blood pressure.  
This human study is funded by the Comvita Ltd and has been subject to ethical review, 
according to the procedures specified by the University Research Ethics Committee, and 
has been given a favourable ethical opinion for conduct. 
 
The trial will commence on (Trial start date) 
 
We have enclosed a subject Information sheet for your information. If you have any 
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Page 1  
 




Period No. _____________________ Day No. to Day No. 
 
 
Please fill in the diary carefully and completely for each day. If you are unsure how to 
answer, please give the best information you can. Please return completed diary to 
Bandhita Saibandith on your next visit. 
 
To be filled in by investigator only! 
 
Date started at: 
 











Please enter the intake of any medication taken during the study with name, dosage per day, 
date started and date stopped. 
 
Medication Dosage Date started - stopped 
e.g. paracetamol 500mg twice 15/1 – 15/01 
1   
2   
3   
4   
5   
6   
7   
8   
9   
10   
11   
12   
13   
14   
15   
16   
17   
18   
19   
20   
21   
   
 
    
213 
 




Please enter the occurrence of all adverse events with start and end date and time. 
 
Adverse Event Date – started Date – stopped 
e.g. headache 15/01 15/01 
1   
2   
3   
4   
5   
6   
7   
8   
9   
10   
11   
12   
13   
14   
15   
16   
17   
18   
19   
20   
21   
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Did you experience any of the following after taking the supplement?  
 
 yes no 








Did you experience 




Did you NOT consume any 




If the answer to the last question above is “yes” then please state numbers of slices or 
quantity of orange juice not consumed and the date and the reason for non-consumption. 
 
 Date missed Reason for non-
consumption 
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I am writing to inform you about a new study that is taking place at the Department of 
Food and Nutritional Sciences at the University of Reading that maybe of interest to you. 
The aim of this study is to investigate the synergistic benefits of olive polyphenols and 
physical activity in the control of blood pressure. 
 
If you would like to take part in this study we can determine your eligibility by asking you 
to give a brief medical history and lifestyle questionnaire and measurements for height, 
weight, waist circumference and blood pressure. We are looking for individuals who are 
at above average blood pressure but who are otherwise healthy. Therefore after giving 
consent, we will ask you to supply a fasted blood sample (not ingesting anything but 
water for 12 hours) so that the fat levels in your blood, blood count and kidney and liver 
function can be determined to assess your suitability for inclusion in this study 
 
The study will begin in June 2015, your participation would be required over 12 weeks. 
During the study you will be asked to wear a physical activity monitor and to consume 
either a supplement capsule or a placebo daily for 12 week study, also you may or may 
not be encouraged to increase your physical activity levels to meet the national 
guidelines. 
 




Miss Bandhita Saibandith, PhD student 
 
The University of Reading 
Department of Food and Nutritional Sciences 
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I am writing to inform you about a new study that is taking place at the Department of 
Food and Nutritional Sciences at the University of Reading that maybe of interest. The 
aim of this study is to investigate the synergistic benefits of olive polyphenols and a 
healthy lifestyle in the control of blood pressure. 
 
If you would like to take part in this study we can determine your eligibility by asking you 
to give a brief medical history and lifestyle questionnaire and measurements for height, 
weight, waist circumference and blood pressure. We are looking for individuals who are 
at above average blood pressure but who are otherwise healthy. Therefore after giving 
consent, we will ask you to supply a fasted blood sample (not ingesting anything but 
water for 12 hours) so that the fat levels in your blood, blood count and kidney and liver 
function can be determined to assess your suitability for inclusion in this study 
 
The study will begin in June 2015, your participation would be required over 12 weeks. 
over the course of the study you will be asked to consume a supplement or placebo pill 
daily for the 12 week study period and you may or may not be encouraged to increase 
your physical activity levels. 




Miss Bandhita Saibandith, PhD student 
 
The University of Reading 
Department of Food and Nutritional Sciences 
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Appendix K: Weekly Physical activity sheets 
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